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SUMMARY
Cigarette smoking is an important risk factor for cardiovascular disease which 
adversly affects the vasculature involving both coronary and peripheral arteries. The 
vasoregulatory function of endothelial cells (ECs) (as indicated by reduced endothelial- 
dependent vasodilatation (EDV) in vivo) is one of the earliest to be affected. Nitric 
oxide (NO) is primarily responsible for vasoregulatory and homeostatic functions of 
ECs. The exact mechanism(s) for smoking-mediated NO dysfunction and its effect on 
EC-derived homeostatic factors are unclear. The majority of earlier in vitro studies 
have used either crude cigarette smoke extract or one isolated component of cigarette 
smoke to examine the effects of smoking on endothelial cells. These models were not 
physiological. Furthermore, ECs from different vascular beds may show distinct 
reactions to different pathophysiological stimuli.
In the first phase of the project, EDV in vivo was correlated with the NO 
biosynthetic pathway in vitro. Flow-mediated EDV of the brachial artery was 
measured, and human umbilical vein ECs (HUVECs) were exposed to serum from the 
same individuals, followed by in vitro measurement of basal (12 hour)- as well as 
stimulated-NO production, endothelial nitric oxide synthase (eNOS) expression and 
eNOS activity. A significant correlation was found between in vivo EDV and 
stimulated-NO levels in vitro Smokers showed significantly decreased EDV as well as 
decreased NO levels and eNOS activity but increased eNOS expression in vitro. In 
vitro, NO levels positively correlated with eNOS activity but negatively correlated with 
eNOS expression indicating that the mechanism(s), which decreased NO levels in 
smokers, also increased the eNOS expression. However, the activity of the latter was 
abnormal. It was also observed that in vivo as well as in vitro NO biosynthesis was 
similarly dysfunctional in light (< one pack/week) versus heavy (> one pack/day) 
smokers, suggesting that exposure to relatively small amounts of smoke initiated 
unknown cellular mechanism(s) to overwhelm the NO biosynthesis. Additionally, 
HUVECs exposed to smokers’ serum showed decreased fibrinolytic and anti­
thrombotic activity in culture.
The second phase of the project was performed using human coronary artery 
ECs (HCAECs) in order to extend the previous findings to an arterial EC line. In 
addition, specific free radical scavengers were used to investigate the role, as well as 
the source of, free radicals in the present model. Smokers’ serum induced similar 
alterations in NO biosynthesis in HCAECs as in HUVECs. It was found that reactive
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oxygen species (ROS), specifically hydrogen peroxide, was responsible (at least in 
part) for up-regulation of eNOS. However, this upregulation did not translate to 
increased activity possibly due to a direct effect of other ROS such as superoxide and 
peroxynitrite on eNOS. In addition, it was demonstrated that endogenous free radical 
sources such as uncoupled eNOS, the mitochondrial electron transport chain and 
xanthine oxidase were involved in NO dysfunction in HCAECs exposed to smokers’ 
sera.
The present project adopted a novel approach to investigate the mechanism of 
reduced EDV and NO biosynthesis in smokers. Data from this project confirm that 
reduced EDV in smokers is associated with dysfunctional NO biosynthesis and ROS 
play a central role in this dysfunction. Additionally, these data suggest that the ROS 
in smoking may arise from both exogenous and endogenous sources and may have a 
paradoxical effect on eNOS protein expression and activity. Finally, smoking also 
appears to decease the availability of EC-derived fibrinolytic and anti-thrombotic 
factors.
IV
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Abbreviations
AHA American Heart Association
AS Atherosclerosis
b h 4 Tetrahydrobiopterin
CaM Calmodulin
CHD Coronary heart disease
CSC Cigarette smoke condensate
CSE Cigarette smoke extract
CVA Cerebrovascular disease
CVD Cardiovascular disease
ECs Endothelial cells
EGM Endothelial growth medium
ETs Endothelins
ETS Environmental tobacco smoke
FAD Flavin adenine dinucleotide
FMN Flavin adenine mononucleotide
HCAEC Human coronary artery endothelial cell
HUVEC Human umbilical vein endothelial cell
HDL High density lipoprotein
LDL Low density lipoprotein
L-NMMA NG-monomethyl-L-arginine
NADPH Nicotinamide adenine dinucleotide phosphate (reduced)
NO Nitric oxide
NOS Nitric oxide synthase
ONOO' Peroxynitrite
PAI Plasminogen activator inhibitor
PAEC Pulmonary artery endothelial cell
ROS Reactive oxygen species
SP Substance P
SOD Superoxide dismutase
t-PA Tissue plsminogen activator
TF Tissue factor
TFPI Tissue factor pathway inhibitor
SMC Smooth muscle cell
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1. INTRODUCTION
1. General
Cigarette smoking is a common cause of premature death, whether from 
cardiovascular disease, respiratory disease, lung cancer or other cancers. It is the single 
most alterable risk factor contributing to premature morbidity and mortality in the 
United States of America (USA), accounting for approximately 430,000 death annually 
(Nelson et al., 1994). The World Health Organization (WHO) projected that global 
mortality from tobacco use will to rise from 3 million in 1990 to 10 million in 2025 
(AHA, 1999).
In the USA the direct medical care cost of smoking is approximately $50 billion 
annually (Miller et al., 1993), which is about 6-8% of American personal health care 
expenditures (Warner et a l, 1999). Smoking cost Americans an estimated $130 billion 
annually in medical care including the costs of smoking during pregnancy, lost 
workdays, loss of output from early death and retirement, and the costs of fires caused 
by smoking (AHA, 1999).
The AHA in “2000 Heart and Stroke Statistical Update ” stated that in the USA 
for the years 1990-94, an average of 430,700 Americans died each year of smoke- 
related illness. The largest fraction of smoke-related deaths, were cardiovascular in 
nature. About one in five deaths from cardiovascular disease are attributable to 
smoking. Environmental tobacco smoke (ETS), also called second hand smoke or 
passive smoke, is responsible for between 37,000 and 40,000 cardiac deaths (AHA, 
1999). Glantz and Parmley (1995) stated that passive smoking is the third leading 
preventable cause of death, after active smoking and alcohol.
Despite overwhelming epidemiological evidence linking cigarette smoking with 
cardiovascular disease, the particular components o f cigarette smoke responsible for 
this relationship and the mechanisms by which they exert their effects have not been 
elucidated (Pittilo, 2000). It is speculated that cigarette smoking adversely affects 
multiple parameters of cardiovascular physiology including blood rheology (Ernst, 
1990), endothelial cells (ECs) (Davis et a l, 1985; Noronha-Dutra et a l, 1993;Nagy et 
a l 1997; Harrison, 1997), leukocyte (Kalra et a l, 1994; Adams et a l, 1997; Blann, 
1998) and platelet (Davis et a l, 1985; Blann, 1998) function. Most of the in vitro 
experimental data regarding the effect of smoking on ECs were obtained from studies
using human umbilical vein endothelial cells (HUVECs) or animal vascular ECs. ECs 
from different vascular beds display marked phenotypic and functional differences 
(Fajardo, 1989; Petzelbauer et a l , 1993: Risau, 1995; Cines et a l,  1998) giving rise to 
the possibility that smoking may have different effects on different vascular beds. In 
addition, Nene et a l, (1997) and Sarkar et a l, (1999) reported that acute smoke 
exposure increases NO production and re-endothelialization in rats, suggesting that the 
pathophysiology of acute exposure to smoke may be different from chronic exposure. 
Furthermore, it is still a matter of debate in the scientific community whether ETS 
exposure is an increased risk for heart disease (Denson, 1999; Lee and Roe, 1999).
1.2 Cigarette smoking
Western Society was introduced to tobacco more than 500 years ago. Columbus 
and his crew were the first to see Indians in San Salvador inhaling the smoke of burning 
leaves through a reed, called tabacum. Columbus’s sailors brought tobacco to Europe. 
Jean Nicot, after whom nicotine is named, used extracts of the tobacco plant to treat a 
wide variety of aliments. By the early part o f the 19th Century, tobacco was rolled in 
paper and smoked as cigarettes (reviewed by Black, 1995).
1.2.1 Chemistry o f  cigarette smoke
The combustion and partial combustion of tobacco in cigarettes yields over 
4000 different constituents (Hoffman and Wyder, 1986). Cigarette smoke can be 
divided into two phases: the tar phase and the gas phase.
The tar or particulate phase is defined as the material trapped when the smoke 
stream is passed through a Cambridge glass-fiber filter that retains 99.9% of all 
particulate material with a size greater than 0.1pm (Pryor and Stone, 1993). The gas 
phase is the material that passes through the filter, which comprises 400-500 individual 
gaseous components (Guerin, 1980). Mainstream smoke comprises 8% of particulate 
phase and 92% of gaseous components. Sidestream smoke (from the burning ends of 
cigarette) contains a higher concentration of the toxic gaseous component than the 
mainstream smoke. ETS consists of approximately 85% sidestream and 15% exhaled 
mainstream smoke (Glantz and Parmley, 1991; 1995). A partial list of chemicals found 
in the mainstream and sidestream tobacco smoke is presented in Table 1.1. O f all the
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Table 1.1 Major chemicals components of cigarette smoke
Mainstream smoke Sidestream smoke
Acetaldehyde
Acroline
Acrylamide
Ammonia
Benzene
Benzanthracene
Benzapyrene
Carbon monoxide
Cresols
Hydrogen cyanide
Nitrogen oxides
Nitrosonomicotine
Nitrosoanatabine
Phenol
Toluene
Acetaldehyde
Acroline
Ammonia 
Benzene 
Benzanthracene 
Benzapyrene 
Carbon monoxide
Hydrogen cyanide 
Nitrogen oxides 
Nitrosonomicotine
Adapted from Powell (1998)
I
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components, nicotine is the addictive substance of cigarette smoke.
The particulate (tar) phase of cigarette smoke contains >1017 radicals/gm and 
the gas phase contains >1015 radicals/puff (Pryor and Stone, 1993). Free radicals in 
cigarette smoke can be divided into two distinct populations. In the particulate phase, 
the principal free radical is a quinone/hydroquinone (Q/QH2) complex, which is an 
active redox system that can reduce molecular oxygen to produce superoxide (O2’). 
Fresh cigarette smoke contains from 300 to 500 parts per million of NO (Cueto and 
Pryor, 1994). In the gas phase the principal free radicals are small oxygen-centered and 
carbon-centered radicals, which are produced in a steady state by oxidation of NO to 
nitrogen dioxide (NO2). These interact with reactive species in smoke such as isoprene. 
The radicals associated with the particulate phase are long-lived, whereas the radicals 
associated with the gas phase have a shorter life span (Church & Pryor, 1985; Pryor et 
al., 1990). Despite their short lifetimes, radical concentrations are maintained at high 
levels in the gas-phase of cigarette smoke because they reach a steady state where they 
are continuously formed and destroyed (Pryor and Stone, 1993). Analysis of cigarette 
smoke demonstrates that the main source of reactive oxygen intermediates and 
hydrogen peroxide (FI2O2) are polyphenols in the particulate phase (Pittilo, 2000). 
Kodama et a l (1997) suggested that the gas phase contains a certain unknown factor 
that produces reactive oxygen metabolites from H2O2 .
1.2.2 Cigarette smoking and cardiovascular disease
1.2.2.1 Epidemiology
The first cohort studies indicating that cardiovascular disease (CVD) is more 
common in smokers than non-smokers were published in the 1950s (Doll and Hill,
1956; Hammond and Horn, 1958). In a prospective investigation, British physicians 
who were followed for 20 years, showed a significant increase in coronary heart disease 
(CHD) (52%) for all ages in men, with the largest effect seen in younger rather than 
older smokers (Doll and Hill, 1954; Doll and Peto, 1976). Hammond and Horn (1958) 
analyzed the death rates of 187,783 men followed for an average of 44 months, and 
showed 52% higher CVD-associated death in smokers than non-smokers. In the CVD 
group there was a 70% higher risk of CHD and a 42% higher risk for cerebrovascular 
disease (CVA) among smokers compared to non-smokers. These authors also noted a
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dose-response relationship for mortality; heavy smokers (> two packs per day) had the 
largest increase in risk. Since then there have been many reports that convincingly 
demonstrated that CVD is the most important cause of smoking-related premature 
death (Flower, 1993). More recently, Manly (1997) has estimated that in the USA one 
fifth of all heart disease-related deaths were due to cigarette smoking and that, as a 
single factor, it doubles the risk of heart failure.
Fowkes et al. (1992) reported that smoking was the principal risk factor for 
aortic aneurysm and peripheral arterial disease and the risk of peripheral arterial disease 
was higher than the risk of heart disease. In the Framingham Heart Study (Kannel, 
1981), the relative risk o f peripheral arterial disease was 3.0, higher than that for any 
other cardiovascular syndrome.
Glantz and Parmley (1991) reviewed 14 epidemiological studies and found a 
consistent increase in the risk of heart disease among those exposed to second hand 
smoke. The risk ratio for both men and women was 1.2. Recently, He et al. (1999) in a 
meta-analysis of 18 epidemiological studies reported that passive smoking is 
consistently associated with an increased relative risk of CHD and identified a 
significant dose-response relation with the amount o f exposure to ETS. However, 
Denson (1999) and Lee and Roe (1999) argued that the available experimental and 
epidemiological evidence to date does not support an association between ETS and an 
increased risk of heart disease.
1.2.2.2 Pathophysiology
The cardiovascular consequences of smoking are primarily due to 
atherosclerosis (AS). The reasons for the development of AS lesions and the clinical 
sequelae that result are exceedingly complex with a multitude of antecedents, the 
interrelation of which is poorly understood (Black, 1995. Table 1.2).
AS is characterized by the formation of intimal fibrofatty plaques that often 
have a central core rich in lipid (Schoen and Cotran, 1999). The contemporary concept 
of the pathogenesis of AS is called the “response to injury hypothesis”, which 
considers AS to be a chronic inflammatory response of the arterial wall initiated by 
some form of injury to the endothelium (Ross, 1986; 1993). Central to this thesis are 
focal regions of chronic endothelial injury resulting in endothelial dysfunction (i.e. 
increased endothelial permeability and leukocyte adhesion), which causes insudation
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Table 1.2 Cardiovascular consequences of smoking
I. Cardiac effects
A Coronary arteries
1. Atherosclerosis in native circulation
a. Myocardial infarctions
b. Fatal infarctions
c. Recurrent infarction
d. Silent ischemia
2. Spasm
3. Restenosis after angioplasty
4. Atherosclerosis in bypass grafts
B. Sudden death
C. Unstable angina pectoris
D. Myocardial arteriolar hyperplasia
II Cerebral effects
A. Atheroembolic brain-infarcts
B. Subarachnoid hemorrhage
C. Transient ischemic attack
D. Recurrent carotid artery stenosis.
III. Other arterial pathology
A. Aortic atherosclerosis
B. Iliofemoral atherosclerosis
C. Intermittent claudication
D. Abdominal aortic aneurysm
E. Renal arteriolar hyperplasia
F. Uteroplacental arterial hyperplasia
Modified from Black (1995)
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of lipoproteins into the vessel wall. This is followed by adhesion and migration of 
monocytes and adhesion of platelets to the focal area of denudation or adherent 
leukocytes. Release of factors from activated platelets and macrophages causes 
migration of smooth muscle cells from the media to the intima. With continued 
accumulation of lipid, macrophages and smooth muscle cells eventually form 
aggregates of foam cells in the intima, which are apparent macroscopically as fatty 
streaks. Further progression is characterized by the deposition of extracellular matrix 
and maturation into a fibrofatty atheroma (Schoen and Cotran, 1999).
Hopkins and Williams (1981) classified the primary risk factors of AS into four 
categories, 1) Initiators - substances that injure the arterial wall, 2) Promoters - 
substances that enhance the deposition of lipids in the arterial wall, 3) Potentiators - 
substances that enhance thrombosis or platelet aggregation, 4) Precipitators - 
substances that are responsible for triggering the clinical events. The only risk factor 
listed as associated with all four of these categories was cigarette smoking.
Endothelial injury is considered to be a key initiating event in the pathogenesis 
of AS (Ross, 1986; 1993). Cigarette smoking causes both morphological and functional 
changes to the endothelium (Pittilo, 2000). Impairment of endothelial vasodilator 
function, which precedes evidence for structural changes in the vessels, is thought to be 
the earliest pathophysiological effect of various risk factors of AS (Adimoolam and 
Cooke, ,1999). Cigarette smoking is also found to be associated with dose-related 
impairment of endothelium-dependent arterial dilation in asymptomatic young adults 
(Celermajer, 1993).
EC-derived NO plays a major role in the regulation of vascular tone (Furchgott 
and Zawadzki, 1980; Plamer et ah, 1987). Node et ah (1997) reported that cigarette 
smoking causes reversible reduction in plasma concentration of NO in young adults. 
Cigarette smoking has been shown to affect the protein and the activity of the NO- 
generating enzyme, endothelial nitric oxide synthase (eNOS) (Wang et al., 2000). In 
addition to its role as a potent vasodilator, NO decreases endothelial permeability 
(Cardona-Sanclemente, 1995) and inhibits monocyte and leukocyte adhesion to ECs 
(Kubes et al., 1991; Bath et a l, 1991), the adherence and aggregation of platelets 
(Cohen, 1995) and smooth muscle cell proliferation (Scott-Burden et al., 1993). 
Cigarette smoking is associated with increased monocyte-EC adhesion in humans 
(Adams et al. 1997), heightened sensitivity of platelet activation and aggregation 
(reviewed by Powell, 1998), and oxidation of lipoprotein (Heitzer et al., 1996).
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Although the mechanisms by which cigarette smoking promotes AS are still unclear, 
cumulative data suggest that owing to its ability to modulate the anti-atherogenic 
property of NO, smoking may initiate and promote atherogenesis.
Although association between chronic smoking and AS is well established, the 
pathophysiology of acute smoke exposure and its biochemical effect on the existing 
pathology of chronic smoke exposure has not been well addressed and is often 
contradictory. Davis et al. (1985) found increased numbers of anucleated EC carcasses 
immediately after smoking, while Blanche et al. (1992) noted increased numbers of 
circulating ECs. Caralis et al. (1992) reported a very strong association between acute 
cigarette smoking and pure coronary spasm in young women. Lekakis et al. (1997; 
1998) found acute cigarette smoking decreased endothelium-dependent brachial artery 
dilatation in both smokers and non-smokers. On the other hand, Nene et al. (1997) 
reported cigarette smoking increased endothelium-dependent vasorelaxation in the rat 
coronary artery in a dose-dependent manner. Similarly, Sarkar et al. (1999) reported 
that acute smoke exposure increased the serum level of NO and endothelial 
regeneration following balloon injury of the thoracic aorta in rats.
The association between ETS and AS and its pathophysiology is still a matter of 
debate. Zhu et al. (1993) and Penn et al. (1993; 1994) showed that exposure to ETS is 
associated with endothelial dysfunction and accelerated AS in laboratory animals. Sun 
et al. (1994), have shown that dietary supplement with L-arginine (the precursor of 
NO) protects cholesterol-fed rabbits from endothelial dysfunction associated with 
exposure to ETS, suggesting impaired endothelial NO production may pathogenically 
be important in this animal model. Glantz and Parmley (1995), in their widely cited 
review suggested that ETS causes cardiovascular pathology by increasing platelet 
activation, accelerating atherosclerotic lesions and causing free radical-mediated tissue 
injury. Celermajer et al. (1996), showed ETS impaired brachial artery dilatation and the 
magnitude of the impairment was directly related to the amount of tobacco exposure. 
These authors suggested that it may represent early arterial damage. However, Denson, 
(1999) and Lee and Roe (1999), in their recent reviews argued that the association of 
ETS and heart disease is weak and could well be a result of various forms of bias (e.g. 
misclassification bias, uncontrolled confounding, publication bias and recall bias).
1.2.2.3 Cigarette smoke components responsible for cardiovascular injury
Cigarette smoke contains a complex mixture of individual components and only 
a small number of these have been examined in isolation. While components such as 
nicotine and carbon monoxide (CO) have been the subject of a number of 
investigations, their damaging effect in model systems are less than those seen with 
whole smoke. More recently, free radicals in smoke have been implicated as an 
important cause of endothelial injury but not without some controversy.
Nicotine is one of the many components of cigarette smoke that has been 
studied in detail. Apart from its diverse pharmacological actions (such as stimulation of 
the adrenergic nervous system, and stimulation of heart rate (HR) and blood pressure 
(BP)), it has been reported to have morphological and functional effect on ECs (Black, 
1995; reviewed by Pittilo 1990). Rats exposed to nicotine showed an increased 
frequency of EC death, which resulted in enhanced transendothelial leakage of 
macromolecules including low-density lipoproteins (LDL) (Lin et al., 1992). However, 
Pittilo (2000) in his review states that these morphological and functional effects were 
much more limited than those observed with whole smoke. Similarly, the clinical 
studies on pipe smokers and users of transdermal nicotine devices suggest that nicotine 
has a minimal effect on accelerating AS and is a minor factor in the pro-thrombotic 
effect of smoking (Benowtiz, 1997). This author suggested that toxins in cigarette 
smoke other than nicotine are the most important causes of acute cardiovascular events.
CO is another constituent, which has been implicated in the CVD associated . 
with smoking. The increased affinity of CO for Hemoglobin (Hb) reduces the 0 2 - 
carrying capacity of the blood (Black, 1995). This author stated that Astrup and 
Kjeldesn (1979) showed that the exposure to higher levels of CO, which occurs with 
smoking can cause necrosis of myofibrils, degeneration of mitochondria and variety of 
other subcellular abnormalities of muscle cells in laboratory animals. Similarly, Pittilo 
(1990) in his review stated that Thomsen (1974) and Webster et al. (1970) showed that 
in an animal model, CO exposure is associated with induction and development of AS. 
However, other studies have failed to demonstrate any relationship between CO 
exposure and EC morphology or the development AS. Hugo et al. (1978) (reviewed by 
Pittilo, 1990) were unable to differentiate between control or treated aorta or coronary 
arteries in relation to CO exposure. Similarly, Armitage et al. (1976) (reviewed by 
Pittilo, 1990) did not observe any enhancing effect of CO in relation to the
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development of AS in pigeons. Later, Thom et al. (1997) reported that CO-exposed 
bovine pulmonary artery ECs release a higher concentration of NO and suggested that 
CO caused oxidative stress through competition for intracellular binding sites, which 
increase the steady state level of NO production and the generation of peroxynitrite by 
the endothelium.
Cigarette smoke has been known for many years to be a rich source of free 
radicals (Lyons et al., 1958). The majority of the current data suggests that the free 
radical components of cigarette smoke may be responsible for the morphological and 
functional damage to the endothelium. Pittilo (2000) has stated that the electron 
microscopic changes seen by Pittilo et al. (1984) in cultured cells following exposure to 
plasma from humans after smoking, were similar to the changes seen by Noronha- 
Dutra and Steen (1982; 1984) in cardiac myocytes following free radical-induced lipid 
peroxidation. Later, Noronha-Dutra et al. (1993) reported that functional changes seen 
in ECs following incubation with the plasma obtained from volunteers after smoking, 
were suggestive of free radical induced oxidative stress. It has been suggested that the 
high level of lipid peroxidation and increased formation of reactive oxygen species 
(ROS) within the vascular wall in AS can overwhelm cellular antioxidant mechanisms 
(Siow et al., 1999). Ota et al. (1997) reported that incubation of isolated rabbit aorta 
with cigarette smoke extract (CSE) inhibits endothelium-dependent relaxation in a dose 
dependent manner and that can be attenuated by co-incubation with a free radical 
scavenger. On the contrary, Leonard et al. (1995a) found no significant differences in 
free radical markers between young adult smokers and non-smokers. Free radical 
activity due to cigarette smoking also appears to be adequately scavenged in young 
adults with diabetes who are free of significant macro-vascular disease (Leonard et al., 
1995b). Maranzana and Mehlhom (1998) suggested that chemical modification of 
glutathione was a key pathogenetic effect of filtered cigarette smoke, whereas free 
radical oxidation was relatively insignificant. Similarly, Su et al. (1998) showed that 
incubation of pulmonary artery ECs with CSE in the presence of various antioxidants 
(including reduced glutathione) did not improve CSE and caused a reduction in eNOS 
activity.
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1.3 Endothelial cells
For a long time the endothelium was considered an inert cellophane-like 
membrane that lines the circulatory system. The primary function of the endothelium 
was thought to be to maintain vessel wall permeability. However, in the 1800s, von 
Recingausen demonstrated that blood vessels were lined by cells and were not merely 
tubes within the tissues. Although Heidenhahn’s in 1891 described the endothelium as 
an active secretory cell system, Starling’s law of capillary exchange (proposed in 1896) 
confirmed the idea that the endothelium was a selective physical barrier. Later, electron 
microscopic studies of vessel walls (Palade in 1953) and physiological studies 
describing the interaction between lymphocytes and the endothelium of post-capillary 
venules (Gowan, 1959) spawned numerous subsequent studies, which led to the current 
view of the endothelium as a heterogeneous organ with synthetic, secretory, 
immunologic and metabolic functions (reviewed by Cines et al., 1998).
In an adult human the endothelium has a surface area equivalent to 1-7 m , 
weighs in the region of 1 kg, and comprises approximately 1-6 x 1013 cells. In every 
organ system endothelial cells regulate the flow of blood cells, and the interchange of 
biological and nutritional molecules between the blood and the tissues. The regulatory 
function is mediated by membrane-bound receptors for numerous molecules including 
hormones (endothelin-1), metabolites (NO and serotonin), proteins (growth factors, 
coagulant, and anticoagulant proteins), and lipid transporting particles. ECs also 
express molecules that regulate cell-cell and cell-matrix interactions (reviewed by 
Cines et al., 1998).
One of the key functions of the endothelium is to regulate blood flow. It does 
this in part through possessing an anti-thrombotic surface that facilitates the movement 
of plasma and cellular constituents throughout the vasculature, and in part through the 
uptake and secretion of vasoactive substances, which dilate or constrict particular 
vessels in response to specific stimuli (reviewed by Cines et al., 1998).
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1.3.1 Origin, development and differentiation
The cardiovascular system forms very early during gestation but the molecular 
events involved in EC differentiation from the mesoderm remain undetermined. Shortly 
after implantation, vascular and hematopoietic stem tissues develop together with the 
formation of the blood islands within the primitive yolk sac. Vascular and 
hematopoietic stem tissues are composed of two cell types: ( 1 ) angioblasts that form 
the outer layer of ECs; and (2) hematopoitic stem cells, in the inner cluster, that form 
the first embryonic blood cells. The embryonic mesoderm is the primary site where the 
angioblasts committed to EC differentiation are found. The initial stimulus for 
angioblast formation is the endoderm. The first angioblasts arise from the lateral 
mesodermal plate and cardiac crescent. Some cells assemble into the endocardium of 
the early heart tube and others migrate into the forming brain. At the base of the 
primitive heart tube other angioblasts form a network of ECs, which develop into 
vitelline vessels, allowing blood cells from the yolk sac to circulate within the embryo. 
Mesenchymally-derived ECs are incorporated into the angiogenic extensions of 
invading vessels to form the vasculature of the major organs (reviewed by Cines et a l, 
1998).
Analysis of murine embryos (in which the genes for specific polypeptide 
growth factors or their transmembrane receptor tyrosine kinases (RTKs) have been 
inactivated) suggested that the initiation of vascular development requires both basic 
fibroblast growth factor (PFGF) and vascular EC growth factor (VEGF). VEGF 
stimulates phosphorylation of its’ corresponding receptor and causes EC replication and 
migration (Beck and D’Amore, 1997). The continued endocardial and vascular 
development, expansion of the vascular tree, and the formation of the vascular wall 
appears to be controlled by two members of a second family of RTKs and their ligands, 
tie- 1  (tyrosine kinase with Ig and epidermal growth factor homology domains) and tie - 2  
or tek (tunica interna EC kinase) (Sato et al., 1995). Mutation of the genes for either of 
these growth factors or their receptors gave rise to embryos with cardiac abnormalities, 
which included vessels with poorly formed walls (reviewed by Cines et a l, 1998). In 
humans, mutation of these receptors leads to smooth muscle cell deficiencies around 
small vessels and microaneurysms (Vikkula et a l, 1996). It appears that careful 
regulation of the activity of tie-1  and tie- 2  is important for continued vascular 
branching and vessel remodeling. Therefore, at least two sets of RTKs, their ligands
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and their programmed expansion influences the assembly of the early vascular tree.
One set of RTKs is required for initiation of vessel formation and EC differentiation, 
and the other is required for establishment of capillary beds, subsequent branching and 
formation of vessel walls (Cines et al., 1998).
The ability of ECs to form capillary-like tubes is influenced by the extracellular 
matrix (ECM), interactions with which are mediated by several kinds of molecules on 
the EC surface (including proteoglycans and protein). The integrin family is the best- 
studied family of receptors that mediates such interactions. Its members cause tethering 
of cells and mediate information transfer. This results in cytoskeletal re-organization at 
specific sites or maintains tissue stability. Intracellular pathways that result in either 
cell replication or programmed cell death can also be activated integrin-ligand binding.
During embryonic development the combination of integrins expressed by 
endothelial cells is constantly changing. This suggests that specific combinations of 
integrins are required at distinct developmental stages (reviewed by Cines et al., 1998).
Initiation of differentiation of embryonic ECs and their subsequent organization 
into specific, organ-related, vascular networks is influenced by the composition and 
structure of the ECM, by cell-cell contact and by angiogenic as well as angiostatic 
growth factors produced as a result of the vascular expansion.
1.3.2 Histochemical characteristics
ECs, vascular smooth muscle cells (VSMCs) and fibroblasts may be 
distinguished in culture by their structural and phenotypic characteristics (Table 1.3). 
ECs are polygonal in shape, about 10-15 pm wide and 25-50 pm long. Their elongated 
prominent nuclei are oriented in the long axis of the vessel influenced by the shearing 
effects of the blood flow (Simionescu and Simionescu, 1983). They show numerous 
blebs and pits on, or near, their surface when examined under the electron microscope, 
(Jaffe etal., 1973).
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Tablel.3 Differentiating characteristics of endothelial cells
Endothelial cell Vascular smooth 
muscle cell
Fibroblast
Cell morphology Polygonal Spindle Spindle
Growth pattern Single layer 
No pattern
Multi-layered 
Parallel arrays
Multi- layered 
Parallel arrays
Weibel-Palade
bodies
Positive Negative Negative
Myofilaments Positive Positive Variable
Presence of major 
blood group 
antigens
Present Absent Absent
von Willebrand 
factor
Positive Negative Negative
Modified from Jaffe et al. (1973)
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The most characteristic feature of ECs is the presence of numerous, uniform, 
infoldings of the cell membrane (60-70 nm in diameter) called plasmalemmal vesicles 
or pinocytic vesicles (Simionescu and Simionescu, 1983). In addition to the nucleus, 
ECs contain organelles such as rough endoplasmic reticulum, attached and free 
ribosomes, Golgi complexes, a few mitochondria, centrosphere regions with two 
centrioles, lysosomes, multivesicular bodies, and glycogen. Thin and thick filaments 
are found either in the junctional zone or on the abluminal cell membrane, whilst 
intermediate-sized filaments are found in the perinuclear region. Rod-shaped granules 
known as Weibel-Palade bodies are found in humans, murine and amphibian 
endothelial cells. They are 0.1 jum thick and 3 pm long and consist of several tubules 
approximately 15 nm thick embedded in a dense matrix. They are frequently used to 
identify isolated EC (reviewed by Simionescu and Simionescu, 1983).
ECs have been shown to possess a wide range of enzymes involved in oxidative 
phosphorylation, anaerobic glycolysis, and desulphation. Some of these such as 
nucleotidase, ATPase and phosphatase, are preferentially located in plasmalemmal 
vesicles (Simionescu and Simionescu, 1983).
ECs have a clearly definable “apical” or luminal surface in contact with the 
bloodstream and a “basal” or abluminal surface, which is in contact with subendothelial 
connective tissue and the ECM (Muller and Gimbrone, 1986). In addition, each has its 
own distinct collection of intrinsic proteins. The luminal EC surface is provided with a 
cell coat (approximately 10-30 nm thick) made up of a fixed layer and a mobile layer. 
The fixed layer comprises chiefly sialic acid but also the oligosaccharide moieties of 
the cell membrane glycoproteins and glycolipids (that might function as recognition 
sites for molecules to be transported by an active process across the endothelium) and 
glycosaminoglycans (heparan sulfate). The mobile layer of ECs is composed of 
adsorbed plasma proteins. One of them, a-2 macroglobulin, appears to protect the 
endothelium against proteolysis (Simionescu and Simionescu, 1983). The surface of the 
endothelium and those of the circulating blood cells possess a negative charge and 
therefore repel each other. Thus, the intact endothelium, because of its charge, 
metabolic activities, and molecular environment, is not attractive for blood cells and is 
non-thrombogenic. By contrast, the sub-endothelial structures, which include the basal 
lamina, collagen, (especially type I and III) and microfibrils, are highly attractive for 
blood cells and are consequently thrombogenic (Simionescu. and Simionescu, 1983).
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1.3.3 Endothelial cell heterogeneity
ECs from diverse tissues are heterogeneous with respect to their appearance, 
function, phenotype and protein expression. Variation in the appearance of the capillary 
endothelium from different vascular sites is thought to reflect differences in function. 
For example within continuous endothelium, which lines the brain and retina, ECs are 
connected by tight junctions that help to maintain the blood brain barrier. By contrast, 
discontinuous endothelium that lines the liver, spleen, and bone marrow sinusoids 
allows cellular trafficking between intercellular gaps. Fenestrated endothelium, which 
lines the intestinal villi, endocrine glands, and kidneys facilitates the selective 
permeability required for efficient absorption, secretion, and filtering (reviewed by 
Cines et al., 1998).
ECs from diverse tissues are heterogeneous also with respect to their surface 
phenotype. One of the clearest examples of EC heterogeneity is demonstrated in the 
expression of homing receptors involved in cell trafficking. In mice, the lung-specific 
EC adhesion molecule (Lu-ECAM-1) is expressed only by pulmonary postcapillary 
ECs and some splenic venules, whilst the mucosal addressin cell adhesion molecule-1 
(Mad-CAM-1) is predominantly expressed on endothelial venules in Peyer’s patches of 
the small intestine. Microvascular ECs derived from the bone marrow show a tendency 
to attach to megakaryocytes and CD34+ progenitor cells. These cells also constitutively 
secrete various stimulating factors such as granulocyte colony-stimulating factor (G- 
CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin- 6  
(IL-6 ) Kit-ligand, that play an important role in the trafficking, proliferation, and 
hematopoietic lineage-specific differentiation (reviewed by Cines et al., 1998). Kanda 
et al. (1997) reported that both the basal and tumor necrosis factor-a (TNFa)-induced 
expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1) differed markedly at both the protein and mRNA levels in 
cultured human aortic EC, vena cava EC and dermal microvascular EC.
There are suggestions that some common functional proteins might differ with 
type of EC. For example von Willebrand factor (vWF), the commonly used marker for 
ECs, is expressed irregularly on capillaries and tumor vessels (Belloni and Tessler, 
1990). In addition, in vivo only 3% of vascular ECs appear to express tissue 
plasminogen activator (tPA). Similarly, the expression of tissue factor (TF) after 
infusion of cytokines or endotoxin is restricted to specific types of vessel (Cines et al.,
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1998). EC derived from the internal mammary artery have been reported to synthesize 
more prostaglandin h  (PGI2) than those from the saphenous vein (Subramanian et al., 
1986).
Evidence suggests that EC heterogeneity develops, in part, as a result of 
variation in exposure to micro and macro-environmental stimuli (mechanical force, 
soluble growth promoters and inhibitors, cytokines, plasma lipids, plasma proteins, 
contact with tissue based cells) and in part as a result of tissue-specific molecular 
diversity.
Many human vascular diseases are often restricted to specific types of vessels. 
For example, the susceptibility of arteries and veins to atherosclerosis differs, as does 
the involvement of platelets in the pathogenesis of arterial and venous thrombosis. 
Vasculitis commonly shows a marked predilection for specific capillaries, arteries, or 
veins or for certain organs. There is marked regional variation in disease expression and 
clinical manifestations even though systemic risk factors are clearly evident. For 
example thrombosis is generally episodic and often localized to single vessels. The 
cause of these variations is unclear, but may partly be explained by the heterogeneity of 
the ECs themselves (reviewed by Cines et al., 1998).
1.3.4 Functional properties
ECs are at the interface between the blood and all other tissues. Apart from 
acting as a selective, permeable, barrier, ECs contribute to the regulation of vascular 
tone, coagulation, fibrinolysis, and have a role in the immune response (Cines et al., 
1998; Dicorleto and Gimbrone, 1996; Gerritsen, 1996).
1.3.4.1 Barrier functions
ECs play a vital role in regulating the exchange of solutes and water between 
the blood and the tissues. Water and small lipid-soluble substances (oxygen, nitrogen, 
and carbon dioxide) can directly diffuse though the cell surface, while large water- 
insoluble lipid molecules are thought to permeate laterally within the lipid bilayer.
Small solutes (amino acids, glucose), anions (Cf, HCO3 '), and cations (Na+, K+) pass 
though intercellular junctions. The mechanisms by which large macromolecules
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traverse ECs are unknown but may be by passage through large pores or via 
plasmalemmal vesicles (reviewed by Gerritsen, 1996)
Additional transport pathways become available in response to tissue injury or 
inflammation. The mechanisms behind this increase in permeability are complex and 
also vary between different vascular beds. Similar to those seen in fenestrated 
endothelium ECs in pericytic venules can contract, opening micron-wide gaps and 
facilitate the extravasation of plasma proteins, up to 50-times. In general, much of the 
leakage is localized to these venular gaps. Nevertheless, increased extravasation can 
occur in the absence of visible gaps, and the augmented permeability persists long after 
closure of the gaps. A change in the number and diameter of the fenestrae may also 
contribute to increase permeability in the fenestrated vascular beds. In addition, a 
number of vasoactive mediators directly increase permeability, including reactive 
oxygen species (ROS), leukotrienes (LTs), bradykinin (BK), histamine, and platelet 
activating factor (PAF). Prostaglandins (PGs) have no direct effect on EC permeability 
but augment the effect of other agents by increasing the blood flow. Cytokines (IL-1, 
IL-2, and TNFa) and endotoxins also increase vascular permeability through multiple 
mechanisms that include cytoskeletal rearrangements and increased production of 
vasoactive mediators (Gerritsen, 1996).
1.3.4.2 Vasoregulatory functions
In addition to functioning as a structural barrier between the circulation and the 
surrounding tissues, ECs secrete mediators that influence vascular hemodynamics. The 
major vasoregulatory molecules secreted by ECs are presented in Table 1.4. By 
releasing vasodilatory substances such as NO and prostacyclin (PGI2), as well as 
vasoconstrictors, (e.g. endothelins (ETs) and PAF), ECs contribute to the regulation of 
the blood pressure and blood flow. These chemically distinct compounds are not stored 
in intracellular granules and their biologic effects are regulated at multiple levels such 
as localization of specific receptors on vascular cells, rapid metabolism, or gene 
transcription (Cines et al., 1998).
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Table 1.4 Vasoregulatory substances produced by the endothelium
Substance Principal Effect Other Effects Secretion Compound Precursor
NO Vasodilatation
(Nitric oxide)
Maintains 
basal tone 
of vessels; 
inhibits 
platelets, 
leukocytes, 
and smooth 
muscle
Paracrine/ 
Constitutive 
and induced 
by various 
molecules
Hetero - L-arginine
diatomic
free radical
PGI2 Vasodilatation
(Prostacyclin)
Retards 
platelet 
aggregation 
and deposi­
tion
Paracrine/ 
Induced 
at site of 
vascular 
perturbation
Eicosanoid Arachidonic 
acid
EDHF Vasodilatation Hyper- 
(Endothelium- polarization
dependent of vascular
hyperpol arizing smooth
factor) muscle
Paracrine/
Induced
Unknown Unknown
PAF
(Platelet-
activating
factor)
Vaso­
constriction
Promotes
leukocyte
adhesion
Juxtacrine/ Phospho- Arachidonic 
Induced lipid acid
ET-1
(Endo-
thelin-1)
Vaso­
constriction
Mitogen for 
smooth 
muscle cells
Paracrine/ 
Induced by 
hypoxia, shear 
stress & ischemia
21 Amino 
acid
Prepro-
endothelin-1
Modified from Cines et al. (1998)
ECs constitutively produce NO, however its production can be modified by a 
number of exogenous chemical and physical stimuli. Other mediators such as PGI2 , ET 
and PAF, are usually synthesized in response to environmental changes (Cines et a l, 
1998).
EC production of NO (a heterodiatomic free radical product generated through 
the oxidation of L-arginine to L-citrulline) is mediated by eNOS (Stamler et al. 1992). 
Shear stress, cyclic strain, thrombin, adenosine 5’-  diphosphate (ADP), BK, substance 
P (SP), and muscarinic agonists, all stimulate eNOS to produce NO (reviewed by Cines 
et a l, 1998). NO maintains basal vascular tone by relaxing vascular smooth muscle 
cells (Loscalzo et a l,  1997), and inhibits adherence and aggregation of platelets 
(Cohen, 1991), leukocyte adhesion (Kubes et a l, 1991; Bath et a l, 1991), and smooth 
muscle cell proliferation (Scott-Burden et a l, 1993). The synthesis, mechanism of 
action and metabolism of NO will be discussed in detail later (Section 1.4).
In resting human ECs, PGI2 (prostacyclin) is neither constitutively present, nor 
stored within the cell. Its synthesis is induced rapidly by humoral and mechanical 
stimuli through distinct pathways. PGI2 acts in a paracrine fashion, is rapidly released 
from ECs and has a relative short half-life. Receptors for PGI2 are present on vascular 
smooth muscle cells, platelets and on the arterial wall. Although PGI2 does not appear 
to regulate basal systemic vascular tone, it may regulate vasoconstriction and platelet 
deposition (reviewed by Cines et a l, 1998).
EDHF (Endothelium-dependent hyperpolarizing factor) was initially described 
in guinea pig mesenteric arteries as an endothelium-dependent, membrane- 
hyperpolarizing factor elicited by acetylcholine (ACh; Bolton et a l 1984) and later was 
described in a number of isolated artery and vein preparations (Nagao et a l, 1991). 
However, the exact chemical nature of EDHF is unknown. In some blood vessels, 
epoxyeicosatrienoic acid (EETs), formed from arachidonic acid by the action of 
cyctochrome P450 may correspond to EDHF. Increased movement of potassium ions 
mediates the hyperpolarization of smooth muscles induced by EDHF. The involvement 
of hyperpolarization to endothelium-dependent relaxation varies with the size of the 
arteries and is prominent in the resistant vessels. In large arteries although both NO and 
EDHF can contribute to endothelium-dependent relaxation, but under normal 
circumstances the role of NO predominates. However, in these arteries, EDHF can 
mediate near-normal endothelium-dependent relaxation when the synthesis of NO is 
inhibited (reviewed by Vanhoutte, 1999).
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PAF (Platelet-activating factor) is synthesized by stimulated ECs in vitro and in 
vivo. The chemical nature of PAF is phospholipid and it acts in a juxtacrine fashion. 
Initially identified as the factor that stimulates platelet activation and aggregation, it 
was later shown to be a potent vasoactive agent as well as an activator of neutrophils. It 
is not constitutively synthesized by ECs but synthesis occurs following stimulation with 
thrombin, BK, histamine, adenosine triphosphate (ATP), leukotriene C4 (LTC4), LTD4 , 
oxidants and bacteria and inhibited by PGI2 (Gerritsen, 1996; Cines et al., 1998).
ETs (Endothelins) are produced by many cell types and include a family of 21- 
amino acid peptides. ET-1 is the most potent vasoconstrictor identified to date. It is 
found primarily in endothelium, whereas ET-2 and ET-3 are present in non-vascular 
tissues. ET-1 is not stored in secretory granules within ECs (reviewed by Levin, 1995). 
A number of stimuli can stimulate ET-1 production, including shear stress, calcium 
ionophores IL-1, transforming growth factor-p (TGFP), vasopressin, thrombin, and 
hypoxia (Gerritsen, 1996). All ETs binds to two types of receptors on mammalian cells, 
ET-A and ET-B. The former primarily mediates the vasoconstricting effect ET-1 on 
vascular smooth muscle cells. The ligation of ET-B on ECs by ET-1 increases the 
release of NO and PGI2 from these cells (reviewed by Levin, 1995).
Angiotensin converting enzyme (ACE) exists predominantly as an ecto-enzyme 
of vascular endothelial cells and plays an important role in vascular homeostasis. It is 
involved in the renin-angiotesin and kalikrein-kinin system through its ability to 
mediate the conversion of angiotensin I (Al) into angiotensin II (All) and to inactivate 
bradykinin (BK). All and BK have opposite effects on vascular tone and on vascular 
smooth muscle cell proliferation (Cambien and Soubrier, 1995). One is a 
vasoconstrictor (All), the other a vasodilator (BK). ACE exists in the plasma 
(circulating hormone), in the interstitium (tissue) or intracellularly (Chai and Johnston,
1995). The circulating form of ACE is found at relatively high concentrations (10 ' 9 M) 
but the membrane-bound form is thought to be more important in regulating blood 
pressure (reviewed by Gerritsen, 1996). Several agents, such as cyclic adenosine 
monophosphate (cAMP), methyl-xanthines, the calcium ionophore A23187, 
glucocorticoid hormones and thyroid hormone have been shown to induce secretion of 
ACE from cultured ECs (Chai and Johnston, 1995).
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1.3.4.3 Coagulatory functions
Another important physiologic function of the endothelium is to facilitate blood 
flow by maintaining an anti-thrombotic surface that inhibits platelet adhesion and 
clotting. However, when the endothelium is perturbed by physical forces or by specific 
chemical factors, EC undergo changes that cause their transformation to a pro- 
thrombotic surface (Cines et al., 1998). The pro- and anti-coagulatory effects of ECs 
are summarized in Table 1.5.
The induction of tissue factor (TF) is the pivotal step in transforming the 
endothelium from an anticoagulant to a procoagulant surface. TF is a protein embedded 
in the phospholipid bilayer. Normal ECs express little or no TF activity (Gerritsen,
1996). Perturbation of ECs by thrombin, cytokines, shear stress, hypoxia, endotoxin or 
oxidized LDL results in an induction of TF (Rapaport and Rao, 1995; Nemerson,
1995). However, recently, the classical view that thrombus formation occurs at a site 
of injury because of a focus provided by the cell surface-bound TF has been brought 
into question by the observation that TF is also found circulating in the blood and has 
the potential to initiate thrombosis (Giesen and Nemerson, 2000; Rauch and Nemerson, 
2000). ECs are one potential source of soluble circulating TF levels of which have been 
reported to be raised in patients with acute myocardial infarction and unstable angina 
(Suefuji et al., 1997; Misumi et al., 1998).
Thrombin is a serine protease generated from prothrombin by coagulation factor 
Xa. The balance between the natural anti-thrombotic and the induced procoagulant 
activities of the endothelium is critically controlled by the generation of thrombin. ECs 
control thrombin generation by expressing thrombomodulin and tissue factor pathway 
inhibitor-1 (TFPI-1), facilitating the activity of the anticoagulant protein C and 
synthesizing its co- factor protein S, and by providing the matrix containing heparan 
sulfate and related glycosaminoglycans that promote the activity of cell/matrix 
associated antithrombin III (AT-III) (reviewed by Gerritsen, 1996; Cines et al., 1998).
TFPI-1 is the principal, endogenous inhibitor, of the TF pathway in vivo (Kato, 
2002). The major pool of TFPI-1 is constitutively expressed by ECs (Bajaj et al., 2001). 
TFPI-1 is not only EC-surface bound but a substantial amount is also secreted in the 
blood (Blann et a l, 2000). The soluble form of TFPI-1 directly inhibits factor Xa,
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Table 1.5 Regulation of hemostasis and thrombosis by the endothelium
Antithrombotic
Thrombomodulin 
Antithrombin III (AT-III)
Tissue factor pathway inhibitor (TFPI) 
Protein C
Heparan sulfate/Glycosamioglycans
Anti-platelet activities
Prostaglandins (PGI2 , PGE2) 
Nitric oxide (NO) 
13-Hydroxyoctadeanoic acid
Fibrinolytic activities
Tissue plasminogen activator (t-PA) 
Urokinase (uPA)
Prothrombotic
Tissue factor (TF) 
Thromobospondin (TSP) 
von Willebrand factor(vWF) 
Factor V
Receptors for factor IX, X
Platelet-activating activities
Platelet activating factor (PAF) 
von Willebrand factor (vWF) 
Subendothelial matrix
Anti-fibrinolytic activities
Plasminogen activator inhibitor-1 
(PAI-1)
Protease nexin
Modified from Cines et a l (1998) and Gerritsen (1996)
whereas surface-bound TFPI-1 on ECs inhibits the TF-factor Vila complex in 
conjunction with factor Xa by translocation into caveolae (Lupu et al., 1997; Ott et al., 
2002). Heparin, endotoxin, thrombin and IL-1B appear to increase the synthesis or 
release TFPI-1 from ECs (Kato, 2002). It has been reported that TFPI-1-deficient mice 
were more prone to atherosclerosis and the occurrence of thrombosis after plaque injury 
was more rapid than that seen in control animals (Westrick et al., 2001). In in vitro cell 
cultures and various animal models, recombinant TFPI-1 has been shown to prevent 
thrombosis and restenosis after arterial injury (Kato, 2002).
In addition, ECs synthesize Factor V, vWF, thromobospondin (TSP) and PAF, 
and express receptors for the coagulation factors IX, IXa, X, and Xa, all o f which may 
play a pro-coagulatory and platelet activating role when there is a shift in the 
antithrombotic equilibrium of ECs (Gerritsen, 1996, Cines et al., 1998).
1.3.4.4 Fibrinolytic functions
Two main structural elements, platelets and a cross-linked fibrin matrix form 
the temporary hemostatic plug to prevent blood loss at a site of vessel injury. This plug 
also contains other large fibrous proteins, such as fibronectin, and provides a scaffold 
for cells to invade the wound and rebuild the tissue. The timing of fibrin matrix 
dissolution must balance with that for the restoration of normal intact tissue. If 
dissolution is too rapid, vascular leakage and bleeding occurs; if too slow, scar tissue is 
formed and may result in the obstruction of a vessel (Lijnen and Collen, 1989;
Gerritsen, 1996). The roles of ECs in fibrinolysis are presented in Table 1.5.
The protease plasmin mediates the lysis of fibrin, which is cleaved by 
plasminogen activators (PAs) from the zymogen, plasminogen. ECs synthesize two 
forms of PA, tissue type (tPA) and urokinase (uPA). Both tPA and uPA are highly 
specific for serine and cleave plasminogen at the same peptide bond (reviewed by 
Gerritsen, 1996). Plasma fibrinolysis is strictly dependent on t-PA (Wun and Capuano, 
1985), whereas u-PA may be primarily involved in the tissue-remodeling process 
(Dano et al., 1985; Van Hinsbergh et al., 1991). t-PA is synthesized mainly in vascular 
ECs and is secreted into the plasma continuously. (Kristensen et al. 1984). Various 
compounds such as histamine, thrombin, retinoids, hemodynamic/oxidative stress,
ACh, SP and smoking can stimulate the constitutive production o f t-PA (Gris et al., 
1991; Kooistra et al., 1994; van Hinsbergh et al., 1998; Newby et al., 1999).
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The activities of the PAs are controlled by potent inhibitors. The predominant 
regulators of t-PA and u-PA are plasminogen activator inhibitor-1 (PAI-1) and -2 (PAI- 
2). PAI-1 is the main, if not the sole, inhibitor of PAs. PAI-1 is synthesized by ECs, 
vascular smooth muscle cells, platelets, and hepatocytes (Van Hinsbergh et a l, 1998). 
Its production is induced by thrombin, histamine, BK, and shear stress, which also 
induce the production of t-PA. Interestingly, IL-1, TNFa and oxidized-LDL reduce t- 
PA expression while increasing PAI-1 expression in culture (reviewed by Gerritsen, 
1996; Kooistra et a l, 1994). Elevated, antigenic levels of t-PA and PAI-1 appear to 
show a negative correlation with t-PA activity and it has been suggested that this 
condition is associated with cardiovascular disease (Kluft, 1994).
1.3.4.5 Immunological functions
Vascular ECs have two key roles in the development of cell-mediated immunity 
(CMI) namely, the presentation of antigen to T cells and the recruitment of 
inflammatory cells to sites of infection or tissue damage (Cines et a l,  1998).
Typically, antigen presenting cells in the tissues include resident macrophages 
and dendritic cells. However, in vitro, cultured human ECs from various vascular beds 
when treated with IFN-y can express MHC class II molecules, allowing them to act as 
antigen presenting cells. In vivo, microvascular ECs have been shown to constitutively 
express both Class I and Class II MHC molecules, this expression being upregulated by 
exposure to cytokines.
In order to stimulate T cells, they must not only have antigen presented to them 
but must also receive co-stimulatory signals. This is usually achieved through CD80 
and CD8 6  (and their respective ligands). However, human ECs primarily provide 
costimulation to T cells through CD58 (reviewed by Cines et a l, 1998).
Once activated, memory T cells in turn activate a variety of EC functions contributing 
to the recruitment of inflammatory cells. These functions include production of 
chemicals that cause vasodilation (and therefore enhance the recruitment of leukocytes 
to the tissues), expression of adhesion molecules that tether and bind circulating 
leukocytes and synthesis of chemokines that contribute to their transendothelial 
migration. Over time the expression of various adhesion molecules on the endothelial 
surface changes. Initially, recruitment of neutrophils is favored, and at a later time other 
leukocytes are recruited. Interestingly, in atherosclerosis the early infiltrate tends to be
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monocyte-rich. Once infiltration develops, a cytokine-rich milieu is generated and 
sustained until the antigen is eliminated. Sustained CMI reactions give rise to 
angiogenesis and tissue remodeling (reviewed by Cines et a l, 1998).
1.3.4.6 Synthesis of cytokines and growth factors
ECs are a rich source of various cytokines, growth factors, and growth 
inhibitors that not only act locally but also act within a given segment of the circulatory 
tree. Therefore, these molecules influence the behavior of adjacent vascular cells and 
interacting blood elements (Dicorleto and Gimbrone, 1996). A list of cytokines and 
growth factors produced by ECs is presented in Table 1.6.
Interleukin-1 (IL-1), which is produced by the endothelium as well as other 
inflammatory cells, has a profound affect on vascular ECs. Its production is induced by 
lipopolysaccharide (LPS), TNFa, and IL-1 itself. In conjunction with TNFa, IL-1 
facilitates thrombus formation by inducing procoagulant activity, inhibiting the 
thrombomodulin/protein C anticoagulant pathway and blocking fibrin dissolution via 
stimulation of PAI-1. IL-1 and TNFa also augment production of PGL, NO and PAF 
by ECs (Mantovani et al., 1998).
Interleukin- 6  (IL-6 ) is produced in very high levels by ECs. Spontaneous 
production of IL- 6  by ECs is unpredictable. Its production can be markedly augmented 
by exposure to IL-1, TNFa, and LPS (Mantovani et a l, 1998). IL- 6  demonstrates a 
wide-range of biological activities, including the stimulation of acute-phase protein 
production by hepatocytes, modulation of T cell activation and promotion of B cells 
differentiation leading to immunoglobulin synthesis (reviewed by Gerritsen, 1996).
Interleukin- 8  (IL-8 ) is a potent neutrophil chemoattractant and activator. The 
endothelial expression of IL- 8  is markedly upregulated by IL-1, TNFa, and LPS 
(Gerritsen, 1996). The influence of IL- 8  on the interaction of polymorphonuclear cells 
with vascular ECs has been the subject of conflicting observations. IL- 8  increases the 
adhesiveness of PMNs for normal EC (Carveth et a l, 1989). By contrast, it has been 
reported to inhibit the binding of PMNs to activated EC (Gimbrone et a l, 1989).
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Table 1.6 Endothelial cell derived cytokines and growth factors
Cytokines Growth factors
Interleukin-1 (IL-1) Platelet-derived growth factor (PDGF)
Interleukin- 6  (IL-6 ) Insulin-like growth factor (IGF-1)
Interleukin- 8  (IL-8 ) Basic fibroblast growth factor (bFGF)
Monocyte chemotctic protein -1 Transforming growth factor beta
(MCP-1) (TGF-p)
Granulocyte- Macrophage colony Heparin-binding EGF-like
stimulating factor (GM-CSF) growth factor
Granulocyte colony stimulating
factor (G-CSF)
Modified from Dicorleto and Gimbrone (1996)
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ECs produce a substantial amount of monocyte chemotectic protein -1 (MCP- 
1), which is thought to be an important mediator of monocyte and T lymphocyte 
migration in a wide variety of inflammatory diseases including atherosclerosis, delayed 
hypersensitive reactions, rheumatoid arthritis, alveolitis and idiopathic pulmonary 
fibrosis. MCP-1 production by EC cells is induced by IL-1, TNFa, LPS, and modified 
LDL (reviewed by Mantovani et a l, 1998).
ECs are also an important source of colony stimulating factors (CSFs) and 
hematopoietic factors, their production being stimulated by various pro-inflammatory 
molecules such as, IL-1, TNFa, LPS and modified LDL (reviewed Mantovani et al., 
1998).
1.3.5 Endothelial cell and leukocyte interaction
Regulation of cell trafficking is also an important role of ECs. During the 
inflammatory process, leukocytes interact with ECs through a multi-step process i.e.
(1) initial formation of a reversible attachment; (2) activation of the attached cells; (3) 
development of firm, shear-resistant adhesion; and (4) spreading and emigration (Cines 
et a l, 1998). These steps are orchestrated by cell surface-molecules expressed by both 
ECs and leukocytes. The surface molecules involved in leukocyte interactions can be 
divided in to two groups: ( 1 ) the selectins and (2 ) those belonging to the 
immunoglobulin supergene family. Important EC adhesion molecules are presented in 
Table 1.7. The earliest visible adhesive event between ECs is rolling of leukocytes on 
the ECs. Initial tethering and rolling is usually mediated by the members of the selectin 
family. However, firm and shear-resistant adhesion is achieved by the immunoglobulin 
supergene family group of receptors (Gerritsen, 1996, Cines et a l, 1998).
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Tablel.7 Adhesion molecules expressed by endothelial cells
Family Ligand Stimulus Leukocyte population binding
E-selectin Selectins Sialyted 
Lewis X
IL-1, TNF 
LPS
Neutrophils, monocytes, 
memory T cells, eosinophils, 
basophils
P-selectin Selectins Sialyted 
Lewis X 
CD15
Thrombin, Neutrophils, monocytes 
histamine,
h 2o 2,
complements
Intercellular 
adhesion 
molecule- 1 
(ICAM-1)
Immuno­
globulin 
super gene
CDlla/CD18 IL-1, TNF 
LPS, INF-y
All
Vascular cell 
adhesion 
molecule- 1 
(VCAM-1)
Immuno­
globulin 
super gene
Very late 
antigen 4 
(VLA4)
IL-1, TNF 
LPS, IL-4
Lymphocytes, monocytes, 
eosinophils, basophils
Platelet- 
endothelial 
cell adhesion 
molecule- 1 
(PECAM-1)
Immuno­
globulin 
super gene
CD31 Unknown Neutrophils, lymphocytes
Modified from Gerritsen (1996)
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1.3.6 Smoking and endothelial dysfunction
Direct evidence that cigarette smoking could result in endothelial injury was 
first obtained from morphological observations on umbilical arteries from smoking 
mothers. Damage was suggested by an irregular appearance of the endothelium and by 
the formation of blebs or microvillous-like projections of the cell membrane. Evidence 
continues to accumulate that cigarette smoke can alter the vascular endothelium not 
only morphologically, but also functionally (Pittilo, 2000).
The majority of existing scientific data suggest that cigarette smoke alters EC 
function by primarily affecting NO production and metabolism, which causes 
atherosclerotic change in the vessel wall, vasoconstriction, and thrombosis (Node et al., 
1997; Powell, 1998; Pittilo, 2000). However, the precise mechanism of cigarette 
smoke-mediated endothelial dysfunction and the alteration of NO biology is unclear 
and existing data are often contradictory. The effect of cigarette smoke on EC-mediated 
NO synthesis, production and metabolism will be discussed in detail later (Section 
1.4.4).
PGI2 , one of the vasodilatory and antithrombogenic molecules secreted by ECs, 
is also affected by cigarette smoking. Pittilo et al. (1982) reported that aortas from rats 
exposed to smoke showed a reduction in PGI2 production in vitro. Similarly, Reinders 
et al. (1986) showed that incubation of cultured human ECs with cigarette smoke 
condensate (CSC) impaired the basal and stimulated production of PGI2 . These authors 
suggested that CSC exerts its inhibitory properties on the level of arachidonate 
mobilization from cellular phospholipid, rather than on cyclooxygenase or 
prostaglandin synthetase. On the other hand, Boutherin-Falson and Blaes (1990) 
reported that incubation of nicotine with HUVECs resulted a dose-dependent increase 
in the basal level of PGI2 . However, at higher doses, nicotine appears to decrease the 
production obtained by thrombin stimulation. They also reported that nicotine 
stimulated EC growth with a maximal effect at 0.05 pg/ml.
The effects of smoking on EC-derived vasoconstrictive factors like ET-1 and 
ACE have been reported. Haak et al. (1994) showed that serum ET-1 is elevated after 
smoking. Similarly, Goerre et al. (1995) showed that smokers had significantly higher 
plasma ET-1 levels within the first ten minutes of smoking, which declined with time. 
Nicotine alone had no effect on plasma ET-1. Adechi et al. (2000) reported that in rats 
acute but not chronic cigarette exposure increased the expression of ET-1 mRNA in
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their cardiovascular tissues. Regarding the effect of smoking on ACE, Haboubi et al. 
(1986) and Nimiomiya et al. (1987) reported serum ACE was lower in smokers. The 
latter authors also noted that smokers who stopped smoking more than 1 0  years 
previously had similar serum ACE levels to non-smokers. Mizuno et a l (1982) showed 
that acute smoking caused a larger, rapid, increase in serum ACE in non-smokers than 
in habitual smokers. On the other hand, Noronha-Dutra et al. (1993) showed that 
HUVECs on incubation with post-smoking plasma released more ACE than those 
incubated with control plasma. It is also well documented that ACE inhibitors improve 
both venous (Chalon et al. 1999) and coronary (Schlaifer et al. 1999) vasodilatory 
functions in smokers.
Data concerning the effect of smoking on TF and TFPI-1 expression or levels 
are limited. Matetzky et al. (2000) have shown that smoking is associated with 
increased TF expression in atherosclerotic plaques from human carotid and aortic root 
plaques from apoE -/- mice. On the other hand, Blann et al. (2000) reported no 
significant difference in soluble TF or TFPI-1 between smokers and non-smokers either 
in controls or in subjects with peripheral arterial disease.
Evidence concerning the influence of smoking on fibrinolytic function has been 
contradictory. Allen et al. (1985) reported that chronic smokers have a lower baseline 
and stimulated t-PA activity but have no significant difference in fibrinolytic inhibitors. 
Allen et al. (1984) found acute smoking increases the baseline t-PA activity level. 
Similarly, Gris et al. (1991) showed chronic smokers had impaired t-PA release after 
venous occlusion with no difference between smokers and non-smokers in baseline t- 
PA and PAI-1 antigen. Simpson et al. (1997) reported that plasma PAI-1 antigen and 
activity was higher in smokers but plasma t-PA antigen expression was the same in 
former smoker and non-smokers. On the other hand, Newby et al. (1999) reported 
plasma t-PA antigen was higher in smokers with markedly impaired capacity of the 
endothelium to release t-PA acutely. They found no significant difference in plasma 
PAI-1 antigen and activity between smokers and non-smokers. Eliasson et al. (1995) 
studied a randomly selected population sample consisting of 604 men and 662 females 
and found no relationship between t-PA and PAI-1 activity and tobacco use. A similar 
finding was also reported by Enderle et al. (2000).
Cigarette smoking is associated with increased monocyte-endothelial cell 
adhesion in humans (Dovgan et al. 1994; Adams et al. 1997). This may be due to an 
effect of smoking on the adhesion molecules of ECs. Shen et al. (1996) have shown
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that CSC induced increased surface expression of ICAM-1, VCAM-land PEC AM-1 on 
HUVECs. They also showed that it is associated with an increase in binding activity of 
nuclear factor-kappa beta (NF-kP) to the consensus motif common to the cell adhesion 
molecules’ genes. Furthermore, they reported that CSC increased the transendothelial 
migration of monocytes across a monolayer of HUVECs by 200%.
1.4 Nitric oxide
The gas NO, once was considered merely to be an atmospheric pollutant 
(Moncada and Higgs, 1993). It is reported to have been prepared first in 1620 by the 
Belgian scientist, Jan Baptist van Helmont. In the 1660s, both Robert Boyle and Robert 
Hook independently generated NO by heating potassium nitrate with glowing charcoal 
in the absence of air. Later in 1772, Joseph Priestley characterized the chemical 
properties of this gas (Moncada, 1996).
In 1980, Furchgott and Zawadzki demonstrated that isolated blood vessels 
would only relax after exposure to some vasodilators if vascular endothelium were 
present. Furthermore, they showed that this phenomenon was dependent on the release 
of a labile substance, which they named endothelium derived relaxing factor (EDRF; 
Cherry et al., 1983). The role of NO in cardiovascular biology was defined when 
Ignarro et al. (1987) using bovine pulmonary vessels, and Palmer et al. (1987) using 
cultured porcine aortic endothelial cells, identified EDRF as NO.
1.4.1 Synthesis o f  nitric oxide
NOS generates NO by catalyzing the O2- and reduced nicotinamide adenine 
dinucleotide phosphate,(NADPH)-dependent oxidation of guanidino nitrogen on the 
amino acid L-arginine. NOS is stereospecific for the L-isomer. The other by-product 
formed in this reaction is citrulline. Citrulline has a 1:1 stoichiometric ratio with NO in 
this reaction (Fukuto and Mayer, 1997). In the reaction, the substrate L-arginine 
undergoes an overall five-electron oxidation in conversion to citrulline and NO with 
NG-hydroxy-L-arginine (L-NHA) as an intermediate (Ludwig and Marietta, 1999).
NOS requires several cofactors and prosthetic groups for activity: thiolate-bound heme, 
tetrahydrobiopterin (BH4), flavin adenine dinucleotide (FAD), flavin adenine
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mononucleotide (FMN). Some isoforms also require calmodulin (CaM) and calcium 
(Ca2+; Gorren and Mayer, 1997). The reaction catalyzed by NOS is shown in Fig. 1.1B.
Measurements of free NO in human plasma have revealed a steady state 
concentration of approximately 3nM (Stamler, et a l, 1992). The total daily production 
o f NO by endothelial NOS was calculated to be about 1728 pmol per person (Kelm and 
Yoshida, 1996).
1.4.1.1 Nitric oxide synthase
There are three distinct isoforms of NOS, the neuronal (nNOS), endothelial 
(eNOS), and inducible (iNOS). Each isomer functions as a dimer, in which each 
monomer consists of two discrete domains, a C-terminal reductase domain (that shows 
extensive amino acid homology with cytochrome P-450 reductase) and an N-terminal 
oxygenase domain, which are joined by a short CaM-binding domain (intermediate 
domain; reviewed by Ludwig and Marietta, 1999). A schematic representation of NOS 
is shown in Fig. 1.1.A.
The reductase domain contains two flavin moieties, one FAD and one FMN. 
FAD is believed to be the primary acceptor for electrons from NADPH, while FMN 
transfers the electrons from FAD to the heme site in the oxygenase domain. The heme 
pocket in the oxygenase domain, is the site where L-arginine and O2 are bound and 
where the catalysis takes place. The intermediate domain, which binds CaM is thought 
to convey conformational change that is necessary for internal electron transfer. The 
role of BH4 is less clear. It binds to the oxygenase domain. It is thought to be a 
dissociable electron carrier. It stimulates dimerization of NOS and enhances the affinity 
of the enzyme for L-arginine. NOS is only active as a dimer. Most data suggest that 
functionally intact NOS dimers contain two equivalents of each cofactor, with the 
exception of BH4 (for which only one equivalent per two equivalents of heme is found). 
Catalytically, the different isoforms may be distinguished on the basis o f their calcium 
dependance. eNOS and nNOS require Ca2+ for activity, whereas calmodulin binding to 
iNOS is so tight that addition of Ca2+ is not necessary (reviewed by Gorren and Mayer,
1997).
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(A) NOS homodimer
NADPH
OXYGENASE DOMAIN
REDUCTASE
DOMAIN
Arg ArgCaM CaM
NOS catalyzed reaction(B)
OH
NH2+ 2e NH+ e O
/ /  / /  / /
R C ---------------  >  R“  C ---------------  >  R ~  C + NO
\  \  /  \  \  
n h 2 o 2 h 2o  n h 2 o 2 h 2o  n h 2
L-Arginine NG-Hydroxy-L-arginine L-Citrulline + Nitric
oxide
Figure 1.1. (A) Schematic representation of the NOS homodimer 
(B) Summary of NOS catalyzed reaction.
Figure A is a schematic representation o f the NOS homodimer. The three 
domains that are common to all isoforms, the cofactor and substrate-binding 
sites, and the presumed electron pathway through the enzyme are indicated.
Figure B summarizes the reaction catalyzed by NOS. In the first step L-arginine 
is hydroxylated to form L-NHA and in the second step L-NHA is converted to 
citrulline and NO (modified from Gorren and Mayer, 1997)
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eNOS was characterized originally as “constitutive”, being stably expressed in 
its characteristic tissues. Numerous subsequent reports have documented that 
transcription of the eNOS gene is regulated in a variety of physiological and 
pathological conditions. The eNOS gene is located on human chromosome 7 and 
contains 26 exons and spans 22 kilobases. The putative promoter region of the eNOS 
gene contains a consensus sequence for a wide variety of transacting factors including 
NF-k(3, IL-6 , AP-1 and (reviewed by Downey and Michel, 1999). eNOS is largely 
membrane bound (Pollock et al., 1991) and localized to small invaginations of the 
plasma membrane called caveolae where it is associated with a protein named caveolin- 
1 (reviewed by Downey and Michel, 1999). The binding of eNOS to caveolin-1 both 
facilitates targeting of the enzyme to caveolae and dynamically regulates e-NOS 
activity. The direct association of caveolin-1 with eNOS markedly attenuates enzyme 
activity. This inhibitory interaction is reversed by Ca2+-CaM (Michel et a l, 1997). The 
eNOS is unique among the NOS isoforms, being dually acylated by myristate and 
palmitate. It is thought that dually acylated eNOS is targeted to caveolae where it is 
inhibited tonically by its association with caveolin-1 in resting cells. Activation of 
upstream signals result in an increase in Ca2+, which promotes the binding of Ca2+-CaM 
to eNOS, thereby displacing caveolin-1 and causing the production of NO. After 
prolonged agonist stimulation, eNOS translocation to the intracellular compartment 
coincides with its depalmitolyation. Finally, the enzyme becomes repalmitolyated and 
associates once again with caveolin-1 , returning to caveolae to await another round of 
agonist activation (reviewed by Downey and Michel, 1999).
1.4.2 Metabolic fa te  o f  nitric oxide
The metabolism of NO in a biological environment is complex and depends on 
the impact of various parameters such as pH, p0 2 , concentration of O2', presence of 
other ‘traps’ (such as hemoglobin) or the distance traveled by NO from the source of 
generation to its metabolic target (reviewed by Kelm and Yoshida, 1996). A 
diagrammatic sketch of NO metabolism in human blood is shown in Fig. 1.2.
In vitro (in aqueous solution), NO is partially oxidized to nitrogen dioxide 
(NO2). This rapidly combines with NO to form dinitrogen trioxide (N2O3), which then 
hydrolyzed to nitrite (N0 2 -)- In an aqueous solution equilibrated with air, the in vitro 
half-life of NO was determined to be 5.6 seconds (s). The biological half-life of NO in
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aqueous solutions appears to be even shorter. At a pC>2 of 700 mmHg the in vitro half- 
life o f NO drops to 3.8s. This suggests that the production of NO via NOS not only 
depends on the presence of molecular O2 but also is greatly dependent on p0 2  
(reviewed by Kelm and Yoshida, 1996). Mammalian cells constitutively produce ROS, 
such as H2O2 and 0 2 *. NO and O2* are free radicals. When exposed to each other, they 
undergo a radical-radical reaction that is three times faster than the reaction rate for 
superoxide dismutase (SOD). Thus, in a compartment in which both NO and SOD 
exist, there may be a propensity for O2 ' to react with NO rather than SOD, depending 
on the relative concentrations of NO and SOD (Harrison, 1997). NO reacts with O2’ to 
form peroxynitrite (ONOO'), which decays rapidly once protonated (Blough et al., 
1985). So the half-life of NO and the ratio of the final NO metabolites in aqueous 
solutions, namely NO2 ' and nitrate (NO3') depends on ambient conditions, including the 
type and amount of ROS produced, the p0 2 ,pH, redox state and thiol concentration 
(Kelm and Yoshida, 1996).
During its passage through the heart, the half-life of NO dissolved in saline . 
solution perfusing the coronary circulation of isolated hearts was in the range of 1 0 0  
milliseconds (ms) (Kelm and Schrader, 1990). Thus, in the intact coronary circulation, 
NO degradation is more than 30 times faster than the degradation under in vitro 
conditions. The shorter biological half-life of NO in vivo, may be due to (1) a 
mechanism that rapidly metabolizes NO to vasoinactive NO2 ' located within the vessel 
wall or heart, at least in the coronary circulation; (2 ) the fact that the action of the NO 
produced is most likely confined to the vicinity of its production site, i.e. it exerts 
autocrine or paracrine effects; and (3) the effective concentration of NO in vivo may be 
controlled by both its rate of formation and its rate of degradation (reviewed by Kelm 
and Yoshida, 1996).
The half-life of NO in blood has been estimated to be as short as 0.46 ms 
(Borland, 1991). In brief, the metabolic pathway of NO in human blood is that NO 
released by ECs rapidly diffuses into either vascular smooth muscle or plasma, where it 
is converted to NO2 ' and S-nitrosothiol (R-SNO). After a short lag period, NO2 ’ 
becomes oxidized by oxyhemoglobin (Hb0 2 ) in the erythrocytes and is excreted in the 
urine as NO3 '. In addition, NO may enter the erythrocyte directly and, via interaction 
with Hb0 2 , form methemoglobin (metHb) and NO3'. The latter pathway may 
predominate in capillaries, where the distance between ECs and adherent red blood cell
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Figure 1.2 Metabolism of nitric oxide in human blood
NO is released from ECs into the vessel lumen and is rapidly oxidized to nitrite (NO 2 ) 
and S-nitrosothiol (R-SNO) in the plasma at the immediate site o f  release. N O f is 
converted to nitrate (NO3 )  via an autocatalytic reaction with oxyhemoglobin (Hb0 2 )  in 
the erythrocytes. Alternatively, a small portion o f NO may reach the erythrocytes 
directly, where it forms either nitrosylhemoglobin (NOHb) or oxidizes to NO 3 ' and 
methemoglobin (metHb), the fraction o f  each depending on the ratio o f  oxygenated and 
non-oxygenated hemoglobin within the erythrocytes, (adaptedfrom Kelm and Yoshida,
1996)
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is short when compared to conductance vessels, where NO has to diffuse to 
erythrocytes located in the center of the blood vessel. The extent to which either of 
these metabolic routes of NO operates depends on the different diffusion rates of 
N 0 /N0 2 -across the erythrocyte membrane, the oxygen saturation of hemoglobin 
(venous versus arterial circulation), and the ambient redox state (reviewed by Kelm and 
Yoshida, 1996).
1.4.3 Function o f  nitric oxide
The biological actions of NO are dictated by the reactions it undergoes with 
different target molecules in cells, membranes, and the extracellular milieu. For each 
target, depending on the amount and duration of induction, NO can exert beneficial or 
detrimental effects. Known targets for NO include: guanylate cyclase, hemoglobin, 
iron/sulphur centres of enzymes (cytochrome c oxidase, ribonucleotide reductase), 
other free radicals (O2’, H2O2) and various genes (Manuel et al., 1998).
1.4.3.1 Physiological roles
The identification of a competitive inhibitor o f NOS, the NG-monomethyl-L- 
arginine (L-NMMA), provided an important tool to investigate the relevance of NO in 
biologic processes (Moncada and Higgs, 1993). L-NMMA prevented both the 
endothelium-dependent vasorelaxation and release of NO in a competitive manner 
(Palmer et al. 1988). Further more, L-NMMA constricts vascular beds and produces a 
hypertensive response in animals and causes vasoconstriction of the forearm arterial 
circulation in humans, thus suggesting that a continuous generation of NO is needed to 
maintain vascular tone (Moncada, 1992). NO reacting with ferrous iron in the heme 
prosthetic group of the soluble guanylate cyclase in vascular SMCs increases the 
intracellular concentration of cyclic guanosine monophosphate (cGMP), leading to 
vascular relaxation (Waldman and Murad, 1988). Apart from its vasodilatory function, 
NO also negatively regulates vasoconstricting factors such as the ETs (Boulanger and 
Luscher, 1990; Wiley and Davenport, 2001). Pharmacological blockade of NOS activity 
suggests that NO plays a significant role in cardiac contractility (reviewed by Kelly et 
al. 1996). Huang et al. (1999) reported that eNOS knockout mice showed increased
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contractility to [3-adrenergic stimulation. NO also has an antiproliferative effect on 
vascular SMCs both in vitro (Garg et al., 1989) and in vivo (Moroi et al. 1998).
EC derived NO inhibits platelet activation and aggregation by a cGMP- 
dependent mechanism. Furthermore, platelets themselves generate NO, which may act 
as a negative-feedback mechanism to inhibit platelet activation. Thus, platelet 
aggregation in vivo may be regulated by platelet-derived NO as well as by that derived 
from ECs (reviewed by Moncada and Higgs, 1993).
NO may also be involved in the interaction of leukocytes with the vessel walls 
(Kubes et al., 1991; Gauthier et al., 1994; De Catarina et al., 1995; Khan et al., 1996). 
Kubes et al., (1991) using inhibitors of NOS showed that NO deficiency increased 
leukocyte adhesion to ECs, which was associated with an up regulation of the leukocyte 
adhesion molecule CD11/18. Similarly, Gauthier et al. (1994) reported that in a rat 
ischemia -reperfusion model exogenous NO decreased leukocyte-endothelial 
interaction by down regulating the EC adhesion molecule, P-selectin. De Caterina et al. 
(1995) showed that NO decreased cytokine-induced endothelial activation (as indicated 
by the decreased expression of ICAM-1, VCAM-1 and E-selectin) and monocyte 
adhesion to ECs.
The production of NO by activated macrophages protects the host against 
infectious agents including bacteria, parasites and viruses and destroys tumor cells. The 
proposed mechanism responsible for these effects involves the reaction of NO with the 
non-heme iron of iron-sulphur complexes resulting in the inactivation of iron-sulphur 
containing enzymes including mitochondial aconitase, cytochrome c oxidase, and the 
DNA synthesis rate-limiting enzyme, ribonucleotide reductase. Inhibition of these 
critical enzymes leads to suppression of mitochondrial respiration, energy metabolism 
and cell replication (reviewed by Manuel et a l,  1998).
NO has also been shown to inhibit apoptosis (programmed cell death) both in 
vitro and in vivo. NO produces this cytoprotective effect by inducing heat shock protein 
(HSP32 and HSP70), activating guanylyl cyclase, suppressing caspase activity and 
inhibiting cytochrome C release from mitochondria (reviewed by Kim et al., 1999).
NO itself is now considered to be a modulator of gene expression and also 
effects the activity of various transactivating factors and DNA binding proteins 
(Manuel et al., 1998). NO decreases cytokine-induced EC activation by inhibiting NF- 
k B  expression and the subsequent expression of adhesion molecules (De Caterina et a l, 
1995) or iNOS activity (Colasanti et a l,  1995). NO has been reported to affect not only
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NF-KBfunction (in part by altering the expression of the NF-KBinhibitor, IkBoc; Peng et 
al., 1995), but other redox sensitive transcription factors, including AP-1 components 
(Pilz et al., 1995). In addition, NO has been reported to modulate inflammation by 
altering the production of soluble cytokines such as TNFa, IL-8 , IL-6 , IFNy, MCP-1 
(reviewed by Manuel et a l, 1998).
1.4.3.2 Pathological roles
NO is produced in small amount by nNOS and eNOS. It is usually triggered and 
the activity of the enzyme is transient. On the other hand iNOS produces large 
concentrations of NO, is independent of stimulating agonists and its activity is 
sustained (reviewed by Drexler, 1999). In most cell types iNOS can essentially be 
expressed in response to appropriate stimuli (reviewed by Nathan and Xie, 1994). In 
the vessel wall iNOS can be induced by certain cytokines and by endotoxin. This 
induction occurs both in ECs and SMCs leading to vascular relaxation that is resistant 
to vasoconstrictors. NO released by iNOS accounts for the vasodilatation and resistance 
to vasoconstrictors, which is characteristic of septic shock (reviewed by Moncada and 
Higgs, 1993). Thus, the physiologic function of NO may become pathologic, causing 
excessive vasodilatation and tissue damage, when generated in large quantities and for 
long periods by the inducible enzyme (reviewed by Moncada and Higgs, 1993; Drexler, 
1999).
Equimolar concentrations of NO and 0 2 ' produce the powerful oxidant ONOO'. 
Under physiological conditions, NO is formed in the picomolar to nanomolar range and 
the O2’ concentration is kept low by SOD, thus ONOO’ production is low (Manual et 
al., 1998). In lower concentrations, ONOO' behaves very similarly to NO (Wever et al., 
1998). However, pathological conditions can greatly increase the synthesis of both NO 
and O2’. When the concentration of NO increases to the micromolar range, it can 
effectively compete with SOD for O2’ to form ONQO' (Manual et al., 1998). High 
concentrations of ONOO' are toxic, initiate iron-independent lipid peroxidation, oxidize 
thiols, damage the mitochondrial electron transport chain, cause protein fragmentation 
by nitration of amino acids and cause cell death (reviewed by Manual et al., 1998 and 
Wever etal., 1998).
Furthermore, decreased production or bioavailability of NO disrupts various 
NO-dependent physiological functions such as, vasoregulation, fibrinolysis and
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hemostasis leading to various pathological conditions such as AS, hypertension, heart 
failure and coronary artery disease (Harrison, 1997; Liao, 1999; Panza, 1999;
Quyyumi, 1999).
1.4.4 Effects o f  smoking on nitric oxide synthesis and metabolism
The majority of data suggest that cigarette smoke decreases the synthesis or 
bioavailability of NO. Contrary data also exists and the exact mechanism(s) by which 
cigarette smoke affects NO biology is still unclear. Celermajer et al. (1993) and 
Lekakis (1997) reported that cigarette smoking was associated with the impairment of 
endothelial-dependent, brachial artery dilatation. Quillen et al. (.1993) reported that 
cigarette smoking caused immediate constriction of proximal and distal epicardial 
coronary arteries and increased coronary vessel tone. Similarly, Ota et al. (1997) 
reported CSE suppressed the release of NO metabolites in cultured human ECs. 
McVeigh et al. (1996), examining the effect of L-NMMA on brachial artery hyperemia, 
suggested that there was an impairment of basal, but not stimulated, NO-mediated 
vasodilatation in long-term cigarette smokers. Kugiyama et al. (1996) infused L- 
NMMA and ACh into epicardial coronary arteries and observed that NO bioactivity 
was decreased in smokers at rest and under acetycholine-stimulated conditions. 
Conversely, Nene et al. (1997) reported that cigarette smoking augments endothelial 
derived-vasorelaxation in the rat carotid artery. Johnson et al. (1999) demonstrated that 
cigarette exposure did not result in any significant alteration of ACh-mediated 
vasorelaxation in the rabbit carotid artery.
Node et al. (1997) measured the serum NO2' and NO3' concentrations in non- 
smokers, current smokers and former smokers in a Japanese population. They reported 
that current smokers had significantly lower levels of the metabolic end product of NO 
than non-smokers and former smokers. Conversely, Rangemark and Wennmalm (1996) 
did not find any significant difference in plasma and urinary nitrate levels between 
female smokers and non-smokers. More recently, Sarkar et al. (1999) reported that 
acute cigarette smoke exposure increases serum NO concentration in rats. Similarly, 
Zhou et al. (2000) found plasma levels of NO were significantly higher in smokers 
compared to non-smokers in a Chinese population.
Similar disagreements exist regarding the mechanisms of cigarette smoke- 
mediated alteration in NO biology. Oxidative stress is one of the suggested mechanisms
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by which cigarette smoke may affect NO oxide production or bioavailability (Murohara 
et al., 1994; Heitzer et a l, 1996; Pittilo, 2000). Cigarette smoke is known to contain a 
large number of free radicals and pro-oxidants (Church and Pryor, 1985). These free 
radicals may react with NO and cause a decrease in its bioavailability (Murohara et al., 
1994; Heitzer et al., 1996) and may give rise to the highly reactive molecule ONOO' 
(Heitzer et al., 1996). Murohara et al. (1994) showed that CSE-induced contraction of 
isolated porcine coronary arteries was significantly attenuated by SOD. Similarly, 
Heitzer et al. (1996, 1999) reported that infusion of vitamin C, or four months vitamin 
E oral therapy, significantly improves endothelial-dependent vasodilatation in the 
forearm. They have suggested that the antioxidant properties of these vitamins 
decreased oxidative degradation of NO leading to improvements in endothelial- 
dependent vasodilatation.
Cigarette smoke may also affect the synthesis or bioavailability of BH4 
(Higman et al., 1996; Wever et al. 1998; Heitzer et al., 1999). Both in vitro (Higman et 
al., 1996), and in vivo (Heitzer et al., 1999), administration of BH4 has been shown to 
improve endothelial-dependent vasodilatation. Wever et al. (1998) and Heitzer et al.,
(1999) speculated that oxidative stress of cigarette smoke may be responsible for the 
dysfunction in BH4 metabolism and uncoupling of the NOS enzyme leading to 
abnormal NO synthesis. In contrast, Leonard et al. (1995a) found no significant 
differences in free radical markers between young adult smokers and non-smokers. 
Leonard et al., (1995b) also reported free radical activity due to cigarette smoking 
appears to be adequately scavenged in young adults with diabetes who are free of 
significant macro-vascular disease. Similarly, Su et al. (1998) reported that incubation 
of pulmonary artery ECs (PAECs) with CSE in the presence of various antioxidants 
such as, catalase, SOD, Vitamin C, Vitamin E, reduced glutathione and dithiothreitol 
did not improve CSE-induced reduction of eNOS activity.
Cigarette smoke also may affect NOS activity by acting on protein and mRNA 
levels (Su et al., 1998; Wright, 1999; Wang et al., 2000, Zhang et al., 2001). Su et al. 
(1998) reported that CSE causes irreversible inhibition of eNOS activity in pulmonary 
artery ECs by decreasing both eNOS protein and eNOS mRNA. Similarly, Wang et al.
(2000) observed a lower eNOS protein concentration in isolated HUVECs from 
pregnant smokers but did not find any decrease in eNOS mRNA concentration or 
eNOS activity. They have suggested that the effects of smoking may be dependent on 
the eNOS genotype. On the other hand, Wright et al. (1999) reported that once a day
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exposure to cigarette smoke increases both NOS protein and mRNA in rat lung. 
Recently, Zhang et al. (2001) showed that treatment of human coronary artery ECs 
with nicotine for 24 hours at concentrations similar to those in the blood of smokers 
resulted in increased mRNA level of eNOS.
1.4.5 Endogenous free radical generating sources and nitric oxide
Like all mammalian cells, the potential enzymatic sources of ROS in ECs 
include the NAD(P)H oxidase system, mitochondrial electron transport chain, xanthine 
oxidase and the uncoupled eNOS (Kojda and Harrison, 1999; Cai and Harrison, 2000).
The NAD(P)H oxidase system appears to be an important superoxide-producing 
enzyme in both ECs and vascular smooth muscle cells. This system may be induced by 
cytokines, physical force, and tissue hormones. Several studies have reported that both 
hypercholestrolemia and diabetes are associated with increased NAD(P)H oxidase 
dependent- O2' production leading to a decrease in NO availability (Cai and Harrison, 
2000).
Xanthine oxidase, a molybdoenzyme present in ECs, is capable of giving rise to 
both 0 2 'and H2O2 . Studies have shown that this enzyme might alter NO availability in 
hypertension as well as in hypercholestrolemia (Kojda and Harrison, 1999; Cai and 
Harrison, 2000).
During ATP synthesis, the mitochondrial electron transport chain produces a 
very small amount of ROS. However, in certain pathophysiological conditions such as 
ischemia-reperfusion or exposure to certain chemicals such as cyanide, the 
mitochondrial electron transport chain shows a significant increase in ROS generation 
(Warnholtz et al. ,2002).
Lastly, the uncoupled eNOS has been shown to be a potentially important 
source of ROS in ECs due to the decreased availability of the intracellular substrate (L- 
arginine) and the co-factor, BH4 (Vasquez-Vivar et a l, 1998). The uncoupling of eNOS 
not only limits NO generation,the ROS produced can react with NO to decrease its 
biological and chemical availability.
With the exception of uncoupled eNOS, the role of these other endogenous free 
radical generating sources in smoking-mediated NO dysfunction has not been 
investigated.
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1.5 Aims of the Project
A review of the existing literature revealed inconclusive, and often 
contradictory, data regarding the mechanism(s) involved in cigarette smoking-induced 
EC dysfunction. Furthermore, a majority of in vitro studies were done in non- 
physiological, in vitro, models. In addition, it has been suggested that ECs from 
different vascular beds may react differently upon exposure to cigarette smoke. The 
general aim of this project was to study the effect of smoking on NO biosynthesis in 
physiologically relevant in vivo and in vitro models as well as in ECs from different 
vascular beds and to identify the role of ROS in the smoking-mediated NO dysfunction. 
An additional aim was to explore the effect of smoking on EC-derived fibrinolytic/anti- 
fibrinolytic and thrombotic/anti-thrombotic factors and their potential interrelationship 
to NO.
The specific aims of the project were:
1. To establish an in vitro model (in HUVECs) for investigating NO 
biosynthesis in smokers that correlates well with an established in vivo model, and to 
explain the effect of smoking on NO biosynthesis, in terms of NO production or 
availability, eNOS protein expression and eNOS activity.
2. To determine the dose effect of smoking on endothelial vasoregulatory 
factors specifically on ET-1 and NO.
3. To explore the potential effect of smoking on EC-derived counter regulatory 
hemostatic factors specifically t-PA, PAI-1, TF and TFPI and their association with NO 
biosynthesis.
4. To reproduce the effects o f smoking observed in HUVECs in a more 
pathophysiologically relevant cell line (HCAECs), and to establish the role of ROS in 
smoking-mediated NO dysfunction.
5. To explore the potential role of endogenous free radical generating sources in 
smoking-mediated NO dysfunction.
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2. MATERIALS AND METHODS
2.1 Preparation of reagents and solutions
Substance P (SP) was purchased from Sigma (St. Louis, MO, USA; Cat # 
S6883). SP was dissolved in 1% bovine serum albumin to give a 10' 5 M solution and 
was kept at -70°C until used. It was found to be stable for 3 weeks. Before each 
experiment the stock solution was diluted to the desired concentration.
A saturated solution of vanadium (III) (Aldrich Chemical Company INC; 
Milwaukee WI, USA, Cat # 20827-2) in 1 M HC1 (VC13/HC1) was prepared by taking 
800 mg of solid VCI3 in a volumetric flask and adding 1M HC1 to bring the level of the 
volume to the 100 ml. The solution was mixed and filtered. The reagent was stored at 
4-8°C and used within 3 weeks.
NADPH (Sigma, Cat # N1630) was prepared by dissolving in 10 mM Tris-HCl 
(pH 7.4). Calmodulin (Calbiochem, San Diego, CA, USA; Cat # 208698) and calcium 
chloride (CaCk) were prepared by dissolving them in double-distilled water (DH2O) to 
the desired concentration.
Primary HUVECs, HCAECs and endothelial cell basal media (EBM, Cat # CC 
3121) and growth media supplements (0.5 ml of 10 pg/ml human recombinant 
epidermal growth factor (hEGF), 0.5 ml 1 mg/ml hydrocortisone, 0.5 ml 50 mg/ml 
gentamicin, 50 ug/ml amphotericin-B, 2ml of 3 mg/ml bovine brain extract and 25 ml 
of fetal bovine serum) (Cat # CC 4143), were purchased from Clonetics (Bio Whittaker, 
Walkersville, MD, USA). Complete endothelial growth media (EGM) was prepared by 
adding growth media supplements to 500 mL of EBM and kept at 4-8° C.
Polyethylene glycol-superoxide dismutase (PEG-SOD, Cat # S 9549), PEG- 
catalase (Cat # C 4963), chelerythrine (Cat # C 2932), BH4 (Cat # T 4425). LNMMA 
(Cat # M 7033), allopurinol (Cat # A 8003) or rotenone (Cat # R 8875), all were 
purchased from Sigma (St. Louis, MO, U.S.A). Apocyanin (Cat # A l,080-9) was 
purchased from Aldrich Chemical Com. (Milwaukee, WI, U .S.A ). All these agents 
were made fresh before each set of experiments and all (except rotenone) were 
dissolved in EGM to the desired concentrations. Rotenone was first dissolved in 
absolute alcohol (200 proof) and then diluted with EGM to the desired concentration.
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2.2 Endothelial cell culture
2.2.1 Primary culture
Upon arrival of the cryopreserved HUVECs or HCAECs, an exact number of 
the cells in the cryovial and the percentage of cell viability was noted from the 
certificate of analysis supplied by the company (Clonetics, Walkersville, MD, USA.
The number of flasks required for experimentation was calculated using the supplier’s 
recommended seeding density (2500 cells/cm2). Flasks were filled with 1 ml EGM for 
every 5 cm2 surface area and kept in a humidified incubator (Precision Scientific,
Model # 5430) at 37°C with 5% CO2 for 30 min to allow the flasks to warm up and 
equilibrate. After the flasks had equilibrated for 30 min, the cryovial containing ECs 
was removed from dry ice and wiped with 70% ethanol. The cap of the cryovial was 
loosened briefly (a quarter turn) to relieve internal pressure, and was then retightened. 
The bottom 3/4 of the cryovial was dipped in a 37°C water bath for 1-2 min until the 
contents were thawed. Thawed cells were resuspended with gentle pipeting and the 
calculated amount of the cell suspension (2500 cells/cm2) was dispensed in to the 
flasks. The flasks were gently rocked to evenly distribute the cells and returned to the 
incubator. Next day, the flasks were observed for cell attachment and the growth media 
changed. After that the media was changed every other day. A successful culture 
usually showed cells with clear non-granular cytoplasm and numerous mitotic figures 
after the second day. The volume o f the media in the flasks was adjusted with 
confluence of the cells as recommended by Clonetics (under 25% confluence, 1ml per 5 
cm2; from 25%-45% confluence, 1.5ml per 5 cm2; over 45% confluence, 2ml per 5 
cm2). Cell culture was continued in the same flasks until cells reached -85%  
confluence.
2.2.2 Subculture process
Once a flask reached 80-90% confluence cells were subcultured. The medium 
from the flask was aspirated and the cells were washed with 5 ml Dulbecco’s phosphate 
buffered saline (DPBS) (Gibco BRL, Grands Island, NY, USA). The cells were treated 
with 2-3 ml trypsin (0.025%)/ethylenediaminetetraacetic acid (0.01%) (T/E) solution 
(Clonetics cat # CC 5012) at room temperature for 5 minutes. The flask was monitored
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under the microscope and trypsinization was allowed for up to 5-6 min or until 90% of 
the cells were detached. T/E was neutralized by adding 4 ml of trypsin neutralizing 
solution (Clonetics Cat # CC 5002). The neutralized cell suspension was then quickly 
transferred to a sterile 15 ml centrifuge tube and centrifuged at 220g (25°C) for 5 min 
(Joun Inc., Model CR4 22). After the centrifugation, most of the supernatant was 
aspirated leaving 100-200 pi and the cell pellet was loosened by flicking the tube. The 
cell pellet was resuspended with 4-5 ml of pre warmed EGM. The concentration and 
viability of the resuspended cells were determined using a Neubauer hemocytometer 
(Hausser Scientific, Horsham, PA, USA) and trypan blue dye (Sigma, Cat # T8154) as 
described in Section 2.2.4. After the cell number per ml was determined, cells were 
either cultured in flasks as described in Section 2.2.1 or plated in tissue culture plate as 
described in Section 2.2.3 below.
2.2.3 Cell culture in multiwell plate
After calculating the concentration of the harvested cells, they were aliquotted in either 
96- or 24 or 12-well, flat-bottomed, tissue culture plates (Primaria, Baxter Scientific 
Products) and kept in the incubator with 5% CO2 at 37°C. The initial seeding 
concentration was 10,000 cells/cm2 i.e. about 3,200 cells per well in 96-well; 20,000 
cells per well in 24-well tissue culture plates; 40,000 cells per well in 12-well tissue 
culture plates (recommended by Clonetics). The following day, plates were observed 
under the microscope for cell attachment and the culture medium was replaced. Cells 
were grown to -85%  confluence and then exposed to various treatments.
2.2.4 Determination o f  cell count and viability
The concentration and viability of the cells after each subculture was 
determined using methods suggested by Clonetics (Endothelial cell systems-Instruction 
for use, Cat # AA-10011-2 Rev). Cells were counted using an improved Neubauer 
hemocytometer and recounted after mixing equal volumes of the cell suspension with 
the vital stain trypan blue (0.4% v/v in DH2O).
The percentage cell viability was calculated using the equation:
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% Cell viability = Number of unstained (living) cells  x l 00
Total cells counted (stained + unstained)
The number of viable cells harvested was then calculated by multiplying 
cells/ml with the percentage viable cells. This number was used to determine the 
seeding volume of the cell suspension for the flasks and tissue culture plates.
2.3 Neutral red assay
The neutral red assay (for cell viability in the experimental model) was 
performed as described by Lowik et al., (1993). In brief, neutral red (NR) (Sigma, cat # 
N 2889) stock solution (1 mg/ml in DH2O) was prepared and stored at room 
temperature. This was diluted with 1.8% NaCl in 1:1 ratio to prepare NR working 
solution before the experiment. Fifty microliters of NR working solution was added to 
each well and incubated at 37°C with 5% CO2 for 1.5 hours. At the end of incubation 
NR solution was removed by inverting the plate, the cells were rapidly washed twice 
with DPBS. The fluid was discarded and blotted dry on a filter paper. The intracellular 
dye was then extracted from the cells by adding 100 pi of 0.05 M NaH2P0 4  in 50% 
ethanol. The optical density was then read at 550 and 650 nm as reference wavelength 
using a microplate reader (Bio-Tek, Model EL311; Highland Park, VT, USA).
2.4 Cell proliferation assay
The cell proliferation assay was performed using a cell proliferation assay kit 
from Chemicon (Temecula, CA, USA; Cat # 2210). The assay is based on the cleavage 
of the tetrazolium salt WST-1 to formazan by cellular mitochondrial dehydrogenase.
One ml of WST-1 reagent and 5 ml of electro-coupling solution from the kit 
were mixed. Ten microliters of the mixed solution was added to each well. The plates 
were incubated at 37°C with 5% C 0 2 for two hours. At the end of incubation, the plate 
was kept on a horizontal shaker (Virion) for 2- 3 min. Optical density was read at 420 
and 650 nm as reference wavelength using the Bio-TeK microplate reader.
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2.5 Nitric oxide assay
NO concentration in the cell culture supernatant or serum was determined by 
the chemiluminesence method as described by Hampl, Walter and Archer (1996) using 
a NO analyzer (Sievers, Model # 280; Boulder, CO, USA). In brief, 5-10 j l x I  of each 
sample was injected into the radical purger of the NO analyzer containing 5 ml of 
VCI3/HCI at 90°C. VCI3/HCI at 90°C can reduce NO2' and NO3' in the sample back to 
NO. Generated NO was then allowed to react with ozone to emit light. The emitted 
light proportional to NO content in the specimens was recorded and traced using NO 
analysis software (Sievers). The concentration of NO in the specimens was calculated 
using a calibration curve produced by a known concentration of nitrite (100 nM to 30 
pM).
2.6 Nitric oxide synthase concentration assay
The eNOS concentration in ECs was determined by using a commercial ELISA 
kit (R&D systems; Minneapolis, MN, USA, Cat # DEN00). The ECs in a culture plate 
were lysed by adding 400 or 800 pi of lysis buffer (R&D systems) to each well and 
incubating for 5 min at 4-8°C. The plate was centrifuged at 300g for 5 min and the 
supernatant collected. eNOS standards were constituted by serial dilution. A hundred 
microliters of assay diluent and 1 0 0  pi of the cell-Iysis supernatant or the standards 
were added to each well of a plate precoated with an anti-eNOS antibody (a 
monoclonal antibody raised against recombinant human eNOS). The plate was then 
incubated for 2  hours at room temperature on the horizontal orbital shaker at low speed. 
At the end of the incubation the plate was washed, 200 pi of eNOS conjugate 
(polyclonal antibody against eNOS conjugated to horseradish peroxidase) was added to 
each well and incubated for two hours. After washing to remove the unbound eNOS 
conjugate, 2 0 0  pi of substrate solution (stabilized H2O2 and tetramethylbenzidine) was 
added to each well and incubated at room temperature for 30 min. The reaction was 
terminated by adding 50 pi stop solution (2.0 N sulfuric acid), the absorption was read 
at 450 nm with correction at 570 nm using the Bio-Tek microplate reader.
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2.7 Nitric oxide synthase activity assay
The enzymatic activity of eNOS was measured by a slight modification of the 
method described by Bedt and Schmidt (1996) using a commercial kit (Calbiochem,
San Diego, CA, USA; Cat # 482700). In brief, 100 pi of samples was added to a 
reaction cocktail containing, 25ul of reaction buffer (50 mM Tris-HCl, 6  pM BH4 , 2 
pM FAD and 2 pM FMN), 1-3 pi of [3H]-L-arginine (55-58 Ci/mmol, lpCi/pl) 
(Amersham Pharmacia Biotech, Inc. Piscataway, NJ; Cat # TRK698), and a final 
concentration of; ImM NADPH, 75 pM CaCh and 0.1 pM calmodulin. The incubation 
was carried out at room temperature for one hour. The reaction was stopped adding 400 
pi of stop buffer (50 mM HEPES and 5 mM EDTA). Hundred microliters of 
equilibrating resin (supplied by the manufacturer) was added to the reaction samples. 
Reaction samples were transferred to a spin cup and centrifuged in a micro-centrifuge 
(Costar, USA) at 5585g for 30 seconds. Eluates were transferred to scintillation vials 
and after adding scintillation fluid, radioactivity was quantitated by using a liquid 
scintillation counter (Packard Instrument Com.; Downers Grove, IL, USA, Model # 
TRI-CARD 1900CA).
2.8 Total protein assay
To compare the amount of total protein isolated by the lysis buffer used in the 
eNOS immunoassay kit (R&D systems; Cat # DEN00) and the homogenization buffer 
(Calbiochem, Cat # 482700) a protein assay kit was used as described previously 
(Sigma, Cat. # 690-A; Saha, 1996). In brief, the standard bovine albumin stock was 
diluted with DH2O to contain 25, 50, 100, 200, 400 pg/ml protein. One hundred 
microliters of each standard and samples were added to a 96-well plate (in duplicate). 
Ten microliters of decoxycholate (DOC; 1.5 mg/ml) solution was added to each well 
and the plate was incubated on a horizontal shaker at room temperature for 1 0  min 
followed by addition of 10 pi of trichloroacetic acid (TCA; 72%) solution. The plate 
was centrifuged at 21 Og for 5 min and the supernatant was discarded without 
dislodging the pellet. To each well, 100 pi of Lowry reagent was added, mixed and 
incubated at room temperature for 20 min. At the end of the incubation period, 50 pi 
Folin and Ciocalteu’s phenol red reagent was added to each well and incubated again at 
room temperature for 30 min. the absorbance was read at 620 nm.
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2.9 Endothelin-1 assay
Endothelin-l level was measured in cell culture supernatants using a kit from 
Amersham Pharmacia Biotech, Inc. (Piscataway, NJ, USA; Cat # RPN 228). In brief, 
the ET-1 standard supplied by Amersham was reconstituted. One hundred microliters 
of assay buffer and 100 pi of standards or samples were added to each well o f a 96 well 
plate. The plate was covered and incubated at 3-5°C. After overnight incubation, the 
plate was washed with 400 pi of wash buffer from the kit. One hundred microliters of 
antibody conjugate (anti- human ET rabbit IgG Fab-horseradish peroxidase) was added 
to each well and incubated for 30 min at 37°C. The plate was washed again and 100 pi 
of enzyme substrate (tetramethylbenzidine/H2 0 2  in dimethylformamide)) was added, 
and incubated for 40 min on the horizontal shaker at room temperature. At the end of 
the incubation, 100 pi of 1.0 M sulfuric acid was added to stop the reaction and the 
absorption was read at 450nm using a Bio-Tek microplate reader.
2.10 Tissue plasminogen activator assay
Tissue plasminogen activator level was measured in cell culture supernatants 
using a kit from Biopool (Ventura, CA, USA; Cat# 1105). In brief, the t-PA standard 
supplied by Biopool was reconstituted. The wells of the antibody-coated plate (anti­
human tPA goat IgG) were reconstituted by adding 50 pi of PET (phosphate buffer 
solution-EDTA-Tween 20) buffer. Twenty microliters of each t-PA standard or sample 
and 50 pi of conjugate solution (anti human t-PA Fab-horseradish peroxidase) were 
added to the wells and incubated for one hour on the horizontal shaker at room 
temperature. The plate was washed and 100 pi of enzyme substrate 
(phenylenediamine/FUCb) was added to each well and incubated for 15 min on a 
horizontal shaker (Virion) at room temperature. Hundred microliters of stop solution 
(0.1 M sulfuric acid) was added and the absorption was read at 492nm using Bio-Tek 
microplate reader.
2.11 Plasminogen activator inhibitor-1 assay
Plasminogen activator inhibitor-1 level was measured in culture supernatants 
using a kit from Biopool (Ventura, CA, U.S.A; Cat#210221). In brief, the PAI-1
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standard supplied by Biopool was reconstituted. The wells of the antibody-coated (anti­
human PAI-1 mouse monoclonal antibody) plate were reconstituted by adding 100 pi 
of PET (phosphate buffer solution-EDTA-Tween 20) buffer. Twenty microliters of 
each t-PA standard or sample and 50 pi of conjugate solution (anti-human PAI-1 - 
horseradish peroxidase) were added to the wells and incubated for two hours on the 
horizontal shaker at room temperature. The plate was washed and 200 pi o f enzyme 
substrate (phenylenediamine/EECh) was added to each well and incubated for 15 min 
on a horizontal shaker (Virion) at room temperature. Fifty microliters of stop solution 
(0.1 M sulfuric acid) was added and the absorption was read at 492nm using a Bio-Tek 
microplate reader.
2.12 Tissue factor assay
Tissue factor level was measured in culture supernatants using a kit from 
American Diagnostica Inc (Greenwich, CT, U.S.A; Cat# 845). In brief, the TF standard 
supplied by American Diagnostica Inc was reconstituted in DH2O. One hundred 
microliters of each TF standard or sample was added to the antibody-coated plate (anti­
human TF murine monoclonal antibody) and incubated for overnight at 4°C. In the next 
morning, 100 pi of detection antibody (biotinylated anti- human TF Fab) was added to 
each well and incubated for one hour. The plate was washed and 100 pi of diluted 
enzyme conjugate (Streptavidine- horseradish peroxidase) was added to each well and 
incubated for one hour. The plate was washed again and 100 pi o f enzyme substrate 
(tetramethylbenzidine) was added, and incubated for 30 min at room temperature. At 
the end of the incubation, 50 pi of 0.5 M sulfuric acid was added to halt the reaction 
and the absorption was read at 450nm using a Bio-Tek microplate reader.
2.13 Tissue factor pathway inhibitor-1 assay
Tissue factor pathway inhibitor-1 was measured in culture supernatants using a 
kit from American Diagnostica Inc (Greenwich, CT, U.S.A; Cat# 849). One hundred 
microliters of each TFPI-1 standard or sample was added to the antibody-coated plate 
(anti- human TF rabbit polyclonal antibody) and incubated for overnight at 4°C. In the 
next morning, 100 pi of detection antibody (biotinylated anti-human TFPI-1 Fab) was 
added to each well and incubated for one hour. The plate was washed and 100 pi of
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diluted enzyme conjugate (Streptavidine- horseradish peroxidase) was added to each 
well and incubated for one hour. The plate was washed again and 100 pi of enzyme 
substrate (tetramethylbenzidine) was added, and incubated for 30 min at room 
temperature. At the end of the incubation, 50 pi of 0.5 M sulfuric acid was added to 
halt the reaction and the absorption was read at 450nm using a Bio-Tek microplate 
reader.
2.14 Experimental design 
2.14.1 Subjects
To identify the effects of cigarette smoke exposure, subjects (male) with a 
history of active smoking and age and sex matched non-smokers were selected. Active 
smokers were classified as: a) light smokers (defined as those who smoked <one pack 
per week), and b) heavy smokers (defined as those who smoked >one pack per day).
All subjects were free of cardiovascular risk factors i.e. hypertension, diabetes, low 
HDL, hyperlipidemia or a family history of premature vascular disease.
2.14.2 Study Design and Sample collection
Subjects were requested to abstain from smoking and caffeinated food or drink 
for the over night hours (6 - 8  hours). On arrival in the morning subjects were allowed to 
rest for 20 min in sitting position. For both smokers and non-smokers, baseline BP and 
HR were recorded and blood samples collected from the antecubital vein by 
venipuncture. For in vitro studies, blood was collected in vacutainer tubes (Becton 
Dickinson Cat #36815) and centrifuged at 1776g for 15 min at 4°C. Serum was 
collected and stored at -70°C until use. Blood for chemical analysis was sent to the 
hospital clinical laboratory for analysis.
After blood collection, an in vivo assessment of endothelial function was done 
by utilizing ultrasonography to measure the brachial artery diameter at rest, during 
reactive hyperemia (leading to flow-mediated endothelium-dependent dilatation) and 
after administration of 400 pg of sublingual nitroglycerin (an endothelium-independent 
dilator) as described by Celermajer et al. (1993). All ultrasonographic scans were
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obtained by the same operator using the same equipment (Acuson L I0 6-11 MHz 
transducer and Acuson Aspen™ System; Mountain View, CA).
The study protocol was approved by Saint Vincent Catholic Medical Centers of 
New York Ethics Committee and written informed consent was obtained from each 
subject.
2.14.3 Determination o f  Endothelium-dependent and Endothelium- 
independent Vasodilatation
The validated analysis method used was described by Celermajer et al. (1993). 
In brief, a pneumatic cuff was inflated around the right forearm to -300 mm Hg for 4.5 
min followed by cuff deflation. Flow-mediated EDV was calculated by dividing the 
maximum vessel diameter at 50-60 s after cuff deflation with average baseline 
diameter. Endothelium-independent dilatation was calculated as the maximum vessel 
diameter at 3-4 min after nitroglycerin administration divided by average baseline 
diameter. The arterial diameter was measured by using ultrasonic calipers for four 
cardiac cycles for each condition and were averaged. Results were expressed as 
percentage changes from the baseline.
2.14.4 Effect o f  serum concentration on cell viability and proliferation
To determine the effect of serum concentration on viability and proliferation of 
ECs, the latter were grown in 96-well tissue culture plates as described in Section 2.2.3. 
Once the cells reached -85% confluence they were incubated for 12 hours with 
different dilutions of serum and/or media (lOOul; 100% serum or media or 50% serum 
and 50% media or 50% media and 50% DPBS). After the incubation, 100 pi fresh 
media was added to each well and the assays were carried out as described in Section 
2.3 and 2.4.
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2.14.5 Determination o f  NO level in culture
To determine NO production, ECs were plated in 24- or 12-well tissue culture 
plates with an initial seeding density of 10,000 cell/cm2 and grown to -85%  confluence 
as described in Section 2.2.3.
To measure basal NO production in culture ECs were incubated with the 400 pi 
(24-well plate) or 800 pi (12-well plate) of 50% serum and 50% media for 12 hour. The 
supernatants were collected by centrifuging the plate at 300g for five min. They were 
stored at -70°C until analysis.
To measure stimulated production of NO in culture, ECs were incubated for 12 
hours as above. At the end of the incubation, the supernatant was removed and wells 
were washed twice with DPBS. After washing, the plates were centrifuged at 300g for 
5 min and the supernatant was discarded. Four hundred microliters of fresh media 
(EGM) was added to each well followed by stimulation with substance P for a given 
length of time.
To identify the optimum time and concentration of substance P stimulation 
some experiments were carried out with several concentration of SP (10 ' 6 M to 10'9M) 
at multiple time points (10, 20 and 30 min). Once the optimum concentration and time 
point were known, the same parameters were used for the remaining experiments.
2.14.6 Determination o f total protein isolated by homogenization and 
lysis buffer
To discover the optimum protein isolation buffer, confluent ECs in 24 well 
plates were treated with either the lysis buffer from the eNOS immunoassay kit (R&D 
systems; Cat # DEN00) or the homogenization buffer from the NO synthase assay kit 
(Calbiochem, Cat # 482700). Protein concentration is each buffer isolate was 
determined by the protein assay described in Section 2.8. The eNOS activity of each 
sample was also determined as described in Section 2.7.
2.14.7 Determination o f  eNOS concentration in culture
The culture plates, which were used to detect baseline (12 hour) NO production, 
were washed twice with DPBS. After each wash, plates were centrifuged at 300g for 5
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min and the supernatant was poured off. ECs cells were then processed and the 
immunoassay performed as described in Section 2.6.
2.14.8 Determination o f  eNOS activity in culture
The same cell lysis supernatant, generated for the eNOS concentration assay, 
was used to determine the eNOS activity. The assay was performed as described in 
Section 2.7. Both the eNOS concentration assay and the eNOS activity assay were run 
simultaneously. The eNOS activity in each sample was adjusted for the specific amount 
of eNOS detected by the immunoassay (Section 2.10.6)
2.14.9 Determination o f ET-1 level in culture
The culture plates, which were used to detect baseline (12 hour) NO production 
were used to determine ET-1 level in culture. The immunoassay was performed as 
described in Section 2.9.
2.14.10 Determination o f t-PA and PAI-1 level in culture
The cell culture supernatant that was used for basal and SP-stimulated NO 
production was also used to determine basal and SP stimulated production of t-PA and 
PAI-1. The immunoassay was performed as described in Section 2.10-2.11.
2.14.11 Determination ofT F  and TFPI-1 level in culture
Both TF and TFPI-1 levels were also determined from same cell culture 
supernatant that was used for NO as well as t-PA and PAI-1 detection. The 
immunoassay was performed as described in Section 2.12-2.13.
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2.15. Statistics
Results are presented as the mean ± standard error of mean (SEM). To compare 
differences between two groups an unpaired Student’s t test or Mann-Whitney U test 
was used as appropriate. Analysis of variance (ANOVA) or repeated-measures 
ANOVA or the Kruskal-Wallis test was used when the comparisons involved more 
than two groups or multiple treatments within the same group as appropriate. For each 
ANOVA, Post hoc Fisher’s PLSD (protected least significant difference) or a paired 
Student’s t test was performed to determine the difference between each individual 
group. Associations between various factors in investigation were examined by linear 
regression analysis or the Spearman’s rank correlation test where appropriate. A value 
of p <0.05 was considered statistically significant. Power analyses were performed 
using the STPLAN statistical software (University of Texas M.D. Anderson Cancer 
Center, Dept, of Biomathematics, TX, U.S.A) and all the other analyses were 
performed using the StatView statistical program (Abacus Concepts Inc., CA, U.S.A).
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3. VALIDATION OF METHODS
3.1 Effects of serum concentrations and incubation time on endothelial cell 
viability in vitro
In order to design a near-physiological in vitro model of cigarette exposure, it 
was imperative to determine the effect of serum concentration on cell viability to 
minimize the non-specific effect of human serum on cultured ECs.
To determine the optimum serum concentration, HUVECs were plated in 96- 
well plates at 10,000 cells/cm2 (3200 cells per well) and grown to -85%  confluence 
(usually 48 hour). Confluent cells were incubated for 12 hours with 50% media and 
50% serum (from smokers or non-smokers) or 100% media/serum. At the end o f the 
incubation period, cell viability was examined using the neutral red assay (Section 2.3 
and 2.10.3).
As can be seen from Fig 3.1, EC viability was significantly (p<0.001) lower 
with 100% serum compared to 50% serum. There was no difference in EC viability 
between the non-smoker and smoker sera in same treatment group (50% or 100% 
serum) but they differed significantly from the media only group (p<0 .0 0 1 ).
These data suggested that 50% serum and 50% medium (EGM) significantly 
improved cell viability in vitro and would be optimum for the 1 2 -hour incubation in the 
present experimental model.
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Fig 3.1 Effects of serum concentrations on endothelial cell viability 
in vitro
ECs were plated in 96 well plates (10,000 cells/cm2) and grown to --85% confluence. 
ECs were then incubated with 50% or 100% medium/serum from  non-smokers, heavy 
smokers or light smokers. After 12 hour, cell viability was determined by a neutral red 
assay (Section 2.3). Results are presented as the mean ±  standard error o f  mean (SEM) 
o f five experiments. Two-way ANOVA: group, p<0.0001; 50% versus 100%, 
p<0.0001.Post hoc Fisher’s PLSD: # Media versus Serum, p<0.0001. '
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3.2 Effects of serum concentrations and incubation time on endothelial cell 
proliferation in vitro
Under normal physiological conditions, ECsare not only viable, they also 
proliferate. In an effort to design an in vitro model where ECs maintain adequate 
physiological growth, the effect of serum concentration on EC proliferation was 
determined.
ECs were plated in 96-well plates at a concentration of 3200 cells per well 
(10,000 cells/cm2) and grown to 80-85% confluence. Cells were incubated for 12 hours 
with 50% and 100% concentration serum from smokers (heavy and light) and non- 
smokers. At the end of the incubation, EC proliferation was determined (Section 2.4).
Result presented in Fig 3.2 shows that EC proliferation was significantly 
(p< 0.004) higher with 50% serum and 50% medium as compared to 100% serum.
These data suggested that ECs incubated in 50% serum and 50% medium for 12 
hours not only had better cell viability but also maintained their proliferative 
characteristics. More importantly, addition of media (EGM) did not significantly alter 
the corresponding effects of smoker and non-smoker serum or heavy - versus light -  
smokers’ serum on EC viability and proliferation. Therefore, this in vitro model was 
thought to be adequate for examining the effect o f smoking on ECs.
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Fig 3.2 Effects of serum concentrations and on EC proliferation 
in vitro
ECs were plated in 96 well plates (10,000 cells/cm2) and grown to ~85% confluence 
ECs were then incubated with 50% or 100% serum from non-smoker, heavy smoker 
and light smoker. After 12 hour, cell proliferation was determined by cell proliferation 
assay (Section 2.4). Results are presented as mean ±SE M  o f five experiments. Two-way 
ANOVA; *50% versus 100% serum, p<0.004.
61
3.3 Effects of substance P concentrations and incubation time on endothelial 
cell nitric oxide production in vitro
Existing data in the literature suggest that in different vascular beds, basal and 
stimulated production of NO may be affected differently by cigarette smoking 
(McVeigh et al., 1996; Kugiyama et al., 1996). It was thought that examination of 
stimulated NO production may give insight into the mechanisms of smoking-mediated 
endothelial dysfunction. SP was selected because of it is a known in vivo and in vitro 
stimulant for endothelial NO production (Furchgott and Vanhoutte, 1989; Smith and 
Lang, 1990).
To determine optimum SP concentration and stimulation time for NO 
production in vitro, ECs were plated in 24-well plates at a concentration of 10,000 
cells/cm2 (20,000 cells per well) and grown to ~85% confluence. Before each 
experiment, fresh medium was added to each well followed by stimulation with varying 
concentrations (10' 6 M, 10' 7 M, 10' 8 M and 10' 9 M) of SP for different periods of time 
(10, 20, 30 min). At the end of incubation, NO in the cell culture supernatant was 
determined by the chemiluminesence method (Section 2.10.4).
Results presented in Fig 3.3, shows that SP significantly increased NO 
production by ECs in a dose (p<0.03) and time (p<0.001) dependent manner in vitro, at 
30 min the maximum effect being achieved with 10' 6 M concentration. Therefore, it 
was thought that stimulation with SP concentration of 10‘6 M for 30 min may be 
optimum to examine the stimulated-production of NO in the present experimental 
model.
62
2400
1900
^  1400 
oa
c
.2 900
c
<DOc
8  400
o
£
-100
10 min 20 min 30 min0 min
_o_ SP 10'6M
- o - SP 10'7M
SP 10‘8M
~~0” SP 10‘9M
Time
Fig 3.3 Effects of substance P concentrations and incubation time on 
NO production in vitro.
ECs were plated in 24-well plates (10,000 cells/cm2) and grown to ~85% confluence. 
Before each experiment fresh media was added to each well followed by stimulation 
with varying molar concentrations (10' 6  M  to 1 O' 9  M ) o f  substance P (SP) fo r  
different time point (10-30 min). Nitric oxide (NO) was determined by the 
chemiluminesence method (Section 2.5). Results are presented as means ±SEM, n=5. 
Repeated-measure ANOVA: SP concentration, p<0,04; time, p  <0.001. Post hoc 
Fisher’s PLSD: *10' 6  M SP  versus 10' 9  M SP, p<0.01; # 10' 6  M SP  versus 10' 8  M SP,
p< 0 .0 2 .
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3.4 Effects of substance P concentrations and incubation time on endothelial 
cell tissue plasminogen activator production in vitro
In order to examine whether or not the same concentration of SP (for the same 
length of time) used to stimulate NO production could be used to stimulate t-PA 
release, ECs were plated in 24-well plates at concentration of 20,000 cells per well 
(10,000 cell/cm2) and grown to ~85% confluence. Fresh media was added to each well 
followed by stimulation with 10’6 M of SP for 20 and 30 min. At the end of the 
incubation, the supernatant was collected and both baseline and stimulated t-PA 
production was determined by ELISA as described in materials and methods (Section 
2.9).
The result presented in (Fig 3.4) shows that ECs treated with 10'6 M 
concentration of SP released significantly higher concentration t-PA in cell culture 
supernatant at 30 min as compared to non stimulated (basal) ECs at 30 min (p<0.002) 
and stimulated ECs at 20 min (p<0.05).
These results suggested that stimulation with SP at a concentration of 10’6 M for 
30 min might be used for examining both t-PA and NO production by ECs in vitro.
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Fig 3.4 Effects of substance P concentration and incubation time on tissue 
plasminogen activator production in vitro
ECs were plated in 24 well plates (10,000 cells/cm2) and grown to ~85% confluence. 
Before each experiment fresh media was added to each well followed by stimulation 
with 10'6 M o f  substance P fo r 20 and 30 min. Basal and stimulated tissue plasminogen 
activator t-PA production was determined by ELISA (Section 2.9). Results are 
presented as mean ± S E M o f five experiments. One-way ANOVA: group, p  < 0.005.
Post hoc Fisher’s PLSD: * 30min-S versus 30 min-B, p<0.002; # 30min-S versus 20 
min-s, p<0.05.
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3.5 Effects of homogenization and lysis buffer on total protein isolation and 
determination of endothelial nitric oxide synthase activity
Detection of eNOS enzyme concentration and activity by commercially 
available kits requires ECs to be lysed or homogenized by separate buffer (i.e. lysis 
buffer, eNOS immunoassay kit, R&D systems; homogenization buffer, NOS assay kit, 
Calbiochem. To detect the exact amount of eNOS enzyme concentration and its 
activity, the ECs needed to be lysed by a buffer that could be used for both kits without 
significantly compromising the integrity of the respective tests. To select the optimum 
buffer, the effect of these two buffers on total protein isolation and on the determination 
of eNOS activity was examined.
ECs were plated in 24-weII (20,000 cells per well) plates and grown to 
confluence. Cells were treated with either homogenization buffer or lysis buffer. The 
total protein isolated by each buffer was measured by protein assay (Section 2.8).
The results presented in Fig 3.5.1, showed that there was no significant 
difference in protein isolation by either buffer (p=0.80).
To determine whether these buffers affect the eNOS activity of their respective 
protein isolates, the eNOS activity of each was determined using the eNOS activity 
assay as described in Section 2.7. Specific eNOS activity for each sample was adjusted 
for the amount of total protein detected and expressed as pmol L-citrulline/min/pg 
protein.
The result presented in Fig 3.5.2, shows higher eNOS activity in protein isolates 
derived using the homogenization buffer. However, eNOS activity was not significantly 
different from the protein isolates derived using the lysis buffer (p=0.54).
These results suggest that protein isolates from cultured EC obtained with the 
homogenization buffer and the lysis buffer were not significantly different in regard to 
their total protein concentration and eNOS activity. Since the lysis buffer is more 
suitable for detection of eNOS concentration by ELISA, this buffer was utilized in the 
present experimental model.
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Fig 3.5.1 Effects of homogenization and lysis buffer on total 
protein isolation
ECs were plated in 24-well plates (20,000 cells per well) and grown to confluence. 
Cells were treated with either homogenization buffer (n=6) or lysis buffer (n=6). Total 
protein isolated by each buffer was measured by a protein assay (Section 2.8). Results 
are presented as means ±  (SEM). Paired t test: no significant difference.
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Fig 3.5.2 Effects of homogenization and lysis buffer on determination 
of eNOS activity
ECs were plated in 24-well plates (20,000 cells/cm2) and grown to confluence.
Cells were treated with either homogenization buffer or lysis buffer. eNOS activity 
o f the total protein isolates were determined by eNOS activity assay as described in
materials and methods (Section 2.7). eNOS activity is expressed as pmol L .
citrulline/min/jugprotein. Results are presented as means ±  (SEM)(n=3). Paired t test: 
no significant difference.
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4. RESULTS
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4.1 Dysfunctional Endothelial Nitric Oxide Biosynthesis in Healthy
Smokers with Impaired Endothelium-Dependent Vasodilatation
This paper has been published in Circulation. 2001;104:1905-1910.
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Abstract
Background—The mechanisms involved in the dysfunction of both endothelium- 
dependent vasodilatation (EDV) and nitric oxide (NO) biosynthesis related to smoking 
are unclear. In this study, EDV was assessed in healthy smokers and nonsmokers in 
vivo and, using serum from the same individuals, was related to the NO biosynthetic 
pathway in vitro.
Methods and Results—Flow-mediated EDV of the brachial artery was measured in 23 
males ( 8  nonsmokers, 15 smokers). Serum was collected, added to confluent (-85%) 
monolayers of human umbilical vein endothelial cells (HUVECs), and incubated for 12 
hours. Basal and substance P (SP)-stimulated NO production was measured. The 
HUVECs used for measuring basal NO production were lysed and both endothelial 
nitric oxide synthase (eNOS) protein expression and eNOS activity were determined. 
EDV was lower in smokers compared to nonsmokers (p<0.001). HUVECs treated with 
serum from smokers compared to nonsmokers showed significantly lower basal 
(p<0.0001) and stimulated (p<0.02) NO production, higher eNOS expression 
(pO.OOOl) but lower eNOS activity (p<0.004). There was a significant positive 
correlation between in vivo EDV and in vitro SP-stimulated NO production (rho=0.57, 
p<0.01), and between basal NO production and eNOS activity (r=0.54, p<0.008), and a 
negative correlation between basal NO production and eNOS protein expression (r= -  
0.60, p<0.003).
Conclusions—This is the first study to combine an in vivo model with a near- 
physiologic in vitro model to demonstrate an association between decreased NO 
production and reduced EDV. Cigarette smoking was associated with reduced EDV, 
NO generation, and eNOS activity in the presence of increased eNOS protein 
expression.
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Introduction
Cigarette smoking, a major cardiovascular risk factor, has been shown to be 
associated with impaired endothelium-dependent vasodilatation (EDV) of different 
vessels. 1' 6 A reduced EDV appears to be one of the earliest pathophysiological effects 
o f various risk factors for atherosclerosis, preceding morphological changes in the 
vessel wall. 1,2 A majority o f data suggest that NO, the primary vasodilator produced by 
endothelial cells (ECs), is affected by cigarette smoking and this is probably 
responsible for the alteration of EDV . 2' 6 However, the precise mechanism of cigarette 
smoke-mediated endothelial dysfunction and the alteration of NO biology is unclear 
and existing data are often contradictory.2 ' 13
The majority of in vitro studies related to smoking used crude cigarette smoke 
extract (CSE) produced by passing cigarette smoke through a buffer solution.6,9,14 This 
model is relevant but probably not physiological. In addition, systematic investigation 
of the correlation between the effects of smoking on EDV in humans, and the NO 
biosynthetic pathway (i.e. NO production, NOS protein expression and NOS activity) 
in a physiological in vitro model is lacking.
Nitric oxide synthase (NOS) generates NO by catalyzing the oxygen- and 
reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidation 
of L-arginine. 15 Evaluation of the relationship between NO production, eNOS protein 
• expression and eNOS activity in the vessel wall of healthy individuals is practically and 
ethically difficult. Therefore, the goal of the present study was to combine an in vivo 
model with an appropriate in vitro model for a systematic evaluation of the mechanisms 
responsible for cigarette smoke-induced dysfunction of the NO biosynthetic pathway. 
Accordingly, flow-mediated brachial artery reactivity was examined in smokers and 
serum from the same individuals was used to assess the effect of smoking on basal and 
stimulated NO production, eNOS protein expression and eNOS activity in vitro.
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Methods
Subjects and study design
Males with a history of active smoking were matched for age and sex with 
individuals who had never smoked. All subjects were free of other cardiovascular risk 
factors (i.e. hypertension, diabetes, low HDL, hyperlipidemia or a family history of 
premature vascular disease) and were not taking any medication.
Subjects were requested to abstain from smoking and caffeinated food or drink 
for 6 - 8  hours (overnight). On arrival in the early morning, subjects were allowed to rest 
for 20 min. Baseline blood pressure (BP) and heart rate (HR) were recorded and blood 
was collected from the antecubital vein. This was followed by an in vivo assessment of 
endothelial function by utilizing ultrasonography to measure the brachial artery 
diameter at rest, during reactive hyperemia (leading to flow-mediated endothelium- 
dependent dilatation) and after administration of 400 pg of sublingual nitroglycerin (an 
endothelium-independent dilator) as described elsewhere. All ultrasonographic scans 
were obtained by the same operator using the same equipment (Acuson L I0 6-11 MHz 
transducer and Acuson Aspen™ System; Mountain View, CA).
Blood for in vitro and biochemical studies (lipid profile and serum cotinine) was 
collected in Vacutainer® tubes and centrifuged at 1776 g (3000 rpm) for 15 min (4°C). 
The serum was collected and stored at -70°C until use. Analysis for the lipid profile 
was done in the hospital’s clinical laboratory and serum cotinine concentrations were 
determined by a commercially available kit (STC Technolologies, Bethlehem, PA).
The study protocol was approved by Saint Vincent Catholic Medical Centers of 
New York Ethics Committee and written informed consent was obtained from each 
subject.
Determination of endothelium-dependent and endothelium-independent 
vasodilatation
The brachial artery scans were read by the same experienced ultrasonographer 
who was blinded to the identity of the participants and stage of the experiment. The 
validated analysis method used has been described elsewhere.2 In brief, a pneumatic 
cuff was inflated around the right forearm to -300 mm Hg for 4.5 min followed by cuff 
deflation. Flow-mediated EDV was calculated by dividing the maximum vessel 
diameter at 50-60 s after cuff deflation by average the baseline diameter. Endothelium-
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independent dilatation was calculated as the maximum vessel diameter at 3-4 min after 
nitroglycerin administration divided by average baseline diameter. The arterial diameter 
was measured by using ultrasonic calipers for four cardiac cycles for each condition 
and then averaged. Results were expressed as percentage change from the baseline.
Endothelial cell culture and treatment
Primary HUVECs from a single donor were purchased from Clonetics 
(BioWhittaker, Walkersville, MD). HUVECs were cultured with slight modification of 
a method described previously. 16 Twenty thousand cells per well were plated in 24- 
well, flat bottom, tissue culture plates (Primaria, Baxter Scientific Products,
Springfield, NJ) with complete endothelial growth media (EGM; 500 ml endothelial 
cell basal media, 0.5 ml of 10 pg/ml human recombinant epidermal growth factor, 0.5 
ml of 1 mg/ml hydrocortisone, 0.5 ml of 50 mg/ml gentamicin and 50 |ag/ml 
amphotericin-B, 2 ml of 3 mg/ml bovine brain extract and 25 ml of fetal bovine serum) 
(Clonetics) and grown to -85%  confluence at 37°C in 5% CO2 . The supernatant was 
removed from confluent cells and incubated with equal volume of serum and EGM for 
1 2  hours (37°C; 5% CO2). All in vitro experiments were carried out, within the second 
passage of the HUVECs after obtaining from the vendor, by the same investigator who 
was blinded to the identity o f the participant and clinical data.
In order to validate the method, the effect of serum from smokers and 
nonsmokers on EC viability and proliferation was investigated using a neutral red 
assay17 and a cell proliferation assay using a commercial kit (Chemicon, Temecula,
CA,) respectively. No significant differences were observed in viability (n=5; neutral 
red assay; mean absorbance: 0.011±0.001 vs 0.012±0.001, p>0.32) and proliferation 
(n=5; cell proliferation assay; mean absorbance: 0.558±0.055 vs 0.570±0.057, p>0.87) 
between smokers and nonsmokers sera treated HUVECs. This allowed the conclusion 
that any differences observed between the effects of serum from smokers and 
nonsmokers were not due to a toxic effect on the endothelial cells.
Determination of nitric oxide production
NO concentrations in the culture supernatants and sera were determined by the 
chemiluminesence method described by Bramam and Hendrix18 using a NO analyzer 
(Sievers, Model # 280; Boulder, CO, USA). Basal NO production in culture was 
measured by incubating HUVECS with equal volume of serum and EGM (total
75
volume: 400 pi) in 24-well tissue culture plates. After 12 hours, basal NO production in 
the supernatant was determined. To measure stimulated NO production in culture, the 
supernatants were removed after 1 2  hours, the cells were washed twice with 
Dulbecco’s phosphate buffered saline (DPBS; Gibco BRL, Grands Island, NY). Fresh 
EGM was added to each well followed by stimulation with 10' 6 M substance P (SP) 
(Sigma; St. Louis, MO, USA) for 30 min.
In both experiments cell culture supernatants were collected and stored at -70°C 
until analysis. All samples were tested in duplicate and NO concentration was 
expressed as nmoI/L after adjusting for background levels.
Determination of nitric oxide synthase protein concentration
The eNOS protein concentration of the HUVECs in culture was determined by 
using a commercial ELISA kit (R&D systems, Minneapolis, MN). The cells that were 
used to detect basal (12 hour) NO production were washed twice with DPBS and cells 
were lysed with 400 pi of lysis buffer. The assay was performed using 100 pi o f each 
cell lysate following the manufacturer’s instructions. All samples were tested in 
duplicate and expressed as pg/ml.
Determination of nitric oxide synthase activity
The same cell lysates generated for the eNOS protein assay were used to 
determine the specific eNOS activity. This was done using a slight modification of the 
method described by Bedt and Schmidt19 using a commercial kit (Calbiochem, San 
Diego, CA). In brief, 100 pi of lysate was added to a reaction cocktail containing 25 pi 
of reaction buffer (50 mM Tris-HCl, 6  pM BH4 , 2 pM FAD and 2 pM FMN), and a 
final concentration of 1 pi of [3H]-L-arginine (55 Ci/mmol, lpCi/pl; Amersham, 
Arlington Heights, IL), 1 mM NADPH, 75 pM CaCE and 0.1 pM calmodulin. The 
incubation was carried out at room temperature for one hour. The radioactivity was 
quantitated using a liquid scintillation counter (Packard Instrument Com., Warrenville, 
IL). Both eNOS concentration and eNOS activity assays were run simultaneously. The 
eNOS activity in each sample was adjusted to the specific amount of eNOS protein 
detected by ELISA and the specific activity of eNOS was expressed as pmol L- 
citrulline/min/pg of eNOS protein.
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Statistical analysis
Results are presented as the mean ± standard error of mean (SEM) and all in 
vitro data are the average of duplicate measurements. The nonsmoker and smoker 
groups were compared using the unpaired Student’s t test. The relationship between 
basal NO production, eNOS protein expression and eNOS activity was assessed using 
linear regression analysis. Correlation between in vivo flow-mediated EDV and in vitro 
SP-stimuIated NO production was assessed by the Spearman’s rank correlation test. A 
value of p<0.05 was considered statistically significant. All calculations were 
performed using StatView (Abacus Concepts Inc.) statistical program.
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Results
Clinical characteristics of the study population
Baseline clinical characteristics of both smokers and nonsmokers are shown in 
Table 1. There was no significant difference between the two groups with exception of 
serum cotinine levels. The latter was significantly higher in smokers compared to 
nonsmokers (218.5± 34.2 vs 8.0±3.4 ng/ml, p<0.0003).
Brachial artery reactivity to flow and nitroglycerin
Baseline brachial artery diameters were not different between smokers and 
nonsmokers (4.4±0.01 vs 4.2+0.03 mm, p=0.48). Flow-mediated EDV of the brachial 
artery was significantly reduced in smokers as compared to nonsmokers (0.5±0.5 vs 
6.1±1.5%, respectively, p<0.001). By contrast, the nitroglycerin-mediated (endothelium 
independent) vasodilatory response of the brachial artery was not different between the 
two groups (19.2+1.4 vs 18.5±2.5%, respectively, p=0.87). The latter results indicate 
that subjects in the study group were apparently free of vascular smooth muscle 
disorder.
Effect of smoking on nitric oxide production
When the NO concentration in the serum from smokers was compared to that 
from nonsmokers no significant difference was found (5473 ± 858 vs 5691+737 
nmol/L, respectively, p=0.87).
HUVECs exposed to smoker’s serum in vitro showed a significantly lower 
basal NO production compared to those exposed to serum from nonsmokers (Figure 
1A; 1266±237 vs 3613±457 nmol/L, respectively, pO.OOOl).
Smokers serum treated, SP-stimulated HUVECs showed markedly lower NO 
release in the cell culture supernatant than the nonsmoker’s group (Figure IB; increase 
from the baseline: 133±74 vs 1057±455 nmol/L, respectively, p<0.02).
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Table 1. Clinical characteristics of the study population
Nonsmoker
(n=8 )
Smoker
(n=15)
(p Value)
Age 33±1 32±2 0.72
Systolic BP (mm/Hg) 118±6 117±2 0.82
Diastolic BP (mm/Hg) 77±3 77±2 0.98
HR (beats/min) 75+4 66±3 0 . 1 1
Total Cholesterol (mg/dl) 176+14 178±11 0.93
LDL (mg/dl) 98±8.0 106±9.0 0.62
HDL (mg/dl) 47+4.5 43±2.9 0.46
LDL/HDL ratio 2.2±0.3 2 .6 +0 .3 0.43
Triglyceride (mg/dl) 111+19.6 163±43.1 0.47
Cotinine (ng/ml) 8±3.4 218±34.2* <0.0003
Values are expressed as mean±SEM. BP = blood pressure, HR = heart rate, LDL = 
low-density lipoprotein, HDL = high-density lipoprotein. Unpaired Student ’s t test: * 
smoker versus nonsmoker, p<0.0003.
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Figure 1. Effects of smoker’s serum on basal and substance P stimulated NO 
production in vitro.
Confluent (-85%) HUVECs were incubated with equal volume o f  medium and serum 
from smokers (n=15) or nonsmokers (n=8) in 24-well plates. A) After 12 hour 
incubation (37°C; 5% CO2) the cell culture supernatant was collected to measure basal 
NO production. B) To measure stimulated NO production, the supernatant was removed 
after 12 hours and fresh media was added to each well followed by stimulation with 
substance P (SP;10'6 M) fo r 30 min. NO production in the cell culture supernatant was 
determined by a chemiluminesence method. Results are presented as means ± SE M  
after adjusting fo r the background. Unpaired Student’s t test: A) Basal NO production,
* smoker versus nonsmoker, p<0.0001; B) SP stimulated NO production, * smoker 
versus nonsmoker, p<0.02.
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Effects of smoker’s serum on eNOS protein expression and eNOS 
activity in vitro
To determine whether the observed changes in in vitro NO production by 
HUVECs were associated with a change in its eNOS protein, cells from the plates used 
to detect basal NO production were lysed and eNOS protein expression was determined. 
HUVECs treated with serum from smokers had significantly higher eNOS protein 
expression as compared to the HUVECs treated with serum from nonsmokers (Figure 
2A; 939.5±51.5 vs 440.8±58.1 pg/ml, respectively, pO.OOOl).
To correlate basal NO production with enzymatic activity, the cell lysates 
utilized above were used to determine eNOS activity. Specific eNOS activity for each 
sample was adjusted for the amount of eNOS protein as detected by ELISA. The cell 
lysates from HUVECs treated with smoker’s serum showed significantly lower eNOS 
activity as compared to cells treated with nonsmoker’s serum (Figure 2B; 1.18±0.13 vs 
1.92±0.19 pmol L-citrulline/min/pg eNOS, respectively, p<0.004).
Relationship between nitric oxide production, eNOS protein 
expression and eNOS activity
On linear regression analysis a significant positive correlation was found 
between in vitro basal NO production and eNOS activity (Figure 3A; r=0.54, p<0.008). 
On the other hand, in vitro eNOS protein expression showed a significant negative 
correlation with basal NO production (Figure 3B; r=-0.60, p<0.003). Additionally, 
eNOS protein negatively correlated with eNOS activity (Figure 4; r= -0.75, pO.OOOl).
Relationship between stimulated nitric oxide production in vitro and 
endothelium-dependent vasodilatation in vivo
The relationship between in vivo EDV and in vitro SP-stimulated NO production 
was determined by the Spearman’s rank correlation test. A significant correlation was 
found between the in vivo and the in vitro model (Spearman’s rho=0.57, pO .O l).
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Figure 2. Effects of smoker’s serum on eNOS protein expression and eNOS 
activity in vitro.
Confluent (-85%) HUVECs were incubated with equal volume o f  medium and serum 
from smokers (n=15) and nonsmokers (n=8) in 24-well plates. After 12 hours cell 
culture supernatant was collected and the HUVECs were lysed. A) eNOS protein 
concentration o f the cell lysates was determined by ELISA. B) eNOS activity o f  the cell 
lysates was determined by detecting the conversion o f  [3H] L-arginine to [3H] L- 
citrulline. Results are presented as means ±SEM. Unpaired Student’s t test: A) eNOS 
protein expression, * smoker versus nonsmoker, p<0.0001; B) eNOS activity, * smoker 
versus nonsmoker, p<0.004.
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Discussion
The association between cigarette smoking and vascular diseases is well 
documented and there is a general consensus that it targets the vascular endothelial 
cells (ECs). However, the exact mechanisms by which cigarette smoke alters EC 
function and induces cardiovascular pathology are not clear. NO, a heterodiatomic free 
radical, is primarily responsible for vasoregulatory and homeostatic functions of ECs. 
Several investigators have suggested that NO and its vasodilatory function is altered by 
cigarette smoking. 1' 6 However, conflicting data also exist. It has been reported that 
cigarette smoking is associated with impairment of EDV in both the brachial and 
coronary artery circulation .2 ' 5 Using the NO antagonist (L-NMMA) several 
investigators have indirectly associated impairment of EDV in smokers with decreased 
NO .3' 5 Conversely, other investigators have found no relationship between cigarette
«7 1 A  'JA  A A
smoking and impaired EDV or decreased NO in various models. ’ ’ ' Similar 
disagreement also exists regarding the effect of cigarette smoke on eNOS mRNA, 
eNOS protein and its activity. Both an increase and a decrease of eNOS mRNA and 
protein have been found in various experimental models.9,11' 13 The majority of in vitro 
data has involved the use of CSE. However, this solution is probably not physiological 
because in the circulation, cigarette smoke has to first bypass the lung. In addition, 
certain toxic components may be neutralized by the anti-oxidants present in the blood. 
Therefore, to simulate a physiological environment in the present study, serum was 
used as a vehicle of cigarette smoke exposure in vitro.
Simultaneous observations of the in vivo (flow-mediated brachial artery 
reactivity) and in vitro (SP-stimulated NO production) model used in the study showed 
a significant reduction in NO production along with a reduction in EDV in the smoker’s 
group compared to the nonsmoker’s group. There was a significant correlation between 
both in vivo and in vitro systems. To our knowledge, the present study demonstrates, 
for the first time, a direct association between in vivo flow-mediated brachial artery 
reactivity and in vitro NO production by ECs treated with serum from the same 
individuals.
The finding of reduced basal NO production by the HUVECs in the smoker’s 
group in the present model complements previous in vitro6 and in vivo3-5 findings that 
cigarette smoking affects basal NO production by ECs. However, no significant
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difference was found between serum NO of smokers and nonsmokers. Similarly, 
Rangemark and Wennmalm23 reported no difference in plasma nitrate (a metabolite of 
NO) between smokers and nonsmokers. These data support the notion that the 
bloodstream concentration of NO may be an unreliable measure of endothelium- 
derived NO. This parameter is affected by various factors such as dietary intake, 
metabolism in the gut, denitrifying liver enzymes, inhalation of atmospheric gaseous 
nitrogen compounds and renal function.24
Analysis of eNOS protein expression in the present experimental model 
revealed a higher eNOS expression in HUVECs treated with serum from smokers. This 
concurs with a previous in vivo study in the rat. 13 However, Su et al. 9 reported that 
CSE inhibited eNOS protein expression in pulmonary artery ECs. The differences 
noted between the two studies probably reflect differences in in vitro experimental 
models (non-physiologic versus near-physiologic). A potential explanation for the 
observation seen in the present study is that a negative feedback mechanism may exist 
between NO levels and eNOS protein expression. Thus, decreased NO generation or 
availability may trigger increased eNOS expression. Several investigators25,26 have 
postulated a negative feedback mechanism between NO and eNOS activity but data on 
eNOS protein are not available. In the present study a strong negative correlation 
between basal NO production and eNOS protein expression in cultured HUVECs 
supports the existence of such mechanisms.
Analysis of eNOS activity from the same cell lysates showed decreased eNOS 
activity in HUVECs treated with serum from smokers. Basal NO production, eNOS 
protein and eNOS activity were measured from the same culture. Thus for each sample, 
a direct relationship of eNOS protein and its activity to NO production was determined. 
The eNOS activity positively correlated with basal NO production and negatively 
correlated with eNOS protein expression. Similarly, Wang et a l}1 found no correlation 
between eNOS protein and its activity in HUVECs isolated from pregnant smokers. 
Thus, in smokers there appears to exist a dissociation between eNOS protein expression 
and activity. Reduced eNOS activity in the presence of increased eNOS protein may be 
due to several factors including the presence of inhibitors, lack of substrate and co­
factors, production of nonfunctional enzyme or an uncoupling effect on eNOS gene
• • 28 29expression and enzyme activity. ’
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Study limitations
In the present study several potential limitations are recognized:
1) The number of subjects enrolled in our study group was relatively small and 
included only males. Thus, the results may not be generalized.
2) Flow mediated-EDV was correlated with in vitro SP-stimulated NO 
production. Although both stimulate NO production, the receptors that mediate the 
individual effects are different27. It is possible that smoking differentially affects these 
receptors and their signaling process.
3) Cigarette smoke-induced endothelial dysfunction is multi-factorial and may 
be related to substrate deficiency, a reduction in eNOS synthase activity, a diminished 
release, or an enhanced degradation of NO .5 In the present study the main focus was on 
NO production, eNOS protein expression and eNOS activity. The influence of other 
factors in the present model cannot be excluded.
Conclusion
This study has taken a novel approach to confirm the association between 
deceased NO production and reduced EDV in cigarette smokers by combining in vitro 
and in vivo physiologic models. In the in vitro model, cigarette smoking was associated 
with increased eNOS protein expression but reduced eNOS activity as well as 
decreased NO production. Further investigation will be required to precisely elucidate 
the mechanisms responsible for the decreased eNOS activity seen in the presence of 
increased eNOS protein expression.
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Abstract
OBJECTIVES—  Investigation of the dose-dependent effects of active cigarette 
smoking on endothelial- nitric oxide (NO) and endothelin-1 (ET-1) biosynthesis.
BACKGROUND—  Limited studies have suggested that active cigarette smoking may 
be associated with a dose-dependent reduction of endothelium-dependent vasodilatation 
(EDV). The underlying biochemical changes that cause this dose-specific effect such as 
changes in the endothelial NO biosynthetic pathway and ET-1 production have not 
been examined.
METHODS—  Flow- and nitroglycerin-mediated reactivity of the brachial artery were 
measured in 8  nonsmokers, 7 light smokers (<1 pack/week) and 8  heavy smokers (>1 
pack/day) and their sera were added to confluent (-85%) monolayers o f human 
umbilical endothelial cells (HUVECs) for 12 hours. Basal and substance P (SP)- 
stimulated NO; and basal ET-1 production were measured. The HUVECs used for 
measuring basal NO production were lysed and both endothelial nitric oxide synthase 
(eNOS) protein expression and eNOS activity were determined.
RESULTS—  Serum cotinine level and pack-years of smoking were significantly lower 
in light smokers compared to heavy smokers (p<0.006 and p<0.004, respectively).
There were no significant differences between heavy smokers and light smokers in 
EDV (p=0.52), basal- (p=0.70) and stimulated- NO production (p=0.95), eNOS protein 
(p=0.40) and eNOS activity (p=0.63). Compared to nonsmokers all the parameters were 
significantly altered in both of the smokers’ groups. No differences were found in 
nitroglycerin-mediated vasodilatation and in vitro ET-1 production among the three 
groups.
CONCLUSION— These results that indicate light smoking may have similar 
detrimental effects on EDV and NO biosynthetic pathway as does heavy smoking.
These data may have important implications concerning the amount of active cigarette 
exposure that imparts cardiovascular risk.
94
Abbreviations and Acronyms
Nitric oxide = NO 
Endothelial cells = ECs 
Endothelium-dependent vasodilatation =EDV 
Endothelial growth media = EGM 
Endothelial nitric oxide synthase = eNOS 
Endothelin-1 = ET-1
Human umbilical endothelial cells = HUVECs 
Substance P = SP
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Introduction
Cigarette smoking is a recognized risk factor for cardiovascular disease and is 
known to promote the development of atherosclerosis and thrombosis (1,2). Endothelial 
dysfunction and early atherogenesis, increased procoagulation and platelet activity as 
well as hypertension and vasospasm have all been documented either clinically or in 
various experimental models (1-3). While this association between smoking and 
cardiovascular risk has clearly been demonstrated, an unanswered question related to 
smoking is whether or not there is a linear dose effect in active smokers. Early 
epidemiological studies suggested a direct dose effect with a greater risk for heavy 
smokers in comparison to lighter smokers (4). However, several recent large 
epidemiological studies, despite showing a trend for more cardiovascular events in 
heavier smokers, have failed to find a significant dose-dependent correlation between 
the risk of cardiovascular disease and the number of cigarettes smoked or the pack- 
years of smoke exposure (5, 6 ). Furthermore, smoking as few as 1-4 cigarettes per day 
was associated with a doubling of risk for coronary artery disease in the Nurses’ Health 
Study (7).
It has been shown that cigarette smoking is associated with a reduction of EDV 
(8-16). However, data regarding the dose-dependent effects of smoking on EDV are 
limited and inconclusive (8,13-15). Celermajer et al. suggested that both active (8 ) and 
passive (13) smoking were associated with a dose-dependent decrease in EDV but in 
other studies this dose-dependent effect was not evident (14,15). We have previously 
described a physiologic in vitro model to study the effects of smoking on the NO 
biosynthetic pathway and validated this model with in vivo measurements of EDV of 
the brachial artery (16). In the present study, the effects of light and heavy cigarette 
smoking exposure on endothelial cell (EC)-derived vasoregulatory factors (NO, ET-1) 
as well as EDV of the brachial artery were assessed to determine whether or not there is 
a dose-dependent effect of active smoking on endothelial vasoregulatory function.
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Material and methods
Subjects and study design. Male volunteers with a history of active smoking were 
matched for age and sex with individuals who had never smoked. Active smokers were 
sub-classified into two groups: light smokers (with smoking habit of < 1  pack/week) and 
heavy smokers (with smoking habit of >1 pack/day). All subjects were free of other 
cardiovascular risk factors (i.e. hypertension, diabetes, low HDL, hyperlipidemia or a 
family history of premature vascular disease) and were not taking any medication.
Subjects were requested to abstain from smoking and foods or caffeinated drinks 
for 6 - 8  hours (overnight). On arrival in the morning, subjects were allowed to rest for 
20 min. Baseline blood pressure and heart rate were recorded, and blood was collected 
from the antecubital vein. This was followed by an in vivo assessment of endothelial 
function by utilizing ultrasonography to measure the brachial artery diameter at rest, 
during reactive hyperemia (leading to flow-mediated endothelium-dependent dilatation) 
and after administration of 400 fig of sublingual nitroglycerin (an endothelium- 
independent dilator) as previously described (8,16). All ultrasonographic scans were 
obtained utilizing the same equipment (Acuson LI 0 6-11 MHz transducer and Acuson 
Aspen™ System; Mountain View, CA).
Blood for in vitro and biochemical studies (lipid profile and serum cotinine) was 
collected in vacutainer tubes and centrifuged at 1776 g (3000 rpm) for 15 min (4°C).
The serum was collected and stored at -70°C until use. Analysis for the lipid profile 
was done in the hospital’s clinical laboratory and serum cotinine concentrations were 
determined by a commercially available ELISA kit (STC Technolologies, Bethlehem, 
PA).
The study protocol was approved by Saint Vincent Catholic Medical Centers of 
New York Ethics Committee and written informed consent was obtained from each 
subject.
Determination of endothelium-dependent and endothelium-independent 
vasodilatation. All brachial artery scans were read by a single, experienced, 
ultrasonographer (JGZ) who was blinded to the identity of the participants and stage of 
the experiment. The validated method of analysis has been published previously (8,16). 
In brief, a pneumatic cuff was inflated around the right forearm to -300 mm Hg for 4.5 
min followed by cuff deflation. Flow-mediated EDV was calculated by dividing the
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maximum .vessel diameter at 50-60 s after cuff deflation with average baseline diameter. 
Endothelium-independent dilatation was calculated as the maximum vessel diameter at 
3-4 min after nitroglycerin administration divided by average baseline diameter. The 
arterial diameter was measured using ultrasonic calipers for four cardiac cycles for each 
condition and was averaged. Diameter measurements were taken at end-diastole, 
coincident with the R wave on a continuously recorded electrocardiographic trace. 
Results were expressed as percentage changes from the baseline.
Endothelial cell culture and treatment. Primary HUVECs from a single donor were 
purchased from Clonetics (BioWhittaker, Walkersville, MD). HUVECs were cultured 
using the method described previously (16). In brief, twenty thousand cells/well were 
plated in 24-well, flat bottom, tissue culture plates (Primaria, Baxter Scientific Products, 
Springfield, NJ) with complete endothelial growth media (EGM) (Clonetics) and grown 
to -85%  confluence at 37°C in 5% CO2 . The supernatant was removed from confluent 
cells and incubated with an equal volume of serum and EGM for 12 hours (37°C; 5% 
CO2). All in vitro experiments were carried out, during the second passage of the 
HUVECs, by the same investigator (RSB) who was blinded to the identity of the 
participant and the clinical data.
Determination of nitric oxide production, eNOS expression and eNOS activity. As
described above, HUVECs were treated for 12 hours with equal volumes of serum and 
EGM (total volume: 400 pi) in 24-well tissue culture plates. After 12 hours, basal NO 
production in the supernatant was determined. To measure stimulated NO production in 
culture the supernatants were removed after 1 2  hours and the cells washed twice with 
Dulbecco’s phosphate buffered saline (DPBS; Gibco BRL, Grands Island, NY). Fresh 
EGM was added to each well followed by stimulation with 10' 6 M substance P (SP) 
(Sigma; St. Louis, MO, USA) for 30 min. Cell culture supernatants were collected and 
stored at -70°C until analyzed. NO concentration in each sample was determined by the 
chemiluminesence method as described previously using a NO analyzer (Sievers,
Model # 280; Boulder, CO, USA) and expressed as nM after adjusting for background 
NO levels (16).
The eNOS protein concentration of the HUVECs in culture was determined 
using a commercial ELISA kit (R&D systems, Minneapolis, MN) and expressed as 
pg/ml as published previously (16).
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The cell lysates generated for the eNOS protein assay were also used to 
determine the specific eNOS activity. This was done using a method described 
previously (16). Both eNOS concentration and eNOS activity assays were run 
simultaneously. The eNOS activity in each sample was adjusted to the specific amount 
of eNOS protein detected by ELISA and the specific activity of eNOS was expressed as 
pmol L-citrulline/min/pg of eNOS protein.
Determination of endothelin-1 production. NO and ET-1 were detected from the 
same cell-culture supernatant. Endothelin-1 concentrations were determined by using a 
commercial ELISA kit (Amersham, Arlington Heights, IL) and expressed as pg/ml after 
adjusting for background levels.
Statistical and power analyses. Results are presented as the mean±standard error o f 
mean (SEM) and all in vitro data are the average of duplicate measurements. One-way 
analysis of variance (ANOVA) was performed to compare values between nonsmokers, 
light smokers and heavy smokers. For each ANOVA, Post hoc Fisher’s PLSD 
(protected least significant difference) was performed to determine each individual 
group difference. The relationships between the degree of smoke exposure (as measured 
by the pack-year and serum cotinine levels) and EDV or NO were determined using 
linear regression analysis. A value of p<0.05 was considered statistically significant.
As new in vitro methods have been described in this study, an accurate 
assumption for the difference between light and heavy smokers in vitro was difficult. 
For in vivo data, Celermajer et al. (8 ) have reported a mean absolute difference of 4% in 
EDV between very light (6 .6 %) and heavy (2.6%) smokers with a pooled standard 
deviation of 2.9%. Although, the grouping criteria for smokers in their study were 
different from ours (pack-years of smoking as opposed to numbers of cigarette 
smoked), the pack-years of smoking in the corresponding groups were comparable 
between the two studies. Using their finding with the assumption that light smokers will 
have higher EDV compared to heavy smokers (i.e. one sided), a sample size of 7-8 in 
each group had an 80% power at a  = 0.05. Power analyses were performed using the 
STPLAN statistical software (version 4.1) and all the other analyses were performed 
using the StatView statistical program (version 4.5).
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Results
Clinical characteristics of the study population. There was no significant difference 
in age, systolic or diastolic blood pressure, heart rate, total cholesterol, LDL, HDL and 
triglyceride level between non-smokers, light smokers and heavy smokers. Serum 
cotinine levels, number of cigarette smoked per day and pack-years of smoking were 
significantly different between all the groups substantiating the smoking status of the 
study population (Table. 1).
Brachial artery reactivity to flow and nitroglycerin. Baseline brachial artery 
diameters were not different between non-smokers (4.2±0.02 mm), light smokers 
(4.3±0.03 mm) and heavy smokers (4.4±0.01 mm)(ANOVA: p=0.6). Flow-mediated 
EDV of the brachial artery was not significantly different between light smokers and 
heavy smokers (1.0±1.0% and 0.1±0.1%, p=0.52), but both were significantly reduced 
compared to nonsmokers (6.0±1.4%; ANOVA: pO.OOl for the groups; Post hoc 
Fisher’s PLSD: p<0.003 for nonsmokers versus light smokers, pO.OOl for nonsmokers 
versus heavy smokers). By contrast, the nitroglycerin-mediated (endothelium- 
independent) vasodilatory response of the brachial artery was not different between all 
the groups (19.1±1.4 % for non-smokers, 22.413.6% for light smokers and 15.713.6% 
for heavy smokers, ANOVA: p=0.34).
Effect of smoking on nitric oxide and endothelin-1 production. HUVECs exposed to 
light smokers’ and heavy smokers’ serum in vitro showed a similar basal NO 
production (Figure 1A; 14181421 versus 11371267 nM, respectively, p=0.62). 
However, compared to the nonsmokers’ group both were significantly lower (36131459 
nM; ANOVA: p<0.0004 for the groups; Post hoc Fisher’s PLSD: pO.OOl for 
nonsmokers versus light smokers, p<0.0003 for nonsmokers versus heavy smokers).
SP- stimulated NO production was similar between light smokers and heavy 
smokers group (A from baseline: 145187 versus 1211120 nM, respectively, p=0.95) but 
compared to nonsmokers group both were significantly lower (A from baseline: 
10571455 nM; ANOVA: p<0.05 for the groups; Post hoc Fisher’s PLSD: p<0.04 for 
nonsmokers versus light smokers, p<0.03 for nonsmokers versus heavy smokers).
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Table 1. Parameters of smoke exposure and endothelial function of the
study population
Non-
Smokers
(n=8 )
Light
Smokers
(n=7)
Heavy
Smokers
(n=8 )
Cigarettes/day — 1 .8 +0 . 6 2 1 ± 1 *
Pack-years — 0.7+0.2 13±3*
Cotinine (ng/ml) 8±3 140+54f 286±26 J||
Baseline diameter (mm) 4.2±0.02 4.3±0.03 4.4±0.01
EDV (%) 6.0+1.4 1 .0 ± 1 . 0 1 0 .1 ±0 . 1  #
Nitroglycerin-mediated 
Dilatation (%)
19.1+1.4 22.4±3.6 15.7+3.6
Values are expressed as mean±SEM.
EDV — Endothelial-dependent vasodilatation
*p  <0.004fo r  light smokers versus heavy smokers.
Post hoc Fisher’s PLSD: For serum cotinine levels: 
f  p<0.02 fo r  nonsmokers versus light smokers 
/ p<0.0001 for nonsmokers versus heavy smokers 
11 p<0.006for light smokers versus heavy smokers
Post hoc Fisher’s PLSD: For EDV (%):
Tf p<0.003for non-smokers versus light-smokers 
# p<0.001 fo r  nonsmokers versus heavy smokers
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Figure 1. Effects of light and heavy smokers’ serum on basal- nitric oxide (NO) 
and endothelin-1 (ET-1) production in vitro.
Confluent (-85%) HUVECs were incubated with an equal volume o f  medium and 
serum from nonsmokers (n=8) or light smokers (n=7) or heavy smokers (n=8) in 24- 
well plates. After 12 h incubation (37°C; 5% CO2)  the cell culture supernatant was 
collected. A) NO production in the cell culture supernatant was determined by a 
chemiluminesence method. B) ET-1 production in the cell culture supernatant was 
determined using an ELISA. A) Basal NO production; one-way ANOVA: group, p  <
0.001. Post hoc Fisher’s PLSD: * nonsmokers versus light smokers, p<0.001; f  
nonsmokers versus heavy smokers, p<0.001; light smokers versus heavy smokers, 
p=0.62. B) Basal ET-1 production; one-way ANOVA: group, p=0.55. The box 
represent the interquartile range (between the 25th and 75c percentiles), the median is 
shown as a horizontal bar within each box. The bars outside each box show the range 
o f  95% o f  all values.
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Basal ET-1 production by the HUVECs treated with nonsmokers’, light 
smokers’ and heavy smokers’ serum were not different between the three groups 
(Figure IB; 283±43 pg/ml, 326±24 pg/ml and 282±17 pg/ml, respectively, ANOVA: 
p=0.55).
Effects of light and heavy smoker’s serum on eNOS protein expression and eNOS 
activity in vitro. HUVECs treated with light smokers’ and heavy smokers’ serum had 
similar eNOS protein expression (Figure 2A; 888±96 versus 974±50 pg/ml, 
respectively, p=0.40). However, both smokers’ groups showed significantly higher 
eNOS protein expression as compared to the nonsmokers (Figure 2A; 440+58 pg/ml; 
ANOVA: pO.OOOl for the groups; Post hoc Fisher’s PLSD: p0 .0003  for non-smokers 
versus light-smokers, pO.OOOl for non-smokers versus heavy-smokers).
The cell lysates utilized above were used to determine eNOS activity and 
specific eNOS activity for each sample was adjusted for the amount of eNOS protein as 
detected by ELISA. The cell lysates from HUVECs treated with either light smokers’ or 
heavy smokers’ serum showed similar eNOS activity (Figure 2B; 1.25±0.21 versus 
1.11 ±0.16 pmol L-citrulline/min/pg eNOS, respectively, p=0.63). However; both of 
these groups showed significantly lower eNOS activity as compared to the nonsmokers 
(Figure 2B; 1.92±0.20 pmol L-citrulline/min/pg eNOS; ANOVA: p<0.02 for the 
groups; Post hoc Fisher’s PLSD: p<0.03 for nonsmokers versus light smokers, p<0.006 
for nonsmokers versus heavy smokers).
Relationship between degree of smoke exposure, endothelium-dependent 
vasodilatation and nitric oxide production. Pack-years of smoke exposure represent 
long-term exposure while serum cotinine represents short-term smoke exposure (2-4 
days). On linear regression analysis no significant correlation was found between EDV 
and pack-years (r=0.14, p=0.62) or serum cotinine levels (r=0.20, p=0.55) in the 
smokers’ groups. Similarly, no relationship could be found between in vitro NO 
production and serum cotinine levels (r=0.30, p=0.33) in the smokers’ groups. These 
results suggest that dose related detrimental effect of smoking on EDV and NO 
production in both short- and long- term may not be linear.
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Figure 2. Effects of light and heavy smokers’ serum on eNOS protein expression 
and eNOS activity in vitro.
Confluent (-85%) HUVECs were incubated with an equal volume o f  medium and serum 
from nonsmokers (n=8) or light smokers (n=7) or heavy smokers (n=8) in 24-well 
plates. After 12 h culture supernatant was collected and the HUVECs were lysed. A) 
eNOS protein concentration o f  the cell lysates was determined by ELISA. B) eNOS 
activity o f  the cell lysates was determined by detecting the conversion o f  [3H] L- 
arginine to [3H] L-citrulline. A) eNOS protein expression; one-way ANOVA: group, 
p  < 0.0001. Post hoc Fisher’s PLSD: * nonsmokers versus light smokers, p<0.0003; f  
non smokers versus heavy smokers, p<0.0001; light smokers versus heavy smokers, 
p=0.40. B) eNOS activity; one-way ANOVA: group, p  < 0.02. Post hoc Fisher’s PLSD: 
* nonsmokers versus light smokers, p<0.03; f  nonsmokers versus heavy smokers, 
p<0.004; light smokers versus heavy smokers, p=0.63. The box represents the 
interquartile range (between the 25th and 75th percentiles), the median is shown as a 
horizontal bar within each box. The bars outside each box show the range o f  95% o f  all 
values.
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Discussion
Impairment of EDV is one of the early steps that link cardiovascular risk factors 
and clinical events (17,18). Using a combined in vivo and in vitro model we have 
previously demonstrated that smoking is associated with reduced EDV, which in part is 
a reflection of decreased production or bio-availability of endothelial NO (16). In this 
study, even a relatively small amount of active cigarette smoking appeared capable of 
overwhelming the biochemical and cellular process of endothelial NO biosynthesis in 
vivo and in vitro.
Degree of smoking, endothelial-dependent vasodilation and the nitric oxide 
biosynthetic pathway. Celermajer et al. found a dose-dependent reduction of EDV in 
relation to pack-years of active smoke exposure (8 ). On the contrary, in our study both 
the active heavy and light smokers had a similar reduction in brachial artery EDV 
compared to non-smokers. It should be noted that in the present study, smokers were 
stratified into two groups by the number of cigarettes smoked as opposed to pack-years 
of smoking. Nevertheless, number of cigarettes smoked per day, pack-years o f smoke 
exposure and serum cotinine levels were significantly lower in Iight-smokers as 
compared to heavy smokers. Interestingly, in a later study, Celermajer et al. reported 
that active and passive smoke exposure caused a similar degree of dysfunction in EDV 
of the brachial artery in the presence of significantly different salivary cotinine levels 
(13). Likewise, Sumida et al. in addition to finding a similar reduction in vasodilatory 
function of the coronary arteries between active and passive smokers also found a 
similar reduction in coronary artery vasodilatory function in individuals with heavy- 
and light-passive smoke exposure (14). More recently, Woo et al. failed to a find a 
dose-dependent relationship between the duration of passive smoke exposure and 
reduced EDV of the brachial artery (15). The above studies are consistent with our own 
in vivo findings and parallel our in vitro observations showing similar alterations in 
basal- and SP-stimulated NO production, eNOS protein expression and activity in both 
heavy and light smokers. These data suggest that active light smoking can induce 
equivalent detrimental biochemical changes leading to abnormal endothelial 
vasodilatory function as active heavy smoking.
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Enothelin-l and smoking. ET-1 is the most potent endogenous vasoconstrictor 
produced by both the ECs and vascular smooth-muscle cells (19). Available data on the 
effects of cigarette smoke or its components on ET-1 levels in the circulation or in 
various tissues are limited. Two early studies suggested that within the first 10 min of 
active smoking there is a rise in plasma or serum ET-1 level, which is followed by a 
decline over time (2 0 ,2 1 ).
More recently, in a rat model acute cigarette exposure was shown to increase the 
expression of ET-1 mRNA in heart and lung tissues, but with chronic cigarette 
exposure, the effect on the ET-1 mRNA in cardiovascular tissues became insignificant 
(22). Similarly, Barbera et al found both ET-1 expression in pulmonary arteries and 
endothelin content in lung tissue extracts were similar between smokers and non- 
smokers (23). These data taken together with our in vitro finding of no difference in 
basal ET-1 production among the three groups suggest that the increase in ET-1 
production in response to active smoking in the healthy individuals is probably a 
transient phenomenon and restricted only to the acute phase of smoking.
Implications of this study. Endothelial function encompasses the regulation of 
vasomotor tone, inflammation in the vessel wall and the balance of the 
thrombotic/thrombolytic factors at the lumen-wall interface (17,18). NO, the potent 
vasodilator secreted by ECs, plays a pivotal role in regulation of all the components of 
endothelial function (17,18). ET-1, the potent vasoconstrictor also secreted by ECs, 
opposes the effects of NO (18,19). Thus, a deficiency in NO or an increase in ET-1 can 
create an unfavorable atmosphere in the lumen-wall interface contributing to 
cardiovascular pathology. The present study investigated the dose-related effect of 
active smoking on these two molecules. Our data on NO and EDV in active smokers are 
consistent with the findings of other studies of active and passive smoke exposure and 
show that the dose-response curve for cardiovascular effects associated with tobacco 
smoke exposure may not be linear (5-7,14,24,25). Furthermore, data from the model 
utilized in the present study suggest that smoking appears to affect only the endothelial 
NO biosynthesis without significantly altering EC-specific ET-1 biosynthesis.
Study limitations. In the present study, several potential limitations are recognized. 
First, while similar in vivo and in vitro results in our study population substantiated our 
findings, the number of subjects enrolled in our study group was relatively small.
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Additional studies in a larger population may be required to exclude a smaller than 
hypothesized difference in bio-physiology of EDV between light and heavy smokers. 
Second, in the present study only EC-specific ET-1 production was measured but 
vascular-smooth muscle cells (19) also contribute to circulatory ET-1. Thus, our data 
should only be interpreted as an EC-specific response to smoking. Third, the 
cardiovascular effects of smoking leading to a clinical event depend on complex 
interactions involving alterations in the biology of the vessel wall, pro-thrombotic and 
pro-inflammatory molecules and cannot be explained solely by the results of this study.
Conclusion. The present study indicates that both heavy and light active smoking 
(substantiated by pack years and serum cotinine) can cause a similar degree of 
endothelial vasoregulatory dysfunction in vivo and similar alterations in NO production, 
eNOS protein and its activity in vitro. Thus, even a small amount of active smoke 
exposure appears to have a significant effect on one of the early pathophysiological 
indicators for atherosclerosis and supports other data that smoking even a small number 
of cigarettes has potentially deleterious effects contributing to cardiovascular risk. 
Furthermore, our study suggests that even a small amount of smoke exposure may 
initiate yet to be defined cellular mechanisms that might overwhelm the biochemical 
process of NO biosynthesis. Additional investigations are required to elucidate such 
molecular and cellular mechanisms of endothelial dysfunction.
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Abstract
Background: Data regarding the effects of smoking on thrombo-hemostatic factors (TF 
& TFPI-1) are limited and on fibrinolytic factors (t-PA & PAI-1) are debatable. The 
current study investigated the smoking-related, endothelial cell (EC)-specific responses 
for these factors and their relation to nitric oxide (NO) production in vitro.
Methods and Results: Serum from 8  nonsmokers and 15 smokers were incubated with 
confluent (-85%) human umbilical endothelial cells (HUVECs) in 24-well tissue- 
culture plates for 12 hours. After the incubation, basal NO, t-PA, PAI-1, TF, TFPI-1 
production and substance P (SP)-stimulated NO, t-PA, PAI-1 production were 
determined. HUVECs treated with smokers’ serum showed lower basal (p<0.02) and 
SP-stimulated (p=0.059) t-PA production but similar basal and stimulated PAI-1 
production (p=0.9 and p=0.6) compared to nonsmokers. Basal t-PA/PAI-1 molar ratio 
was significantly reduced in smokers (p<0.005). TFPI-1 level in the cell culture 
supernatant was also significantly lower in smokers compared to nonsmokers group 
(p<0.05) with no difference in TF level between both groups (p=0.5). Both basal . 
(pO.OOl) and SP-stimulated (p<0.05) NO production were significantly reduced in 
smokers. Basal TFPI-1 in culture correlated positively with basal NO production 
(r=0.42, p=0.04), and negatively with serum cotinine level (r= -0.6, p=0.01). 
Conclusions: These results indicate that cigarette smoking is associated with alterations 
in EC-derived fibrinolytic (t-PA) and anti-thrombotic (TFPI-1) factors. To our 
knowledge this is the first demonstration that EC-derived TFPI is affected by smoking 
and endogenous NO or the degree of smoke exposure may influence TFPI levels in an 
EC milieu.
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Introduction
Cigarette smoking is associated with an increased risk of acute myocardial 
infarction and sudden cardiac death1. It has been hypothesized that alterations of 
antithrombotic and fibrinolytic functions in the blood or at the vessel-wall interface are 
responsible for the majority of these acute events in smokers1,2. The exact mechanisms 
underlying this dysfunction are yet to be elucidated. Cigarette smoke-induced 
alterations of endothelial cell (EC) function appear to be one of the potential 
mechanisms for this dysfunction.
ECs play a central role in vascular homeostasis by maintaining a delicate 
balance between vasodilating (NO) and vasoconstricting (endothelin-1) factors, 
thrombotic (tissue factor (TF)) and anti-thrombotic(Tissue factor pathway inhibitor-1 
(TFPI-1)) factors, as well as fibrinolytic (tissue plasminogen activator (t-PA)) and anti­
fibrinolytic factors (plasminogen activator inhibitor-1 (PAI-1)),3. Data regarding the 
effects of smoking on thrombo-hemostatic factors (TF & TFPI-1) are limited and on 
fibrinolytic factors (t-PA & PAI-1) are debatable with increase, decrease or in change of 
these molecules having been reported2,4'6.
Nitric oxide (NO), in addition to its vasoregulatory function is involved in 
maintaining anti-thrombotic properties of various cells including ECs and platelets . We 
and others have shown that the NO biosynthesis or bioavailability is reduced in 
smokers7. However, the possible inter-relations between endothelial NO, TF, TFPI-1, t- 
PA and PAI-1 production in smokers are not known. In this study, utilizing a previously 
validated in vitro model7, the effect of smokers’ serum on endothelial production of 
these hemostatic molecules was examined.
114
Methods
Subjects
Healthy male nonsmokers (n=8 ) and active smokers (n=15) (mean age: 33.0+1.4 
and 31.8±2.2, respectively) were requested to abstain from smoking and foods or 
caffeinated drinks overnight. The following morning, after a ten minutes rest period, 
their serum was collected and stored at -70°C until use. The mean cigarette exposure in 
smokers was 8±3 pack-years and 12+3 cigarettes/day. All subjects were free of other 
traditional cardiovascular risk factors (i.e. hypertension, diabetes, low HDL, 
hyperlipidemia or a family history of premature vascular disease) and were not taking 
any medication. The serum cotinine concentrations were determined by ELISA (STC 
Technologies). The study protocol was approved by Saint Vincent Catholic Medical 
Centers o f New York Ethics Committee and written informed consent was obtained 
from each subject.
Endothelial cell culture and determination of homeostatic parameters in vitro
Primary HUVECs were purchased (Clonetics). The vitro experiments were 
performed as previously described7. In brief, serum from nonsmokers and smokers were 
incubated with confluent (-85%) HUVECs in 24-well tissue-culture plates for 12 hours. 
After the incubation, basal NO, t-PA, PAI-1, TF, TFPI-1 production and substance P 
(SP)-stimulated NO, t-PA, PAI-1 production were determined. All parameters were 
measured from the same cell culture supernatant. NO concentration in each sample was 
determined using a NO analyzer (Sievers). Hemostatic variables were determined 
utilizing commercially available ELISA kits [(American Diagnostica (TF and TFPI) 
and Biopool AB (t-PA and PAI-1)]. The parameters were expressed in their respective 
units after adjusting for the background levels. t-PA/PAI-1 molar ratio was calculated 
by using a formula published previously8.
Statistical analyses.
Results are presented as the mean±standard error of mean (SEM). Unpaired 
Student’s t test was used compare the group differences. Linear regression analysis was 
used to examine the association between in vitro EC-derived thrombo-hemostatic
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parameters, NO and smokers’ serum cotinine level. A value of p<0.05 was considered 
statistically significant.
Results
In vitro effect of smokers’ serum on endothelial cell-derived nitric oxide and 
hemostatic parameters.
HUVECs exposed to smoker’s serum in vitro showed a significantly lower basal 
and SP-stimulated NO production compared to nonsmokers (1.3±0.2 versus 4.0±0.5 
uM, p<0.001; and A baseline: 0.1±0.1 versus 1.1±0.5 uM, p<0.05, respectively) as 
previously reported7.
In the cell culture supernatant, TF antigen level from HUVECs treated with 
smokers’ serum were not different from that of nonsmokers’ (19.0±3.5 versus 15.0±5.8 
pg/ml, respectively, p=0.6). However, the smokers’ showed a significantly lower TPFI 
level compared to the nonsmokers (5.7±0.4 versus 8.2+1.3 ng/ml, respectively, p=0.04)
HUVECs treated with smokers’ serum showed significantly lower basal t-PA 
production as compared to the nonsmokers (2.3±0.3 versus 4.9±1.1 ng/ml, p<0.02). 
Similarly, SP-stimulated t-PA release was lower in smokers compared to nonsmokers 
(A% baseline: 15.0+4.4% versus 36.0+12.0%) although this difference did not quite 
reach significance (p=0.059). Additionally, both basal and SP-stimulated PAI-1 
concentrations were similar between smokers and nonsmokers (81.6±6.1 versus 
82.5±16.6 ng/ml, p=0.95; and 7.3±1.4 versus 6.0+1.7 ng/ml, p=0.6, respectively). Basal 
t-PA/PAI-1 molar ratio was significantly reduced in smokers compared to nonsmokers 
(0.02+0.01 versus 0.04±0.01, respectively, p<0.005).
Relationship between endothelial-derived hemostatic parameters, nitric oxide and 
serum cotinine.
On linear regression analysis no significant correlation was found between basal 
NO and t-PA (r=0.33, p=0.12), PAI-1 (r=0.05, p=0.84) or TF (r=0.17, p-0.43). Only 
basal TFPI-1 positively correlated with basal NO (r=0.42, p=0.04). In the smokers’ 
group, serum cotinine correlated negatively with basal TFPI-1 (r= -0.60, p=0.01) and no 
apparent association with other parameters was found.
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Figure 1. Effect of smokers’ serum on basal (12hr) release of EC-derived 
thrombo-hemostatic parameters in vitro.
Results are presented as means ±SE M  after adjusting fo r  the background.
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Discussion
Thrombosis appears to be the main cause of mortality and morbidity in cigarette 
smokers. Burke et al. 1 have demonstrated that sudden cardiac death in smokers was 
mainly associated with thrombosis regardless of the underling plaque pathology 
(erosion or rupture) and was not associated with the number of lipid-rich vulnerable 
plaques. ECs are an important source of opposing vascular homeostatic factors that 
regulate important physiological functions. Using serum from male smokers this study 
provides further evidence of the potential alteration in endothelial anti-thrombotic and 
fibrinolytic properties that may contribute to an acute thrombotic event in smokers.
The classical view that thrombus formation occurs at a site of injury because of 
a nidus provided by the cell surface-bound TF has been broadened by the observation 
that TF antigen is also found circulating in the blood and has the potential to initiate 
thrombosis9,10. Several studies have suggested that significantly higher level of
11 19circulating soluble TF are found in patients with acute MI and unstable angina ’ . 
Potential sources of these soluble circulating TF include EC, vascular smooth muscle 
cell, monocyte and leukocytes9,10. It has been suggested that increased expression of TF 
on the cellular surface is associated with increased soluble TF 9,1°. Data concerning the 
effect of smoking on TF expression or level are limited and the contribution of ECs in 
this regard is not known. Matetzky et al.4 have shown that smoking is associated with 
increased TF expression in atherosclerotic plaques from human carotid and aortic root 
plaques from apoE -/- mice. On the other hand, Blann et al.5 reported no significant 
difference in soluble TF between smokers and non-smokers either in controls or in 
subjects with peripheral arterial disease. In our in vitro study (12 hour incubation) there 
was no significant difference in EC-derived soluble TF antigen between smokers’ and 
nonsmokers’ group. It has been proposed that apoptotic ECs are one of the potential
  n  i  a  1 o  n
sources of TF ’ ’ . We have previously reported that in the present model smokers’ 
serum did not alter EC viability or promote EC apoptosis and this may explain why 
there was no difference in EC-derived TF between smokers and nonsmokers in the 
present study.
Nevertheless, in the same cell culture supernatant there was a significant 
decrease in EC derived TFPI-1 secretion in smokers. TFPI-1 is not only EC-surface 
bound but a substantial amount is also secreted in the blood 1. The soluble form of 
TFPI-1 directly inhibits factor Xa, whereas surface-bound TFPI-1 on ECs inhibits TF-
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factor Vila complex in conjunction with factor Xa by translocation into caveolae14,15. 
Thus, the lower TFPI-1 antigen level in smokers as observed in this study may indicate 
either decreased production or an increased translocation of TFPI from the cell surface 
to the cytoplasm. Regardless of the mechanism, smokers had a relative increase of the 
TF/TFPI-1 ratio and conceivably an increase in thrombotic potential. Additionally, 
TFPI-1 showed a significant negative correlation with the serum cotinine level 
suggesting a possible dose-related effect of smoking on TFPI.
The structural support of a thrombus is provided by a matrix of cross-linked 
fibrin. A timely dissolution of the fibrin matrix is essential to inhibit pathological 
propagation of a thrombus3. The lysis of fibrin is mediated by plasmin that is activated 
by t-PA, which in turn can be inhibited PAI-1. It has been suggested that t-PA/PA 1-1 
ratio or more appropriately their molar ratio is a useful indicator of fibrinolytic 
balance8. The effect of smoking on t-PA and PAI-1 are controversial and conflicting 
results have been reported2,6. More recently, Newby et al.2 have shown that in smokers, 
SP-stimulated t-PA antigen and activity are decreased with no change in PAI-1 antigen 
or activity in both the peripheral and coronary circulation. Our in vitro data are 
consistent with their finding and indicate that SP-stimulated t-PA release was decreased 
in smokers with no change in basal and stimulated PAI-1 antigen. However, in our in 
vitro model, basal t-PA production and t-PA/PAI-1 molar ratio were also significantly 
reduced in smokers. This is inconsistent with the data of Newby et al.2 who found 
increased basal plasma level of t-PA in smokers. The cause of this discrepancy is not 
known but this could be due to differences between the models (in vivo versus in vitro).
Yang and Loscalzo16 utilizing L-arginine proposed that NO may be involved in 
regulation of TF expression in ECs but they also found that basal levels of NO have 
little effect on TF induction. In the present in vitro model, there was no correlation 
between basal NO and TF levels. On the other hand, a relatively weak but significant 
positive correlation was found between TFPI-1 antigen and NO. As a significant portion 
of TFPI-115 resides in the same micro-domain (caveolae) as eNOS17, cross talk or an 
overlapping of the signal transduction pathways of these two molecules is conceivable. 
Whether this correlation represents such an effect or simply a general manifestation of 
endothelial dysfunction requires further investigation.
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Study limitations
1) The finding in this study should be interpreted as only EC-specific responses 
as other types of cells9,10 can also produce these hemostatic factors under inquiry. 
Additionally, whether these observed changes in HUVECs extend to arterial ECs 
requires further confirmation.
2) A limitation of sample volume did not allow us to examine the activities of 
the thrombo-hemostatic parameters. However, as one molecule was the specific 
counter-regulator of the other and were examined in a static environment, it is likely 
that the relative concentration of each molecule would reflect the specific thrombo- 
hemostatic function.
Conclusion
The present study investigated the potential effect of smoking on EC-derived 
factors that could influence local thrombo-hemotasis. The data suggest that the 
endothelial contribution to local thrombo-hemostasis is dysfunctional in smokers both 
in terms of limiting the initiation of thrombus formation (TFPI-1) and also in promoting 
its effective dissolution (t-PA). Future studies will be needed to confirm whether such 
alterations of hemostatic molecules exist in vivo and contribute to the increased acute 
cardiac events in smokers.
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A b stract
Background— Our group has previously shown that human umbilical vein endothelial 
cells (HUVECs) exposed to smokers’ serum decreased nitric oxide (NO) production 
and endothelial nitric oxide synthase (eNOS) activity in the presence of increased 
eNOS expression. In the present study, we examined whether these observations 
extended to human coronary artery endothelial cells (HCAECs). Additionally, the role 
of reactive oxygen species in the observed alterations was examined.
Methods and Results—HCAECs were incubated with serum from 10 nonsmokers and 
15 smokers for 1 2  hours with or without the addition of either polyethylene glycol- 
superoxide dismutase (PEG-SOD, 300U/mL), PEG-SOD+PEG-catalase (lOOOU/mL), 
chelerythrine (3pM) or tetrahydrobiopterin (BH4, 20pM). At the end of incubation, 
NO, eNOS protein, and eNOS activity were measured from the same culture. HCAECs 
incubated with smokers’ serum alone showed significantly lower NO production 
(P 0 .007 ) and eNOS activity (P 0 .005) but higher eNOS expression (P 0 .005 ) 
compared to nonsmokers. In smokers, addition of either PEG-SOD, PEG-SOD+PEG- 
catalase or BH4  significantly (P<0.05) improved NO levels and eNOS activity. 
Interestingly, in the same smokers, a significant decrease in eNOS expression was only 
seen with the addition of PEG SOD+PEG-catalase (P<0.005) and treatment with PEG- 
SOD alone insignificantly increased eNOS expression.
Conclusions— The present study indicates that in vitro, HCAECs show similar 
changes in NO biosynthesis as HUVECs when exposed to smokers’ serum and also 
confirms that oxidative stress plays a central role in smoking-mediated dysfunction of 
NO biosynthesis in endothelial cells. Furthermore, these data support other studies 
suggesting a role for hydrogen peroxide in the up-regulation of eNOS.
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Introduction
Dysfunctional nitric oxide (NO) biosynthesis, as indicated by reduced 
endothelial dependent vasodilatation (EDV), precedes the morphological changes in the
1 3vessel wall associated with various atherosclerotic risk factors including smoking ' . In 
a recent investigation, our group demonstrated that smoking was associated with 
reduced EDV and the serum from these same smokers decreased nitric oxide (NO) 
availability and endothelial nitric oxide synthase (eNOS) activity but up-regulated 
eNOS protein in human umbilical vein endothelial cells (HUVECs)3. While HUVECs 
are a well-recognized model for investigating endothelial function, they are of venous 
origin. Since atherosclerotic changes are uncommon in veins, a study in arterial 
endothelial cells (ECs) was warranted for a more appropriate pathophysiological 
interpretation of our previous observations.
Excessive generation of reactive oxygen species (ROS) such as superoxide 
(O2 ), hydrogen peroxide (H2O2) and their products has been implicated as a final 
common pathway for the development of endothelial dysfunction by various 
cardiovascular risk factors, and ROS may be responsible for the observed changes in 
NO biosynthesis including the up regulation of eNOS4'6. Specifically, recent studies 
have proposed hydrogen peroxide (H2O2) as a potential inducer of eNOS up- 
regulation6. The protein kinase C (PKC) pathway has also been implicated in increasing 
eNOS expression7 as well as increasing O2 ' and H2O2 production, especially in the 
setting of diabetes8,9. However, a fundamental pathophysiological difference between 
smoking and other risk factors is that, in cigarette smoking, a substantial amount of free 
radicals are introduced exogenously and additionally cigarette smoke contains >4,000 
known and >100,000 unknown constituents10. Therefore, it is unknown whether these 
same mechanisms are also involved in smoking-mediated dysfunction of NO 
biosynthesis.
The aims of the present study were to extend our previous observations in an 
arterial cell line (human coronary artery endothelial cells (HCAECs)), and with the use 
of cell-permiable-polyethylene glycol-superoxide dismutase (PEG-SOD), PEG- 
SOD+PEG-catalase, chelerythrine (a PKC inhibitor) and tetrahydrobiopterin (BH4) to 
investigate the potential role of free radicals in the observed smoking-related alterations 
of the NO biosynthetic pathway.
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Methods
Subjects and study design
Males with a history of active smoking (n=l 5) were matched for age and sex 
with individuals who had never smoked (n=10). All subjects were free of other 
cardiovascular risk factors (i.e. hypertension, diabetes, low HDL, hyperlipidemia or a 
family history of premature vascular disease) and were not taking any medication.
Subjects were requested to abstain from smoking and caffeinated food or drink 
over night (6 - 8  hours). In the next morning, venous blood was collected and the serum 
was isolated and stored at -70°C until use. Analysis for the lipid profile and the glucose 
was done in the hospital’s clinical laboratory and the serum cotinine level was 
determined by a commercially available kit (STC Technolologies). The study protocol 
was approved by Saint Vincent Catholic Medical Centers of New York Ethics 
Committee and written informed consent was obtained from each subject.
Endothelial cell culture and treatment
Human coronary artery endothelial cells (HCAECs) were purchased from 
Clonetics and were cultured using a slight modification of a method described 
previously3. In brief, forty thousand cells were plated in 12-well, flat bottom, tissue 
culture plates with complete endothelial growth media (EGM, Clonetics) and grown to 
-85%  confluence at 37°C in 5% CO2 . The confluent cells were then incubated with an 
equal volume of serum and EGM (i.e. 400pl of serum and 400pl of EGM; total 
volume: 800pl) for 1 2 -hours (37°C; 5% CO2) with or without the addition of either 
polyethylene glycol-superoxide dismutase (PEG-SOD, 300U/mL), PEG-SOD+PEG-' 
catalase (lOOOU/mL), chelerythrine (3 pM), or tetrahydrobiopterin (BH4, 20 pM). All 
treatments (PEG-SOD, PEG-catalase, BH4 and cheleryhtrine) were made fresh before 
the experiments to their desired concentrations by dissolving in EGM. In the respective 
wells, HCAECs were pretreated for 30 minutes with these substances before the serum 
was added.
All experiments were done within the 2nd passage in our laboratory after 
obtaining from the vendor (3rd passage). Each set of experiments in smokers and 
nonsmokers (with or without treatment) were done simultaneously utilizing the same 
batch of HCAECs.
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Determination of nitric oxide levels
Following a 12-hr incubation, NO levels in the cell-culture supernatants were 
determined by the chemiluminesence method utilizing a NO analyzer (Sievers, Model # 
280) as previously described3. All samples were tested in duplicate and NO levels were 
expressed as pM/mg total protein after adjusting for the background NO level in each 
sample and the total protein concentration in each well.
Determination of eNOS protein concentration
The eNOS protein concentration of the HCAECs in culture was determined in 
each experiment by using a commercial ELISA kit (R&D Systems). The cells that were 
used to detect 12-hour NO production were washed twice with phosphate buffer and 
cells were lysed with lysis buffer from the kit. The assay was performed using 100 pi of 
each cell lysate following the manufacturers’ instruction. All samples were tested in 
duplicate and expressed as pg/mg total protein after adjusting for the total protein 
concentration in each well.
Determination of total protein concentration
The total protein in each well was determined from the same cell lysates 
generated for the eNOS protein following the micro-Lowry method, with a slight 
modification, utilizing a commercial kit (Sigma). In brief, 100 pi o f each standard and 
samples were added to a 96-well plate (in duplicate). Ten microliters of decoxycholate 
(1.5 mg/ml) solution was added to each well and the plate was incubated on a 
horizontal shaker at room temperature for 1 0  min followed by addition of 1 0  pi of 
trichloroacetic acid (72%) solution. The plate was centrifuged at 210g for 5 min and the 
supernatant was discarded without dislodging the pellet. Then, to each well, 100 pi of 
Lowry reagent was added, mixed and incubated at room temperature for 20 min. At the 
end of the incubation period, 50 pi Folin and Ciocalteu’s phenol red reagent was added 
to each well and incubated again at room temperature for 30 min. The absorbance was 
read at 620 nm. The protein concentrations of the unknown samples were extrapolated 
from the calibration curve constructed with the known standards.
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Determination of eNOS activity
The same cell lysates generated for the eNOS protein assay were used to 
determine the specific eNOS activity. This was done utilizing a commercial kit 
(Calbiochem) following a method described previously3. In brief, 100 pi of lysate was 
added to a reaction cocktail containing 25 pi of reaction buffer (50 mM Tris-HCl, 6  pM 
BH4 , 2 pM FAD and 2 pM FMN), 3 pi of [3H]-L-arginine (58 Ci/mmol, luCi/pl; 
Amersham), 1 mM NADPH, 75 pM CaCb and 0.1 pM calmodulin. The incubation was 
carried out at room temperature for one hour. The radioactivity was quantitated using a 
liquid scintillation counter (Packard Instrument). Both eNOS concentration and eNOS 
activity assays were run simultaneously. The eNOS activity in each sample was 
adjusted to the specific amount of eNOS protein/mg total protein and the specific 
activity of eNOS was expressed as pmol L-citrulline/min/pg eNOS protein/mg total 
protein.
Statistical analysis
Data were normalized with linear transformation where appropriate and 
presented as the mean ± standard error of mean (SEM). The baseline values between 
nonsmokers and smokers were compared using the unpaired Student’s t test. The effect 
of various treatments between and within groups was compared either by analysis of 
variance (ANOVA) or repeated measures ANOVA where appropriate. For each 
ANOVA or repeated measures ANOVA, differences between each individual 
treatments were compared with Post hoc Fisher’s PLSD (protected least significant 
difference) or paired Student’s t test where appropriate. A value of PO .05  was 
considered statistically significant. All calculations were performed using the StatView 
statistical program (version 4.5, Abacus Concepts Inc.).
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Results
Clinical characteristics of the study population
Baseline clinical characteristics of both smokers and nonsmokers are shown in 
Table 1. There was no significant difference between the two groups with the exception 
of serum cotinine levels, which were significantly higher in smokers.
Effects of smokers’ serum and various treatments on nitric oxide level
HCAECs exposed to smokers’ serum alone showed a significantly lower NO 
level in the cell culture supernatant compared to those exposed to serum from 
nonsmokers (Figure 1; 0.12±0.04 versus 0.31±0.10 pM/mg of total protein, p<0.02).
In nonsmokers, the addition of either PEG-SOD (0.35±0.20 pM/mg o f total 
protein), PEG-SOD plus PEG-catalase (0.24±0.10 pM/mg of total protein), 
chelerythrine (0.33+0.20 pM/mg of total protein) or BH4 (0.39±0.30 pM/mg of total 
protein), did not have a significant effect on the NO level (Figure 1; repeated measures 
ANOVA, p=0.90).
On the other hand, in smokers, compared to baseline, a significant increase in 
NO levels was seen (Figure 1; repeated measures ANOVA; for the group, p<0.02) with 
either PEG-SOD (0.37±0.09 pM/mg of total protein; paired students’ t test, p<0.02), 
PEG-SOD plus PEG-catalase (0.36±0.10 pM/mg of total protein; paired students’ t test, 
p<0.02), or BH4 (0.33±0.10 pM/mg of total protein; paired students’ t test, p<0.03) 
treatment. However, chelerythrine treatment alone did not have any significant effect 
(0.22±0.10 pM/mg of total protein, p=0.30).
Effects of smokers’ serum and various treatments on eNOS protein 
expression
HCAECs treated with serum from smokers had a significantly higher eNOS 
protein expression compared to those treated with serum from nonsmokers. Figure 2 
(3778±272 versus 2281+270 pg/mg of total protein, respectively, p<0.001).
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Table 1. Clinical characteristics of the study population
Nonsmoker
(n=1 0 )
Smoker
(n=15) (P)
Age (yrs.) 31±1 33±1.4 0 . 2 0
Total Cholesterol (mg/dL) 180±7 173±8 0.60
LDL (mg/dL) 107±8.0 99±8.0 0.43
HDL (mg/dL) 49+2.5 54±3.0 0.50
LDL/HDL ratio 2 .2 +0 . 2 1.9±0.2 0.33
Triglyceride (mg/dL) 116±22 1 1 0 ± 1 2 0.80
Glucose (mg/dL) 96±4.1 97±3.5 0.90
Cotinine (ng/mL) 7±3 107+16 <0 . 0 0 0 1
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Figure 1. Effects of smoker’s serum on NO production in vitro.
Confluent (-85%) HCAECs were incubated with equal volume o f  medium and serum 
from  nonsmokers (n=10) or smokers (n=15) (with or without treatment as indicated) in 
12-well plates. After 12-hour incubation (37°C; 5% COg), the cell culture supernatant 
was collected. NO production in the cell culture supernatant was determined by a 
chemiluminesence method. Results are presented as me an±SEM after adjusting fo r  the 
background and the total protein in each well. Unpaired Student’s t test: * p  <0.02 
versus nonsmokers ’ baseline; paired Student’s t test: f  p<0.04 versus smokers ’ 
baseline.
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The addition of either PEG-SOD (2779±439 pg/mg of total protein), PEG-SOD plus 
PEG-catalase (2213±180 pg/mg of total protein), chelerythrine (2436±172 pg/mg of 
total protein) or BH4 (2797+365 pg/mg of total protein), did not have any significant 
effect on eNOS expression in HCAECs treated with the serum from nonsmokers, 
(Figure 2; repeated measures ANOVA, p=0.51)
In smokers, compared to baseline, a significant decrease in eNOS expression 
was seen only with PEG-SOD plus PEG-catalase (3030±260 pg/mg of total 
protein)(Figure 2; repeated measures ANOVA: p<0.004 for the group; paired students’ 
t test, p<0.02 versus baseline). The eNOS expression with PEG-SOD plus PEG- 
catalase treatment was also significantly lower than both PEG-SOD alone (4030±288 
pg/mg of total protein; paired students’ t test, p<0.005) and chelerythrine (3832+188 
pg/mg of total protein, paired students’ t test, p<0.005) treatment. When compared to 
the baseline, treatment with PEG-SOD alone insignificantly increased eNOS expression 
(paired students’ t test, p=0.23). BH4 treatment alone was partially effective in 
decreasing eNOS expression from baseline (3297+240 pg/mg of total protein, paired 
students’ rtest, p=0.14).
Effects of smokers’ serum and various treatments on eNOS activity
The cell lysates utilized above were also used to determine eNOS activity. 
Specific eNOS activity for each sample was adjusted for the amount of eNOS 
protein/mg total protein as detected by ELISA. The cell lysates from HCAECs treated 
with smoker’s serum alone showed significantly lower eNOS activity when compared 
to cells treated with nonsmoker’s serum alone (Figure 3; 0.26±0.03 versus 0.50±0.08 
pmol L-citrulline/min/pg eNOS/mg of total protein, respectively, p<0.004).
In nonsmokers, the addition of PEG-SOD, PEG-SOD plus PEG-catalase, 
chelerythrine or BH4, did not have any significant effect on eNOS activity (Figure 3; 
repeated measures ANOVA, p=0.85).
In smokers, compared to baseline, a significant increase (Figure 3; repeated 
measures ANOVA; for the group, p<0.007) in the activity of each unit of eNOS was 
seen with either PEG-SOD (0.37±0.09 pmol L-citrulline/min/pg eNOS/mg of total 
protein; paired students’ / test, p<0.04), PEG-SOD plus PEG-catalase (0.41±0.06 pmol 
L-citrulline/min/pg eNOS/mg of total protein; paired students’ t test, p<0.02) or
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Figure 2. Effects of smoker’s serum on eNOS protein expression in vitro.
Confluent (-85%) HCAECs were incubated with equal volume o f medium and serum 
from nonsmokers (n=10) or smokers (n=15) (with or without treatment as indicated) in 
12-well plates. After 12 hours, cell culture supernatant was collected and the HCAECs 
were lysed. eNOS protein concentration o f the cell lysates was determined by ELISA. 
Results are presented as meandSEM after adjusting fo r  the total protein in each well. 
Unpaired Student’s t test: * p<0.001 versus smokers ’ baseline; paired Student’s t test'.f 
p<0.02 versus baseline or PEG-SOD or chelerythrine in smokers.
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BH4 (0.33±0.24 pmol L-citrulline/min/pg eNOS/mg of total protein; paired students’ t 
test, p<0.03) treatment. The addition chelerythrine did not have any significant effect 
(0.29±0.03 pmol L-citrulline/min/pg eNOS/mg o f total protein, p=0.25). Although with 
either PEG-SOD or BH4, the activity of each unit of eNOS in smokers was increased 
from the baseline, it was still significantly lower compared to nonsmokers (ANOVA: 
p<0.008 for the group; Post hoc Fisher’s PLSD: p<0.03 for nonsmokers versus PEG- 
SOD or BH4 or chelerythrine in smokers). Only with PEG-SOD plus PEG-catalase did 
the activity of each unit of eNOS became similar to that of nonsmokers (Post hoc 
Fisher’s PLSD: p=0.30 for non-smokers versus PEG-SOD plus PEG-catalase treatment 
in smokers). Thus, in our model, scavenging of both O2" and H2O2 was essential to 
normalize the activity of each unit of eNOS protein in smokers.
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Figure 3. Effects of smoker’s serum on eNOS activity in vitro.
Confluent (-85%) HCAECs were incubated with equal volumes o f  medium and serum 
from nonsmokers (n=10) or smokers (n—15) (with or without treatment as indicated) in 
12-well plates. After 12 hours, the cell-culture supernatant was collected and the 
HCAECs were lysed. eNOS activity o f  the cell lysates was determined by detecting the 
conversion o f  [3H] L-arginine to [3H] L-citrulline. Results are presented as the mean± 
SEM after adjusting fo r  the specific amount o f  eNOS protein/mg total protein. Unpaired 
Student’s t test: * p<0.02 versus nonsmokers ’ baseline; paired Student’s t te st.f p<0.04 
versus smokers ’ baseline; ANOVA: p<0.008fo r  nonsmokers ’ baseline versus all 
treatment in smokers, Post hoc Fisher’s PLSD: f  p<0.03 versus nonsmokers ’ baseline.
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Discussion
The present study indicates that in our in vitro model, smokers’ serum caused a 
similar dysfunction in NO biosynthesis and up-regulation of eNOS in HCAECs as was 
demonstrated previously in HUVECs3. The improvement of NO level and eNOS 
activity with, either PEG-SOD, PEG-SOD+PEG-catalase or BH4, confirms that free 
radicals play a significant role in the smoking-related dysfunction o f NO biosynthesis. 
The significant down-regulation of eNOS protein seen with PEG-SOD+PEG-catalase 
suggests a potential role for H2O2 as a modulator of eNOS expression.
Cigarette smoke contains large quantities of free radicals11. Although 
involvement of exogenous free radicals has been proposed in smoking-related 
dysfunctional NO biosynthesis, the effects of free radical scavengers in various 
smoking models have been inconsistent12' 15. In the present model, the increase in NO in 
the supernatant as well as the increase in eNOS activity with cell-permeable PEG-SOD 
or PEG-SOD+PEG-catalase in smokers indicates that ROS play a significant role in the 
smoking-mediated dysfunction of NO biosynthesis. The exact origin o f free radicals in 
our model is unknown. The gas-phase radicals in cigarette smoke are only stable for a 
short duration (seconds) but the tar-phase radicals are stable for hours to months10,11,1<5. 
These tar-phase radicals, which can auto-oxidize to form O2" and H2O2 in biological 
fluids11>16, are a likely cause for the observed alterations in NO biosynthesis.
A reaction between O2’ and NO gives rise to preoxynitrite (ONOO'), which is 
known to avidly oxidize BH4, an essential cofactor for eNOS17. A deficiency or 
oxidation of BH4 by ROS can uncouple the eNOS enzyme and cause the enzyme to 
produce O2' instead of NO therefore increasing the oxidative stress17,18. In the present 
study, addition of exogenous BH4 in smokers also improved the NO level and the 
eNOS activity. Several investigators in both in vivo and in vitro models of smoking 
have previously demonstrated that addition of BH4 increases NO availability15,17,19. All 
these data suggest that oxidation of BH4 could contribute to the dysfunctional NO 
biosynthesis in smokers. Thus, both exogenous as well as endogenous free radical 
generating mechanism(s) appear to participate in the oxidative stress in smokers.
Indeed, the effectiveness of cell-permeable PEG-SOD and PEG-catalase in our study 
and the lack of effect of non-cell-permeable SOD and catalase in other studies12,14,15 
support a potential contribution of free radicals from endogenous source(s). Whether 
other endogenous free radical sources such as the mitochondrial electron transport
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chain, xanthine oxidase and NAD(P)H oxidase are involved in smoking-mediated NO 
dysfunction are unknown and require further investigation.
Several recent studies have shown that reduced NO biosynthesis in various 
cardiovascular pathologic conditions may be associated with increased eNOS 
expression rather than a decrease in eNOS expression6,8. Both H2O2 and protein kinase 
C have been shown to be involved in the up-regulation of eNOS in various models6,7. In 
the present model, the significant down-regulation of eNOS with PEG-SOD+PEG- 
catalase (causing conversion of O2" to H2O2 and then subsequent conversion to H2O and
O2) along with small increases in eNOS with PEG-SOD alone (causing conversion of 
0 2 'to  H2O2) suggest a role for H2O2 in the up-regulation of eNOS. The exact source of 
H2O2 in our model is not known. It may have originated from components of cigarette 
smoke in the serum, and/or from the conversion o f O2" by endogenous SOD present in 
the extra or intracellular space. On the other hand, this study did not find that the 
chelerythrine (a PKC inhibitor) altered NO availability, eNOS activity or eNOS 
expression. Therefore, PKC does not appear to play a significant role in smoking- 
mediated dysfunction of NO biosynthesis in the present model.
It is interesting to note that, in the present study, even though the NO levels in 
smokers normalized to that of nonsmokers with either PEG-SOD or PEG-SOD+PEG- 
catalase or BH4 treatment, the activity of each unit of eNOS was still lower with either 
PEG-SOD or BH4 compared to nonsmokers. Only with PEG-SOD+PEG-catalase did 
the eNOS activity normalize to that of nonsmokers. Thus, the relatively higher eNOS 
protein expression with PEG-SOD or BH4 treatment in smokers compensated for its 
relatively lower activity leading to normal NO levels. The cause of the relative lower 
activity with PEG-SOD or BH4 compared to PEG-SOD+PEG-catalase in smokers, was 
mostly likely attributable to the fact that PEG-SOD or BH4 did not scavenge H2 O2 . 
Although H2O2 appears to play a role in upregulation of eNOS, it is a ROS and can give
90rise to hydroxyl radicals , which can affect the activity of eNOS protein. Therefore, it 
not surprising that the scavenging of both O2 ' and H2O2 in smokers had the most 
optimum response on eNOS activity in the present model.
A critical question remains as to why the increased expression of eNOS protein 
did not translate into an improvement of NO availability in smokers’ serum alone. In 
our study, the decreased eNOS activity of the HCAECs lysates treated with smoker’s 
serum alone, even after supplementation with various cofactors, indicates that up- 
regulated eNOS was dysfunctional. This dysfunction of eNOS activity could be a direct
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and compound (O2', H2O2 and their derivatives) effect of ROS on the eNOS protein 
itself. It is conceivable that once structural changes in eNOS protein have occurred, 
addition of cofactors would be ineffective. However, our data suggest that H2O2 and its 
derivatives were the minor participants in this alteration. When PEG-SOD was added to 
smokers’ serum all O2' would have been converted to H2O2 . This had only a mild 
detrimental effect on eNOS activity, since NO availability was normalized although at 
the expense o f higher eNOS expression. Therefore, the most likely free radicals that 
caused a reduction of eNOS activity in HCAECs exposed to smokers serum alone, were 
O2' and its derivatives such as ONOO\ Recently, Zou et al.21 reported that the zinc- 
thiolate center of eNOS is 10-100 times more susceptible than BH4 to oxidative damage 
by ONOO' and also proposed that ONOO’ releases zinc from eNOS protein and forms 
disulfide bonds between the monomers of eNOS causing uncoupling of the enzyme. 
Additionally, the duration (short versus long) as well as the amount of exposure to free 
radicals could also influence the catalytic activity of eNOS protein. Therefore, it is 
conceivable that persistent oxidative stress would decrease or uncouple the activity of 
up-regulated eNOS. Additional studies would be required to identify the specific 
mechanism(s) for this dysfunction.
Study limitation
First, in the present model all subjects were male, and female hormones have 
been demonstrated to influence eNOS expression as well as its activity22. Therefore, 
additional investigations will be required to establish whether the serum from female 
smokers would have similar effects on NO biosynthesis as in male smokers. Second, 
exogenous BH4 may act as an antioxidant directly17,23 and the potential effect of BH4 
cannot be excluded in the present model. Third, the focus of our study was the potential 
role o f ROS in smoking-mediated NO dysfunction. Recently, asymmetric 
dimethylarginine, an endogenous inhibitor o f L-arginine, has been identified as an 
important cause of NO dysfunction . Its potential role in the present model cannot be 
excluded.
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Conclusion
This study found a similar dysfunction of NO biosynthesis in HCAECs as was 
previously reported in HUVECs. Furthermore, the data from this study confirm that 
ROS are the most likely cause for the smoking-mediated dysfunction of the NO 
biosynthetic pathway and that H2O2 contributes to the up-regulation of eNOS protein. 
However, this up-regulation of eNOS may not translate into increased NO availability 
if the central mechanism, that is, oxidative stress due to ongoing formation of ROS is 
not reduced.
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Abstract
Objectives—This study investigated the role of endogenous free radical generating 
sources in smoking-related dysfunctional NO biosynthesis in human coronary artery 
endothelial cells (HCAECs).
Background—Excessive free radical generation has been proposed as the leading 
mechanism for dysfunctional NO biosynthesis in smoking. However, the source of free 
radicals is unclear. Cigarette smoke contains high levels of free radicals. In addition, 
these radicals can potentially arise from endogenous sources as well. The role of these 
endogenous sources in smokers is unknown.
Methods—In the first set of experiment HCAECs were incubated with serum from 
eight nonsmokers and 10 smokers for 12 hours with or without the addition of either 
LNMMA (lOOpM), apocyanin (30pM, NADPH oxidase inhibitor), allopurinol 
(lOOpM, xanthine oxidase inhibitor) or rotenone (2pM, mitochondrial electron 
transport chain inhibitor). Following incubation, NO levels and eNOS protein 
expression were measured from the same culture. In the second set o f experiment, in 
smokers sera, allopurinol, rotenone and tetrahydrobiopterin (20juM) were added in 
combination and NO levels, eNOS protein and eNOS activity were measured.
Results—HCAECs exposed to smokers’ serum alone, had a significantly lower NO 
level (P<0.007) in the cell-culture but expressed higher level of eNOS protein 
(P<0.005) compared to nonsmokers. In smokers, only allopurinol or rotenone treatment 
significantly (P<0.05) improved NO availability. However, the NO levels were still 
lower compared to nonsmokers (P<0.05). Interestingly, when rotenone, allopurinol 
and tetrahydrobiopterin were added in combination in smokers, the NO level, eNOS 
expression as well as eNOS activity were normalized to that of nonsmokers. 
Conclusions— To our knowledge this is the first demonstration that, in addition to 
uncoupled eNOS, other endogenous free radical generators such as xanthine oxidase, 
the mitochondrial electron transport chain may play important an role in smoking- 
mediated dysfunctional endothelial NO biosynthesis.
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Introduction
Our group has previously demonstrated in both human umbilical vein 
endothelial cells (HUVECs) and human coronary artery endothelial cells (HCAECs) 
that, in vitro, smokers’ serum altered NO biosynthesis by reducing NO availability and 
eNOS activity while increasing eNOS protein expression (1,2). The precise 
mechanism(s) underlying the dysfunction was unclear. However, oxidative stress, due 
to increased cellular level of oxygen-derived-free radicals (reactive oxygen species 
(ROS)), is likely to be one o f the important causes o f dysfunctional NO biosynthesis in 
smokers. Indeed, in an earlier study, utilizing the present model it was found that 
addition of either cell-permeable polyethylene glycol- superoxide dismutase (PEG- 
SOD), PEG-SOD plus catalase or tetrahydrobiopterin (BH4) improved the observed 
alterations in NO biosynthesis (2).
The tar phase of cigarette smoke contains >1017 radicals/gm and the gas phase 
contains >1015 radicals/puff (3). However, it remains to be established whether a 
substantial portion of these free radicals reach the circulation to directly effect 
endothelial NO biosynthesis. A few studies have suggested that free radicals generated 
from smoking were adequately scavenged in both diabetic and non-diabetic young 
adult smokers although contrary data also exists (4-7). Nevertheless, in addition to 
these free radicals, cigarette smoke contains over 4000 compounds and some o f them 
are pro-oxidant (3,8). These pro-oxidant elements are capable of reacting with oxygen 
in biological fluids and giving rise to ROS (3,8). Like any mammalian cell, endothelial 
cells can also produce ROS by endogenous mechanisms (9). Recently, oxidation of 
tetrahydrobiopterin (BH4) and subsequent uncoupling of eNOS has been proposed as an 
endogenous source of ROS in smoking (10,11). In addition to the uncoupled nitric 
oxide synthase, other potential endogenous sources in ECs include mitochondrial 
electron transport chain, xanthine oxidase and NAD(P)H oxidase (9). These sources 
have been implicated in the pathophysiology of other cardiovascular risk factors (9). 
However, it is unknown whether these endogenous free radical generating sources play 
any role in smoking-related dysfunctional NO synthesis in endothelial cells (ECs).
In this study, the role of the above mentioned endogenous free radical 
generating sources was evaluated in smoking-mediated dysfunction of NO biosynthesis 
in human coronary artery endothelial cells (HCAECs).
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Material and Methods
Subjects and study design
Males with a history of active smoking were matched for age and sex with 
individuals who had never smoked. All subjects were free of other cardiovascular risk 
factors (i.e. hypertension, diabetes, low HDL, hyperlipidemia or a family history of 
premature vascular disease) and were not taking any medication.
On arrival in the morning blood was collected and centrifuged at 1776 g (3000 
rpm) for 15 min (4°C). The serum was isolated and stored at -70°C until use. Analysis 
for the lipid profile was done in the hospital’s clinical laboratory and serum cotinine 
concentrations were determined by a commercially available kit (STC Technolologies, 
Bethlehem, PA). The study protocol was approved by Saint Vincent Catholib Medical 
Centers of New York Ethics Committee and written informed consent was obtained 
from each subject.
Endothelial cell culture and treatment
Primary human coronary artery endothelial cells (HCAECs) were purchased from 
Clonetics (BioWhittaker, Walkersville, MD). HCAECs were cultured with slight 
modification of a method described previously(l). Forty thousand cells were plated in 
1 2 -well, flat bottom, tissue culture plates with complete endothelial growth media 
(EGM, Clonetics) and grown to -85%  confluence at 37°C in 5% CO2 . In the first- 
phase, the confluent cells were incubated with an equal volume of serum and EGM for 
12-hours (37°C; 5% CO2) with or without the addition of either 100pM L-NMMA, 
30pM apocyanin (NADPH oxidase inhibitor), lOOpM allopurinol (xanthine oxidase 
inhibitor) or 2uM rotenone (mitochondrial electron transport chain inhibitor). Before 
the addition of serum, HCAECs were pretreated for 30 minutes with these substances 
before the serum was added.. In smokers, improvement in the NO synthesis was seen 
only with certain treatments. In the second-phase of experiments, these treatments and 
20pM tetrahydrobiopterin (BH4) were added in combination to the smokers’ sera. All 
in vitro experiments were carried out, within the second passage of the HCAECs after 
obtaining them from the vendor.
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Determination of nitric oxide production
NO concentrations in the culture supernatants were determined by the 
chemiluminesence method utilizing the NO analyzer (Sievers, Model # 280; Boulder, 
CO, USA) as previously described (1). All samples were tested in duplicate and NO 
concentration was expressed as pM/mg total protein after adjusting for the background 
NO level in each sample and the total protein concentration of each well.
Determination of eNOS protein concentration
The eNOS protein concentration of the HCAECs in culture was determined by 
using a commercial ELISA kit (R&D Systems, Minneapolis, MN). The cells used to 
detect 12-hour NO production were washed and lysed with lysis buffer from the kit. 
The assay was performed using 100 pi of each cell lysate following the manufacturers’ 
instruction. All samples were tested in duplicate and expressed as pg/mg total protein 
after adjusting for the total protein concentration of each well.
Determination of total protein concentration
The total protein in each well was determined from the same cell lysates 
generated for eNOS protein measurement following the micro-Lowry method, with a 
slight modification, utilizing a commercial kit (Sigma, St. louis, MO). In brief, lOOpl 
of each standard and samples were added to a 96-well plate (in duplicate). Ten 
microliters of decoxycholate (1.5 mg/ml) solution was added to each well and the plate 
was incubated on a horizontal shaker at room temperature for 1 0  min followed by 
addition of 10 pi of trichloroacetic acid solution (72%). The plate was centrifuged at 
210g for 5 min and the supernatant was discarded without dislodging the pellet. Then, 
to each well, 100 pi of Lowry reagent was added, mixed and incubated at room 
temperature for 20 min. At the end of the incubation period, 50pl Folin and Ciocalteu’s 
phenol red reagent was added to each well and incubated again at room temperature for 
30 min. The absorbance was read at 620 nm. The protein concentrations of the 
unknown samples were extrapolated from the calibration curve constructed with the 
known standards.
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Determination of eNOS activity
This experiment was done in only the second phase of the experiments. The 
same cell lysates generated for the eNOS protein assay were used to determine the 
specific eNOS activity. This was done using a slight modification of the method 
described previously (1) using a commercial kit (Calbiochem, San Diego, CA). In brief, 
100 j l l I  of lysate was added to a reaction cocktail containing 25 jul of reaction buffer (50 
mM Tris-HCl, 6  juM BH4, 2 juM FAD and 2 juM FMN), 3 pi of [3H]-L-arginine (58 
Ci/mmol, 1 pCi/pl; Amersham, Piscataway, NJ), 1 mM NADPH, 75 juM CaCh and 0.1 
pM calmodulin. The incubation was carried out at room temperature for one hour. The 
radioactivity was quantitated using a liquid scintillation counter (Packard Instrument 
Com., Downers Grove, IL). Both eNOS concentration and eNOS activity assays were 
run simultaneously. The eNOS activity in each sample was adjusted to the specific 
amount of eNOS protein/mg total protein and the specific activity of eNOS was 
expressed as pmol L-citrulline/min/pg eNOS protein/mg total protein.
Statistical analysis
Results are presented as the mean ± standard error of the mean (SEM). The 
baseline values between nonsmokers and smokers were compared using the unpaired 
Student’s t test or Mann-Whitney U test where appropriate. The effect of various 
treatments in both smokers and nonsmokers was compared with the respective baseline 
value by paired Student’s t test. The effect of multiple treatments in smokers’ was 
compared with the baseline value of nonsmokers by either analysis of variance 
(ANOVA) or Kruskal-Wallis test where appropriate. For each ANOVA or Kruskal- 
Wallis test, differences between each individual treatments Post hoc Fisher’s PLSD 
(protected least significant difference) or Mann-Whitney U test where appropriate. A 
value of P<0.05 was considered statistically significant. All calculations were 
performed using the StatView (version 4.5, Abacus Concepts Inc.) statistical program.
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Results
Clinical characteristics of the study population
Baseline clinical characteristics of both smokers and nonsmokers are shown in 
Table 1. There was no significant difference between the two groups.
Effects of oxygen radical generation inhibitors on NO production
HCAECs exposed to smoker’s serum alone showed a significantly lower NO 
level in the cell culture supernatant compared to those exposed to serum from 
nonsmokers (Figure 1; 0.11±0.04 versus 0.62±0.20 pM/mg of total protein; /?<0.005).
In cultures treated with serum from nonsmokers, the addition of L-NMMA 
significantly decreased NO production by HCAECs when compared to baseline values 
(0.31 ±0.13 uM/mg of total protein; paired students’ /test, £><0.04). By contrast, the 
other inhibitors used had no effect (apocyanin- 0.62 ±0.22 pM/mg of total protein; 
allopurinol- 0.62 ±0.22 pM/mg of total protein; rotenone- 0.50 ±0.22 pM/mg of total 
protein; paired t test-£>>0.50 for each treatment versus baseline in nonsmokers).
In smokers, compared to the baseline, the addition of neither L-NMMA 
(0.14±0.03 pM/mg o f total protein; paired students’ t test, j?>0.50) nor apocyanin 
(0.20±0.07 pM/mg of total protein; paired students’ / test, £>=0.30) had any significant 
effect on the NO level. On the hand, the addition of allopurinol (0.23 ±0.10pM/mg of 
total protein; paired students’ t test,£=0.05) as well as rotenone (0.37±0.10 pM/mg of 
total protein; paired students’ t test,£><0.01) significantly increased the NO level. 
Although, the addition of either allopurinol or rotenone improved NO levels in 
smokers, they were still significantly lower compared to nonsmokers’ baseline NO 
levels (ANOVA: £><0.004 for the group; Post hoc Fisher’s PLSD: £><0.05 for 
nonsmokers baseline versus L-NMMA, apocyanin, allopurinol, or rotenone in 
smokers).
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Table 1. Clinical characteristics of the study population
Nonsmokers
(n=8)
Smokers
(n=10)
(p Value)
Age (yr.) 31+1 3312 0.44
Total Cholesterol (mg/dL) 181±8.4 17118.6 0.44
LDL (mg/dL) 107±8.7 9919.0 0.53
HDL (mg/dL) 49±3.0 5013.5 0.83
LDL/HDL ratio 2.210.2 2.110.3 0.67
Triglyceride (mg/dL) 124128 116117 0.79
Glucose (mg/dL) 9615.1 9614.8 0.99
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Figure 1. Effects oxygen radical generation inhibitors on NO production in vitro.
Confluent (-85%) HCAECs were incubated with equal volume o f  medium and serum 
from nonsmokers (n-8) or smokers (n—10) (with or without treatment as indicated) in 
12-well plates. After 12-hour incubation (37°C; 5% CO 2) the cell culture supernatant 
was collected. NO production in the cell culture supernatant was determined by a 
chemiluminesence method. Results are presented as mean±SEM after adjusting fo r  the 
background and the total protein in each well. Unpaired Student's t test: * p< 0.02 
versus nonsmokers ’ baseline; paired Student’s t te st.f p<0.04 versus nonsmokers ’ 
baseline, / p<0.05 versus smokers ’ baseline. ANOVA: p<0.004fo r  nonsmokers ’ 
baseline versus all treatments in smokers, Post hoc Fisher’s PLSD: § p<0.05 versus 
nonsmokers ’ baseline
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Effects of oxygen radical generation inhibitors on NO production on eNOS 
Protein Expression in Smokers and Nonsmokers
HCAECs exposed to serum from smokers had a significantly higher eNOS 
protein expression as compared to the HCAECs treated with serum from nonsmokers 
(3737+511 versus 2394+242 pg/mg of total protein, respectively, P<0.05).
In nonsmokers, the addition of either L-NMMA (2608+157 pg/mg of total 
protein), apocyanin(2743±167 pg/mg of total protein), allopurinol (2810±269 pg/mg of 
total protein) or rotenone (2446±275 pg/mg of total protein) did not have any 
significant effect on eNOS expression in HCAECs (paired students’ t test, P>0.20 for 
all versus baseline in nonsmokers).
In smokers (when compared to baseline) L-NMMA (3720±229 pg/mg of total 
protein), apocyanin (3555±203 pg/mg of total protein), allopurinol (3499±471 pg/mg of 
total protein) and rotenone (3043±244 pg/mg of total protein) did not effect eNOS 
expression (Figure 2; paired students’ t test,/?>0.08 for each treatment versus baseline 
in smokers). Compared to the baseline eNOS expression of non smokers, all the 
individual treatments in smokers had higher eNOS protein expression (Figure 2. 
ANOVA: /?<0.008 for the group; Post hoc Fisher’s PLSD: p<0.02 for nonsmokers 
versus L-NMMA, apocyanin and allopurinol in smokers).
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Figure 2. Effects of oxygen radical generation inhibitors on NO production on 
eNOS protein expression in vitro.
Confluent (-85%) HCAECs were incubated with equal volume o f  medium and serum 
from  nonsmokers (n=8) or smokers (n=J0) (with or without treatment as indicated) in 
12-well plates. After 12-hours cell culture supernatant was collected and the HCAECs 
were lysed. eNOS protein concentration o f the cell lysates was determined by ELISA. 
Results are presented as mean±SEM after adjusting fo r  the total protein in each well. 
Unpaired Student’s t test: * p<0.001 versus smokers ’ baseline; ANOVA: p<0.008fo r  
nonsmokers ’ baseline versus all treatment in smokers, Post hoc Fisher’s PLSD: f  
p<0.03 versus nonsmokers ’ baseline.
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Effects of combined treatments on human coronary artery cells exposed to 
smokers’ serum
In order to further investigate the alterations in NO and NOS levels in EC 
treated with serum from smokers, allopurinol, rotenone and were added in combination 
with BH4 the NOS co-factor.
With the combined treatment, the NO level in the supernatant of EC cultured 
with smoker’s serum normalized to that in cultures treated with serum from 
nonsmokers’ (0.71±0.21 juM/mg of total protein and 0.70±0.21 juM/mg of total protein 
respectively; Figure 3A. ANOVA: /?<0.05 for the group; Post hoc Fisher’s PLSD: 
p= 0.95 for nonsmokers baseline versus combination treatment in smokers, p<0.03 for 
smokers baseline (0.10±0.05 pM/mg of total protein) versus nonsmokers baseline).
The eNOS activity of the cell lysates treated with serum from smokers and 
allorpurinol, rotenone and BH4(0.45±0.10 L-citrulline/min/pg eNOS/mg total protein) 
was similar to that of cultures treated with nonsmokers’ serum (0.51±0.11 pmol L- 
citrulline/min/pg eNOS/mg total protein) (Figure 3B. Kruskal-Wallis test: p<0.03 for 
the group; Mann-Whitney U test: p=0.52 for combination treatment in smokers versus 
nonsmokers baseline, p<0.003 for smokers baseline (0.30±0.02 pmol L- 
citrulline/min/pg eNOS/mg total protein) versus nonsmokers baseline).
Similarly, with the combination treatment, the eNOS protein expression in 
smoker’s serum-treated cultures (2597± 352 pg/mg of total protein) also normalized to 
that of cultures treated with serum from nonsmokers (2632±253 pg/mg of total protein; 
Figure 3C. ANOVA: p<0.03 for the group; Post hoc Fisher’s PLSD: p=0.95 for 
treatment in smokers versus combination nonsmokers baseline, p<0.03 for smokers 
baseline (4464±717 pg/mg of total protein) versus nonsmokers baseline).
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Figure 3. Effects of allopurinol, rotenone, and tetrahydrobiopterin (BH4) 
combination on NO production, eNOS expression and activity in vitro.
Confluent (-85%) HCAECs were incubated with equal volume o f  medium and serum 
from  nonsmokers (n=6) or smokers (n=6) (with or without treatment as indicated) in 
12-well plates. After 12 hours each parameter was detected as described in the method 
section. Results are presented as meandSEM. ANOVA or Kruskal- Wallis test: p<0.05 
fo r  the group, Post hoc Fisher’s PLSD or Mann-Whitney Utest: *p> 0.50 versus 
nonsmokers ’ baseline, f  p<0.03 versus nonsmokers ’ baseline.
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Discussion
The present study demonstrated that specific inhibitors of the mitochondrial 
electron transport chain and xanthine oxidase independently improved the dysfunction 
of NO biosynthesis in HCEACs exposed to smokers’ serum. Furthermore, when these 
molecules were combined with BH4 (an essential cofactor for eNOS) the NO level, 
eNOS expression and eNOS activity in smokers normalized to that of nonsmokers. To 
the best o f our knowledge this the first demonstration that in addition to uncoupled 
eNOS, other endogenous free radical generating sources such as mitochondrial electron 
transport chain and xanthine oxidase play a important role in NO dysfunction in 
smokers.
The role of endogenous free radical sources in smoking. Previously, with the use of 
cell-permeable free radical scavengers, our group has demonstrated in HCAECs that 
excessive ROS generation was responsible for the smoking-related increase o f eNOS 
protein expression as well as the decrease in NO availability and eNOS activity (2). 
These ROS could potentially arise from radicals present in cigarette smoke itself (i.e. 
exogenous) as well as from endogenous sources. However, involvement o f these 
endogenous sources in smoking-related NO dysfunction has not been investigated 
simultaneously or in detail. Several recent studies using exogenous BH^ including one 
of our previous investigations, have suggested that in smokers, uncoupled eNOS 
resulting from BH4 oxidation could be an endogenous source of ROS (2,10,11). In 
addition to uncoupled eNOS, other important endogenous sources for ROS in ECs 
include the mitochondrial electron transport chain, xanthine oxidase and NAD(P)H 
oxidase (9). In the present study, a significant increase in NO was seen with both a 
xanthine oxidase inhibitor (allopurinol) and a mitochondrial electron transport chain 
inhibitor (rotenone) in cultures incubated with serum from smokers, although both were 
significantly lower than the baseline non-smoker serum NO level. Similarly, with 
smoker’s serum, both the addition of allopurinol or rotenone showed a small decrease 
in eNOS expression although they were still higher compared the baseline level with 
nonsmoker’s serum. These data suggest that in our model both xanthine oxidase and the 
mitochondrial electron transport chain are involved in the smoking-related dysfunction 
of NO biosynthesis, presumably by contributing to the total free radical burden.
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Although there are no previous data regarding the involvement of xanthine oxidase and 
the mitochondrial electron transport chain in NO dysfunction in smokers, these sources 
have been shown to be involved in smoking-related cellular dysfunction in the rat 
gastric mucosa ( 1 2 ), and in human lymphocytes (13).
It has been reported that L-NMMA, a competitive inhibitor of L-arginine, 
decreases NO and increases superoxide production in normal vessels (14) as well as by 
isolated various isoforms of NOS (15-17). In the present study, L-NMMA was used to 
determine whether in ECs treated with serum from non-smokers the inhibition o f NO 
production by eNOS, and the consequent increase in free radical level from this source, 
would be enough to significantly increase the eNOS expression. With L-NMMA 
treatment in nonsmokers the NO level was reduced to half of the baseline level while 
the eNOS protein was only slightly up-regulated. Even with L-NMMA the decreased 
NO level in nonsmokers serum treatment was approximately three times higher than the 
smokers’ serum baseline NO level. In a previous study our group found that when 
smokers serum treated HCAECs were given BH4 alone, there was no significant effect 
on eNOS expression (2). These data taken together suggest that the observed alterations 
in cultures treated with smoker’s serum were probably not due to increased free radical 
generation by eNOS alone and additional sources were also involved. This is consistent 
with the findings in this study. Indeed, when allopurinol, rotenone and BH4 were used 
in combination in smoker’s serum treated cultures, the NO level, eNOS expression and 
eNOS activity all became equivalent to that of nonsmokers.
Implications of this study. Dysfunction of NO biosynthesis by endothelial cells is one 
of the earliest changes in the pathophysiology of cardiovascular disease due to various 
risk factors including smoking. Data from the present study suggest that cigarette 
smoking not only introduces free radical exogenously but also induces intracellular free 
radical generating sources that contribute to the dysfunction of NO biosynthesis. 
Therefore, it is conceivable that in smokers, irrespective of the exogenous free radical 
load, prolonged exposure to a small dose, or inadequate removal, o f free radicals can 
potentially overwhelm the biochemical process of NO biosynthesis. These data provide 
a possible cellular mechanism as to why even relatively small amounts of cigarette 
smoke might have a detrimental effect on NO biosynthesis as previously demonstrated 
by our group (18).
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Study limitation. First, it should be noted that vascular smooth muscle cells also 
contribute to the total free radical burden in the blood vessels, especially though the 
NAD(P)H oxidase pathway(19) Therefore, our data should be interpreted as only 
endothelial cell specific responses. Secondly, the focus of our study was free radical- 
mediated effects related to NO biosynthesis, but cigarette smoke contains over 4,000 
known and over 100,000 unknown constituents (20) and the potential influence of these 
substances cannot be exclude in our model. Lastly, while involvement o f the 
endogenous free radical sources has been demonstrated, the exact mechanism(s) 
involved in this cigarette smoke-induced dysfunction are unknown and will require 
additional study.
Conclusion
Excessive free radical generation is one of the primary causes of NO 
dysfunction in smoking. The present study demonstrates that in addition to free radicals 
(exogenous) derived from cigarette smoke and present in serum, endogenous free 
radical sources can further amplify the total cellular free radical burden in response to 
exposure to serum from smokers. These data may have important implications 
concerning preventive and therapeutic strategies against cigarette smoke exposure.
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5. DISCUSSION
Cigarette smoking is a major cardiovascular risk factor (AHA, 1999). It is 
associated with the development of atherosclerosis in both coronary and peripheral 
arteries (Powell, 1998). Endothelial injury is considered to be a key initiating event in 
the pathogenesis of AS (Ross, 1986; 1993). Impairment of endothelial vasodilator 
function is the earliest pathophysiological effect of various risk factors for AS including 
cigarette smoke (Adimoolam and Cooke, 1999). NO is the primary vasodilator secreted 
by the ECs. It has been shown to be affected by cigarette smoke (Celermajer et al.,
1993; McVeigh et a l, 1996 and Kugiyama et a l, 1996; Lekakis et a l, 1997; Ota et a l, 
1997). The exact mechanism(s) of cigarette smoke-mediated endothelial dysfunction 
and alteration of NO biology remain unknown and are often contradictory.
In recent years, assessment of flow-mediated EDV has emerged as the standard 
in vivo non-invasive technique for investigating endothelial vasoregulatory function. 
Studies have used this technique to evaluate endothelial NO production/availability 
indirectly. Direct assessment of the NO biosynthetic pathway (NO production or 
availability, eNOS protein expression and eNOS activity) in healthy human subjects is 
difficult because bloodstream NO is an unreliable measure of EC-derived NO (Kelm 
and Yoshida, 1996). Furthermore, practically as well as ethically it is not appropriate to 
expose healthy individuals to an invasive procedure such as biopsy of the endothelium. 
The NO biosynthetic pathway can be easily assessed in an in vitro model. However, the 
majority of in vitro models assessing the effects of smoke exposure used either 
commercially available CSC or crude CSE produced by passing cigarette smoke 
through a buffer solution (Vayssier et al., 1998; Nagy et al., 1998; Su et al., 1998; Shen 
et al., 1996; Ota et al., 1997). These non-physiological solutions may have a non­
specific toxic effect on ECs. In addition, in blood, the concentration o f toxic 
components of cigarette smoke may be dissimilar to these solutions (CSE, CSC). 
Therefore, it was thought that assessment of EDV in smokers in combination with 
exposing the ECs to serum collected from the same individuals would be a more 
practical, as well as a more appropriate, physiological alternative. HUVECs were 
chosen for the initial studies because these cells are most commonly used for in vitro 
studies related to endothelial function. In the in vitro model, cell viability as well as 
proliferative characteristics were validated to exclude the influence of direct toxic 
effect of smokers’ serum on the investigated parameters.
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5.1 Smoking, in vivo endothelial-dependent vasodilatation and 
nitric oxide biosynthetic pathway in vitro
Utilizing the in vivo model with the present in vitro model, it was found that 
smokers had decreased flow-mediated EDV and serum from these smokers also 
decreased SP-stimulated as well as basal NO levels in HUVECs. There was a 
significant correlation between in vivo and in vitro models. This was the first combined 
in vivo and in vitro demonstration that cigarette smoking affects endothelial NO 
biosynthesis. These data on smoking-mediated NO dysfunction are consistent with 
previous in vitro (Ota et al., 1997) as well as in vivo (Celermajer et al., 1993; Lekakis 
et al., 1997; McVeigh et al., 1996 and Kugiyama et al., 1996) studies.
The analysis o f eNOS protein concentration in the present experimental model 
however, revealed a higher eNOS expression in HUVECs treated with smoker’s serum. 
These data were inconsistent with the report of Su et al. (1998) that CSE caused 
irreversible inhibition of eNOS protein expression in pulmonary artery ECs as well as 
with the data of Wang et al. (2000) that HUVECs isolated from pregnant smokers 
demonstrated lower eNOS protein expression. However, Wright et al., (1999) reported 
findings similar to ours that eNOS expression was upregulated in rat lung after once 
daily exposure to cigarette smoke. Such up-regulation of eNOS has also been reported 
by several recent studies in various NO-deficient conditions including early 
hypercholestrolemia, hypertension and diabetes (Kanazawa et al., 1996; Bouloumie et 
a l, 1997; Hink et al., 2001). Nevertheless, the variable results between studies could be 
attributable to either differences between the models, the duration of exposure, as well 
as the stage of the pathological process.
The cause of the upregulation of eNOS was less clear. Since there was a 
significant negative correlation between NO and eNOS expression, it was speculated 
that probably a feedback mechanism exists between NO level and eNOS expression. 
However, later studies in this project suggest a more likely cause for this upregulation.
The analysis of eNOS activity from the same cell lysates showed a decrease in 
protein adjusted eNOS activity in HUVECs treated with smokers’ serum. eNOS 
activity correlated with basal (12 hour) NO level in the cell culture supernatant. These 
results indicated that in smokers an increase in eNOS protein concentration may not 
increase the production or availability of NO. Similarly, Wang et al. (2000) did not find
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a correlation with eNOS protein and its activity in HUVECs isolated from pregnant 
smokers. eNOS requires several cofactors and prosthetic groups for its activity: 
thiolate-bound heme, NADPH, BH4, FAD, FMN, and CaM and Ca2+ (Gorren and 
Mayer, 1997). It has been reported that cigarette smoking affected these cofactors 
(particularly BH4) independently (Higman et a l, 1996; Robert et al. 1998; Heitzer et 
al., 1999) causing the uncoupling of the enzyme leading to O2’ production instead of 
NO. The later studies in this project indicated that this mechanism might partly be 
responsible for the decreased eNOS activity in HUVECs treated with the smokers’ sera 
in the present experimental model.
5.2 Heavy and light Smoking, and endothelial vasoregulatory 
functions
While an association between smoking and cardiovascular risk has been 
demonstrated, an unanswered question is whether or not there is a linear dose effect 
relationship between EDV and endothelial NO biosynthesis in active smokers 
(Celermajer et al., 1993 and 1996; Sumida et al., 1998; Woo et al., 2000). To address 
this issue, in the second study of this project, the effect of smoking < one pack of 
cigarettes/week (Light smoking) or > one pack of cigarettes/day (heavy smoking) was 
investigated both in vivo and in vitro. In addition, the dose effect of smoking on EC- 
derived ET-1 was determined. ET-1 is the most potent vasoconstrictor secreted by ECs. 
Therefore, the relative ratio of ET-1 and NO can alter the vasodilatory capacity o f a 
vessel.
It was found that both heavy and light smokers showed a similar decrease in 
EDV. These data were consistent with the reports of Celermajer et al. (1996) and 
Sumida et al. (1998), which demonstrated that active and passive smoke exposure 
caused a similar degree of dysfunction in EDV of the brachial artery and the coronary 
arteries respectively. The latter also showed a similar reduction of vasodilatory function 
in individuals with heavy- and light-passive smoke exposure. In the present study, it 
was observed that HUVECs exposed to serum from heavy and light smokers showed 
equivalent alterations in basal- and SP-stimulated NO production, eNOS protein 
expression as well as eNOS activity. However, cigarette smoking as well as the degree 
of smoke exposure, did not have a significant effect on EC-derived ET-1 production. 
Serum cotinine levels (a surrogate marker for short-term cigarette smoke exposure) and
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the pack-years of exposure (long time exposure) had no correlation with EDV in vivo or 
with NO in vitro in smokers. Collectively, these observations provided further 
supportive data for the concept that the dose-effect of cigarette smoking on NO 
biosynthesis or EDV may not be linear.
The cause of this non-linear effect of smoking on EDV and NO biosynthesis is 
unclear. Cigarette smoke contains large amounts of free radicals. Free radicals 
specifically 0 2 ’can react with NO and limit its biological and chemical half-life (Kojda 
and Harrison, 1999). However, reports on the role of free radicals in smoking-mediated 
cellular dysfunction have been inconsistent (Murohara et a l, 1994; Heitzer et al., 1996; 
Su et al., 1998 Leonard et al., 1995). Nevertheless, one potential explanation could be 
that there is a threshold for direct free radical burden from smoke exposure, beyond 
which the mechanism for NO biosynthesis is overwhelmed. However, in this study all 
smokers abstained from smoking over night (6-8 hours) and some of them even for 
days (light smokers). It was unclear whether or not exogenous free radicals from 
cigarette smoke alone were sufficient enough to overwhelm the NO biosynthetic 
process. Therefore, an alternative hypothesis was proposed that cigarette smoke 
exposure might have also initiated endogenous cellular mechanism(s), which amplified 
the impact of cigarette smoke exposure and consequently overwhelmed the NO 
biosynthetic pathway. Results from the later studies in this project provided further 
evidence to substantiate this hypothesis.
5.3 Smoking, endothelial cell-derived hemostatic factors and 
nitric oxide
Cigarette smoking increases the risk of myocardial infarction and stroke, which 
represent thrombotic events (Black 1995; Burke et al., 1997). ECs play a significant 
role in vascular hemostasis by contributing to the delicate balance of thrombotic /anti­
thrombotic factors, and fibrinolytic /anti-fibrinolytic factors (Cines et al., 1998). 
Recently, circulating TF has emerged as a potentially important indicator for increased 
intra-vascular thrombosis (Suefuji et al., 1997; Misumi et al., 1998; Giesen and 
Nemerson, 2000; Rauch and Nemerson, 2000). TFPI-1 is the principal physiological 
inhibitor o f TF (Bajaj et al., 2001). Tissue plasminogen activator (t-PA) is the principal 
mediator of the degradation of intra-vascular fibrin. Both TFPI-1 and t-PA are 
primarily synthesized by ECs (Cines et al., 1998). Plasminogen activator inhibitor-1
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(PAI-1), is the most efficient inhibitor of t-PA and is synthesized by several types of 
cells including ECs (e.g. vascular smooth muscle, platelets and hepatocytes) (Cines et 
al., 1998). Data regarding the effects of smoking on thrombo-hemostatic factors (TF & 
TFPI-1) are limited (Blann et al., 2000; Matetzky et al., 2000) and on fibrinolytic 
factors (t-PA & PAI-1) are controversial (Newby et al. 1999 and 2001; Eliasson et al., 
1995; Enderle et al., 2000). The effect of smokers’ serum on these factors and their 
association with NO was explored in the present study.
It was observed that supernatant from HUVECs exposed to smokers’ serum had 
significantly lower TFPI-1 level than that from HUVECs exposed to non-smokers’ 
serum. However, TF levels were not significantly different between the groups. It was 
also found that both basal and SP-stimulated t-PA were significantly lower in smoker’s 
serum treated cells. The PAI-1 levels were not different between groups but the t- 
PA/PAI-1 molar ratio was significantly decreased in the smoker’s serum treated group. 
These data collectively suggest that smoking may result in alterations in the endothelial 
contribution to vascular anti-thrombotic as well as fibrinolytic properties leading to 
increased thrombotic potential. These observations add to the growing number of 
potential causes for increased thrombotic events in smokers.
While in the smoker’s serum treated HUVECs, EC-derived NO, t-PA and TFPI- 
1 were all decreased, the NO levels did not correlate with t-PA and had only a weak 
positive correlation with TFPI-1. On the other hand, serum cotinine levels had a 
relatively stronger negative correlation with TFPI-1. In light of our previous finding (no 
correlation with NO and serum cotinine) the significance of these associations are 
unclear and additional investigation will be required to further clarify these findings.
This study confirmed pervious data by other investigators (Newby et al. 1999 
and 2001) and additionally provided novel information regarding the effects of 
smoking on ECs-derived TFPI-1. However, the functional outcome of these findings 
remains to be determined, as activity levels of these factors were not measured in vitro.
5.4 Smoking-mediated nitric oxide dysfunction in human coronary 
arterial endothelial cells and reactive oxygen species
All of the previous studies in this project were performed in HUVECs.
Although HUVECs are a well-recognized model for investigation, they are of venous 
origin. The data from these cells are often viewed with skepticism (Cines et al., 1998).
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In addition, there are suggestions that some common functional proteins expression 
might differ among different EC lines (Subramanian et al., 1986; Belloni and Tessler, 
1990; Drake et a l, 1993). Therefore, it was imperative to confirm the findings in 
HUVECs in an arterial cell line. In the second phase of experiments, human coronary 
artery endothelial cells (HCAECs) were used to confirm the previous findings. In 
addition, with use of either cell-permeable polyethylene glycol-superoxide dismutase 
(specific scavenger of C>2')5 PEG-SOD plus PEG-catalase (specific scavenger of H2O2), 
chelerythrine (a protein kinase C (PKC) inhibitor) or BH4 (a critical cofactor of eNOS) 
the role of ROS in the observed alterations was examined.
Similar to our previous results in HUVECs, the HCAECs exposed to smokers’ 
serum showed decreased NO availability, increased eNOS expression and decreased 
eNOS activity. The NO availability in the cell-culture supernatant from HCAECs 
exposed to smokers’ serum was improved with the addition of either PEG-SOD or 
PEG-SOD plus PEG-catalase. These data indicated that, in the present model, ROS 
contributed to the decreased NO availability seen in HCAECs treated with smoker’s 
serum. The tar-phase of cigarette smoke contains a radical generating system (a mixture 
of quinones, semiquinone and hydroqinone) that is demonstrated to be stable for hours 
to months and can auto-oxidize to produce 0 2 'and H2O2 in biological fluids (Pryor,
WA and Stone, K. 1993; Pryor et al., 1998; Smith and Fischer, 2001). Therefore, in the 
present model, cigarette smoke was a possible source of ROS. Additionally, consistent 
with several previous studies (Higman et al., 1996; Heitzer et al., 1999 Ueda et al., 
2000), it was also found that addition of exogenous BH4to the smokers sera normalized 
the NO availability. Thus, in the present model, oxidation of BH4 and subsequent 
uncoupling of eNOS appeared to be an additional mechanism for increasing the 
oxidative stress and NO dysfunction in smokers. Although a potential direct free radical 
(specifically O2 ') scavenging effect o f BH4 (Patel et al., 2002) was not excluded in the 
present model, the previous inconsistent results with non-cell-permeable free radical 
scavengers (Higman et al., 1996; Su et al., 1998) as opposed to the effectiveness of 
cell-permeable free radical scavengers in the present model suggests a role for both 
exogenous- as well as endogenous-derived free radicals in smokers.
Although both free radical scavengers and BH4 increased the NO availability, 
the effect of each treatment on smoking-mediated up-regulation of eNOS was different. 
The addition of PEG-SOD alone showed a further small (insignificant) up-regulation of 
eNOS. On the other hand, PEG-SOD plus PEG-catalase was associated with a
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significant decrease in eNOS protein. These data suggested indirectly that H2O2 was a 
potential inducer of eNOS up-regulation in the present model. This was consistent with 
other reports in various models (Drummond et al., 2000; Cai et al., 2001).
The eNOS activity of the cell lysate from HCAECs exposed to smokers’ serum 
was significantly improved from baseline with the addition of PEG-SOD, PEG-SOD 
plus PEG-catalase or BH4. However, with PEG-SOD or BH4 treatment, the activity of 
each unit of eNOS was only partially restored. Full normalization o f eNOS activity was 
only observed with PEG-SOD plus PEG-catalase treatment. The difference in the 
eNOS activity between these treatments was most likely attributable to the fact that 
only PEG-SOD plus PEG-catalase scavenged H2O2. However, with PEG-SOD or BH4, 
increased eNOS expression compensated for relatively lower eNOS activity leading to 
normalized NO level. These data suggested that even though H2O2 appeared to play a 
role in eNOS up-regulation, scavenging both O2" and H2O2 was essential to fully 
normalize the activity of eNOS.
The mechanism responsible for the decreased eNOS activity in the presence of 
upregulated eNOS protein in smokers’ serum alone remains speculative. This effect 
was possibly due to a direct effect of ROS on eNOS protein leading its structural 
changes. From the data in this study, H2O2 and its derivatives appeared only moderately 
deleterious for the activity of eNOS because relatively higher eNOS expression was 
successful in normalizing the NO level when H2O2 was not scavenged (i.e. PEG-SOD). 
Therefore, the likely radicals for the observed dysfunction of eNOS activity in 
smokers’ serum alone were 0 2 'and its derivatives including ONOO'. In a recent study 
it was reported ONOO' releases zinc from eNOS and caused the uncoupling of eNOS 
(Zou. et al., 2002). Other potential factors that might have influenced the eNOS activity 
include duration (12 hour) as well as level (uncontrolled) of exposure to ROS. Further 
investigation will be required to identify the exact mechanism for this dysfunction.
The addition of chelerythrine (PKC inhibitor) in smokers’ serum did not have 
any significant effect on any of the studied parameters. Although PKC was 
demonstrated to be involved in endothelial ROS generation and NO dysfunction 
specifically in diabetic models (Hink et al. 2001), data from this study suggested that 
the participation of PKC pathway was insignificant in smoking-mediated NO 
dysfunction.
In summary, these data indicated that excessive generation of ROS and the 
consequent oxidative stress was the central mechanism for the observed dysfunction of
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smoking-mediated NO biosynthesis and also suggested that reduction of ongoing 
oxidative stress was essential for normalization of NO biosynthesis.
5.6 Endogenous sources of reactive oxygen species in smoking- 
mediated nitric oxide dysfunction
As indicated above, increased levels of ROS were the primary cause of 
smoking-mediated NO dysfunction either from exogenous sources or endogenously 
from uncoupled eNOS. However, there are other endogenous sources of ROS such as 
NAD(P)H oxidase, mitochondrial electron transport chain and xanthine oxidase that 
have been shown to be involved in the pathophysiology of endothelial dysfunction 
related to other cardiovascular risk factors (Kojda and Harrison, 1999; Cai and 
Harrison, 2000). The potential contribution of these sources in smoking-mediated NO 
dysfunction has never been investigated. Therefore, utilizing specific inhibitors, the 
involvement of these potential sources of ROS in smoking-mediated NO dysfunction 
was explored.
It was found that either allopurinol (an inhibitor of xanthine oxidase) or 
rotenone (an inhibitor of mitochondrial electron transport chain) treatment increased the 
NO availability in the cell-culture supernatant from HCAECs exposed to smokers’ 
serum, while apocyanin (an inhibitor of NADPH oxidase) did not. However, this 
increase in NO availability was still significantly lower than the NO level in the cell- 
culture supernatant from HCAECs exposed to non-smokers’ serum. Similarly, with the 
addition of allopurinol or rotenone to HCAECs treated with serum from smokers, 
eNOS expression showed only a small, insignificant decrease and was still higher when 
compared to that in HCAECs treated with serum from non-smokers. These data 
suggested that xanthine oxidase and the mitochondrial electron transport chain did not 
act alone but rather each contributed to the total free radical burden in smoking- 
mediated NO dysfunction.
It has been shown that L-NMMA decreases NO production and increases O2" 
generation from various isoforms of NOS (Vasquez-Vivar et al, 1998; Pou et al., 1999; 
Shi et al., 2002). The addition of L-NMMA to the non-smokers sera deceased the NO 
level significantly, but the eNOS expression increased only marginally. The reduction 
of NO levels with the addition of L-NMMA to non-smoker’s serum was still 
approximately three times higher than the baseline NO level in cultures treated with
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serum from smokers. Therefore, it was unlikely that free radicals generated from eNOS 
alone Were responsible for the observed changes. Indeed, when allopurinol, rotenone 
and BH4 were added in combination to smokers’ sera, the NO availability, eNOS 
protein expression and eNOS protein became equivalent to that stimulated by sera from 
nonsmokers. It should be noted, as mentioned above, due to a potential direct 
antioxidant effect, BH4 might have had a dual effect in the present model, that is, it 
prevented the uncoupling of eNOS and consequent 0 2 ' generation as well as scavenged 
the O2" directly.
These data provided the first evidence that in addition to uncoupled eNOS, the 
mitochondrial electron transport chain and xanthine oxidase are involved in smoking- 
mediated NO dysfunction. These data also raise the possibility that irrespective o f the 
exogenous level of free radicals, smoking can also initiate endogenous mechanisms 
leading to increased free radical generation. Therefore, in situations where there is 
inadequate removal of, or continuous exposure to, small doses of free radical, the 
biochemical processes of NO synthesis may be overwhelmed. Thus, these data provide 
a potential explanation as to why even relatively small amounts of cigarette smoke 
could have such a detrimental effect on NO biosynthesis as previously observed in an 
earlier study of this project.
5.6 Study limitations
Although a good correlation was found between in vivo and in vitro models, in 
vivo continuous shear stress plays an important role in modifying the EC function. In 
the present study all the in vitro experiments were done in a static environment. 
Therefore, it is unclear whether present observations would be modified in the presence 
of continuous shear stress. In addition, in vivo vascular responses are a composite result 
of interactions between ECs, vascular smooth muscle cells as well as multiple 
extracellular elements. In the present in vitro model only EC-specific responses were 
examined.
Similarly, unlike in vivo models, in vitro models are likely to have limited 
metabolism of toxic substances leading to a massive build up without recovery. 
Therefore, the timeline of observed dysfunction in the present in vitro model might not 
be applicable to an in vivo situation.
Data from the existing literature suggest radicals present in the tar phase of 
cigarette smoke are sufficiently long-lived (hours to months) to pass through the
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pulmonary circulation, into the blood steam to produce an adverse effect on vascular 
beds (Pryor, WA and Stone, K. 1993; Pryor et al., 1998; Smith and Fischer, 2001). 
Serum from smokers’ was used in this project. However, due to a lack of resources 
(electron spin resonance spectroscopy) a direct demonstration of the radical systems in 
the present model was not possible. In addition, the primary focus of the project was to 
investigate smoking-mediated effect on endothelial function (i.e. NO biosynthetic 
pathway and hemostaic markers). Specific free radical scavengers and inhibitors o f free 
radical generating sources were utilized to provide indirect evidence for a role of free 
radicals and their potential sources in the observed dysfunction. To further confirm our 
findings, additional studies will be needed to provide a direct evidence for the role of 
these exogenous and endogenous free radical sources in smoking-mediated NO 
dysfunction.
5.7 Conclusion
Cigarette smoking is globally an important cause of mortality related to 
cardiovascular disease. The studies in this project investigated the cause and the 
potential mechanisms behind one of the earliest manifestations (dysfunctional NO 
biosynthesis) in cardiovascular pathophysiology related to smoking. Utilizing a novel 
approach, this project confirmed that reduced EDV seen in smokers was most likely 
due to deceased endothelial NO availability. The data from this project indicate that 
ROS were the central players in smoking-mediated NO dysfunction and suggest that 
these ROS can potentially arise from exogenous and endogenous sources. Furthermore, 
the data from this project also showed that while certain ROS might play a role in up­
regulation eNOS, the functional capability of this up-regulated enzyme would be 
influenced by the surrounding oxidative milieu. Finally, smoking appears to decease 
the availability of ECs-derived fibrinolytic and anti-thrombotic factors in an EC milieu.
5.8 Future work
Data from this project confirmed several prevailing hypotheses and also 
provided novel as well as potentially important mechanistic and exploratory data 
related to smoking and endothelial function. If time and resources permitted, it would 
have been interesting to investigate:
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1.) The molecular mechanism behind eNOS upregulation in the present model, 
that is, whether it is due to a increased rate of transcription of the eNOS gene or is 
secondary to an increase in the stability of the eNOS message once it is formed.
2.) The exact mechanism behind the decrease in eNOS activity, that is, whether 
it is due to oxidation of the zinc-thiolate cluster of eNOS or due to the presence of 
endogenous inhibitors of eNOS such as asymmetric dimethyl arginine (ADMA).
3.) The mechanism(s) responsible for smoking-related alteration o f EC-derived 
hemostatic molecules as well as their functional significance.
4.) The direct contribution of exogenous and endogenous free radical sources in 
the present model as well as the potential mechanism behind their induction.
5.) The effect of continuous shear stress on all of the above-observed 
phenomena in the present model.
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APPENDIX
Names and addresses of the manufactures or suppliers of instruments 
and chemicals
Abacus Concepts, Inc. Calbiochem
1984 Bonita Ave. 10394 Pacific Center Court
Berkeley, CA 94704 San Diego, CA 92121
USA USA
Acuson Chemicon
1230 Shorebird Way 28820 Single Oak Drive
Mountain View CA 94039-7393 Temecula, CA 92590
USA USA
Aldrich Chemical Co. Clonetics
P.O. Box 2060 8830 Biggs ford Rd.
Milwaukee WI 53201 Walkersville, MD 21793-0127
USA USA
American Diagnostica Inc Costar
222 Railroad Ave. One Alewife Center
Greenwich, CT 06836-1165 Cambridge, MA 02140
USA USA
Amersham Pharmacia Biotech, Inc. Fisher Scientific
800 Centennial Avenue 52 Fadem Road
Piscataway, NJ 008855-1327 Springfield, NJ 07081
USA USA
Baxter Scientific Products GIBCO BRL
100 Raritan Center Parkway P.O. Box 68
Edison, NJ 08818 Grand Island, NY 14072-0068
USA USA
Becton Dickinson Hausser Scientific
P.O. Box 243 935 Horsham Road, Suite C
Cockeysville, MD 21030 Horsham, PA 19044
USA USA
Biopool Jouan Inc.
6025 Nicolle Street R.R. 12, Box 104
Ventura, CA 93003 Winchester, VA 22601
USA USA
Bio-Tek Instruments Packard Instrument Com.
Highland Park, Box 998 2200 Warrenville Road
Winooski, VT 05404-0998 Downers Grove, IL 60515
USA USA
R & D Systems 
614 McKinley Place N.E. 
Minneapolis, MN 55413 
USA
Sievers
6060 Spine Road 
Boulder, CO 80301 
USA
Sigma Chemical Co.
P.O. Box 14508 
St. Louis, MO 63178 
USA
STC Technologies Inc.
150 Webster Street 
Bethlehem, PA 18015-1389 
USA
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